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AbstrAct
SYMPATHETIC RENAL DENERVATION FOR RESISTANT HYPERTENSION. 
IMPACT ON BLOOD PRESSURE AND ON SURROGATE MARKERS OF TAR-
GET ORGAN DAMAGE.
Catheter‑based sympathetic renal denervation (RDN) is a new treatment option 
for resistant hypertension (rHTN) and its clinical impact is yet to be fully understood.
The aim of this study was to evaluate the impact of RDN in blood pressure (BP) 
and in 2 recognized surrogate markers of target organ damage (TOD): left ventricle 
(LV) hypertrophy (assessed by echocardiogram) and proteinuria (evaluated by the uri‑
nary albumin to creatinine ratio (ACR), at 1 year follow up.
All patients with rHTN under maximal tolerated antihypertensive drug therapy sub‑
mitted to RDN since July‑2011 were included in a prospective single centre registry. 
All clinical variables, medication, laboratory values, 24‑hour ambulatory BP measure‑
ments (ABPM) and echocardiogram results were recorded in an electronic database 
at baseline and at 1‑year follow‑up. The following objectives were addressed: changes 
on office and ABPM BP, on LV mass and structure, on ACR and renal function, as well 
as procedure safety. 
Since 2011, 318 patients with rHTN were referred for RDN, of which 65 were 
considered to have true rHTN refractory to drug therapy and accepted for RDN. From 
those, 31 had a complete 1‑year follow‑up data at the time of the present analysis and 
are reported here. At 12 months there was a significant decrease in either office and 
ABPM systolic and diastolic BP, with 84% of patients considered responders to RDN 
regarding SBP and 71% for DBP. There was also a significant decrease in LV mass, 
from 152.3g/m2 to 135.7g/m2 (p<0.001) and in ACR, from 25.9mg/g to 14.8mg/g 
(p=0.007), independent of diabetes status, with no significant changes in renal func‑
tion. No clear linear correlations were found, between changes in BP and either LV 
mass or ACR, both surrogates of HTN related TOD. There were no major complications 
related with RDN. These results suggest benefits of RDN in recognized markers of 
HTN organ damage, which if confirmed are expected to translate to an improvement in 
clinical endpoints beyond BP control.
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To a wonderful family
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summAry
Hypertension is a leading cause of death in developed countries, and although 
there have been large investments in drugs aiming its control, there is still a stag-
gering contrast between its high prevalence and the low rates of adequate con-
trol. A subset of patients with suboptimal blood pressure control have drug-resistant 
hypertension, in the pathophysiology of which chronic sympathetic hyperactivation 
is significantly involved. Sympathetic renal denervation has recently emerged as a 
device-based treatment for resistant hypertension. In this review, the pathophysiolog-
ical mechanisms linking the sympathetic nervous system and cardiovascular disease 
are reviewed, focusing on resistant hypertension and the role of sympathetic renal 
denervation. An update on experimental and clinical results is provided, along with 
potential future indications for this device-based technique in other cardiovascular 
diseases.
Hypertension
Hypertension (HTN) is the leading global risk factor for cardiovascular mortality, 
with a prevalence worldwide projected to be approximately 3.5 billion in 2015, with 7.8 
million related deaths each year1. Its strong association with myocardial infarction, heart 
failure, stroke, end‑stage renal disease and cardiovascular death, is well established, 
with 54% of stroke and 47% of ischemic heart disease attributable to high blood pres‑
sure (BP) worldwide,2 and it seems to have a continuous relationship between BP and 
cardiovascular risk from values as low as 115/75 mmHg, doubling the cardiovascular 
risk for every 20/10mmHg in pressure.1, 3
Meanwhile, effective blood pressure lowering has consistently been shown to 
reduce overall cardiovascular risk 4, but the rates of adequate BP control remains sub‑
optimal, despite the large amount of available antihypertensive drugs, from different 
classes and strong scientific evidence supporting their use, with only 37% of treated 
hypertensive patients, achieving recommended BP values, in European countries. 5 
The blame for such very low rates of BP control cannot be attributable only to 
poor treatment management. The complex pathophysiology underlying human BP con‑
trol, with multiple interconnected systems, has certainly a relevant role for the failure in 
achieving HTN treatment control. 
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There are at least two main systems responsible for BP control: renal‑based and 
vascular‑based. The renin‑angiotensin‑aldosterone system (RAAS), plays a major role 
in renal control of salt and water homeostasis, but also in peripheral vascular resis‑
tance, acting directly through angiotensin but also by activating the sympathetic nerve 
system (SNS). Other mediators are also important, although their role is not so well 
understood. 
For the last decades, RAAS system has been the central focus of HTN treatment 
and management. Availability of secure, efficacious and evidence proved drugs block‑
ing this system, as led to neglect the contribution of other systems, namely the autono‑
mous nervous system, for raising and maintaining high BP values.
The SNS and its possible role in the pathogenesis of HTN, has been receiving 
increasing attention. A more complete understanding of how the SNS could help to 
control the long‑term level of BP has developed recently and supports a complete new 
approach to treat resistant HTN.
sympAtHetic nerve system
More than one hundred years have passed since Gaskell and Langley first elu‑
cidated us on the structure and function of the autonomous system, the sympathetic 
and parasympathetic system, and could show, that they are both distributed to the 
same body structures, their effects are antagonistic, and they subservice the functions 
of organic life, and are not under the control of the will.6 Later, Cannon has extended 
this, by pointing out the critical role of the SNS in preparing the body to struggle and 
to increase its powers of defence.7 Under SNS stimulation, the pupil dilates to increase 
perception of light, the heart beats faster and forcibly to supply the muscles with blood, 
the visceral blood vessels area constrict, raising the blood pressure and driving the flow 
from the digestive area, whose functions are inhibited, to the muscles, the heart, the 
lungs and the brain.
Sympathetic nerve system control. Under physiological conditions, the 
autonomic nervous system, adjusts circulation in keeping with behaviour, environ‑
ment and emotions, via rapid changes in the cardiac output and regional arteriolar 
resistance. The neural control of the circulation operates via parasympathetic neu‑
rons that innervate the heart, and via three main classes of sympathetic efferents, 
the barosensitive, the thermosensitive and the glucosensitive, that do innervate the 
blood vessels, the heart, the kidneys and the adrenal medullae. Their control cen‑
ters are all located in the central nerve system: the rostral ventrolateral medulla, the 
spinal cord, the hypothalamus and the nucleus of solitary tract. The rostral ventro‑
lateral medullae, the nodal point for most, if not all, sympathetic reflexes that involve 
cardiovascular regulation, is the primary centre for BP control.8, 9 It is linked to hypo‑
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thalamic centres, influencing sodium and water balance, but also, to the cortex, 
specially the limbic cortex, responsible for rapid behaviour‑related adjustments of 
sympathetic tone.8
Sympathetic nerve system effectors. The thermosensitive group of cardio‑
vascular efferents is primarily cutaneous vasoconstrictors activated by hypothermia, 
emotions and hyperventilation. The glucosensitive are activated by hypoglycemia and 
physical exercise and controls the release of epinephrine (EP) by the adrenal medulla. 
These two types of efferents presumably have a secondary role in short and long‑term 
regulation of BP.10, 11
The large group of barosensitive sympathetic efferents, under the input influence 
of arterial baroreceptors, have a dominant role on short and long‑term regulation of BP. 
Regardless of the organ or tissue that they innervate, these neurons have an ongoing 
activity at rest. They control the heart, the release of norepinephrine (NE) from the 
adrenal medullae, vasoconstriction of resistance arterioles and play a major influence 
in kidney function, where they control renin secretion, sodium reabsorption and renal 
blood flow.12
The SNS has also a special relation with adrenal medullae. Preganglionic sympa‑
thetic nerve fibres pass directly from medio‑lateral horn cells of the spinal cord into the 
two adrenal medullae, ending directly on modified neuronal cells that secrete EP and 
NE directly into blood.13 Anatomically, those sympathetic adrenal nerve fibres can go 
along with the sympathetic postganglionic renal fibres and in this way may be affected 
by renal denervation procedures.
Sympathetic nerve system neurotransmitters. The sympathetic fibres 
secrete one of two synaptic transmitter substances, acetylcholine or NE. All pregan‑
glionic neurons are cholinergic, it means, they secrete acetylcholine as neurotransmit‑
ter that excites the postganglionic neurons. Most of those postganglionic neurons are 
adrenergic, meaning that they secrete NE as a neurotransmitter, with the exception of 
postganglionic sympathetic fibres to the sweat glands, which are cholinergic.13
The NE secreted by terminal nerve endings is removed from site by reuptake 
into the adrenergic nerve endings through an active transport mechanism, account‑
ing for 50 to 80% of secreted neurotransmitter. The remaining neurotransmitter may 
diffuse away to the surrounding tissue and blood being destroyed later, by cate‑
chol‑O‑methyl transferase in the liver. Small amounts are also destroyed by local tis‑
sue monoamine oxidase enzyme. Although NE secret directly to tissue as a lifespan 
of a few seconds, once in blood, remains active from one to several minutes, until 
destroyed in the liver.13
Epinephrine and NE stimulates an effector organ through a membrane receptor, 
that either changes cell membrane permeability to ions (sodium, potassium or calcium) 
or altering an intracellular second messenger enzyme, the adenylcyclase, causing the 
intracellular formation of cAMP, which will initiate many different intracellular actions. 
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There are at least two known types of adrenergic receptors, alfa and beta receptors 
and many subtypes of them. For a more comprehensive review, the receptors and their 
function are listed in Table.1.
Table 1: Types and functions of adrenergic receptors.
Alpha Receptors Beta Receptors
α1
postsynaptic
α2
presynaptic
β1
postsynaptic
β2
postsynaptic
Gq protein coupled
Activation phospholi‑
pase C
Gi protein coupled
Inhibits Adenyl Cyclase
Gs protein coupled
Activates Adenyl Cyclase
Vasoconstriction:
• Skin
• Gut
• Kidney
• Brain
Smooth muscle cells 
contraction:
• Ureter
• Vas deferens
• Urethral spinchter
• Uterus
• Cilliary body
Glucose metabolism:
• Gluconeogenesis
• Glucolysis
Glucose metabolism:
• Inhibits insulin release
• Stimulates glucagon 
release
• Contraction of anal 
sphincter
• Inhibits release of EP
Heart:
• Chronotropic +
• Dromotropic +
• Inotropic +
• ↑ LVEF
Renine release ↑ by 
juxtaglomerular cells
Hunger ↑
• ↑ ghrelin release by 
stomach
SMC relaxation:
• Bronchus
Bronchioles
• Detrusor muscle
• Uterine muscle
Urethral sphincter 
Contraction:
Renin release by justa‑
glomerular cells
Glucose metabolism:
• Inhibits insulin re‑
lease
• Stimulate glucolysis 
and gluconeogene‑
sis
Lipolysis
Vasoconstriction of:
• Coronary arteries
• Veins
↓ Motility of gastrointestinal system 
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The beautifulness of this system, and its complexity, drives from the fact that using 
just two different kinds of neurotransmitters, NE and EP, it can initiate many different 
actions, depending on the target tissue, type of receptor and the relative affinity of the 
neurotransmitter for the receptor.
This mechanism must have been developed during a vast period, through innu‑
merable intermediate stages. Therefore, we are now in possession of a complex mech‑
anisms which discharge energy under strictly controlled fashion and adequate stimu‑
lation. 
sympAtHetic control of blood pressure
Blood pressure is primarily a function of peripheral arterial resistance, but also of 
cardiac output, which in turn, is dependent of heart rate, myocardial contractility and 
venous blood return, the later, also dependent on smooth muscle venous tonus. All 
under SNS control. 
The neural control of BP and overall circulation uses the vast complex SNS and 
the more localized parasympathetic neurons that do innervate the heart and lungs.
As explained, the background activity of the barosensitive group of SNS effer‑
ents, is presumably the most crucial for long‑term physiological regulation of BP and it 
seems, that in hypertensive humans, the rise in the activity of barosensitive sympathetic 
efferents is not restricted to renal nerves but is generalized,8, 12, 14‑16 partly explaining 
the cluster relationship held by HTN and other metabolic disturbances. Regardless 
of the organs or tissues they innervate, they show continues ongoing activity at rest 
(the sympathetic tone) and they discharge in burst synchronized with arterial pulse 
and respiration, being responsible for short term fluctuation of BP.10, 17, 18 They control 
the heart, the release of NE from adrenal gland, constricting resistance arterioles, the 
kidneys, increasing renin secretion, tubular sodium reabsorption and renal blood flow, 
most likely, exerting a long‑term control on BP.12, 19 
Atrial stretch or volume expansion has a strong inhibition effect on the renal SNS 
efferents. It appears that the selective control of renal SNS efferent by volume recep‑
tors, might be the most important of these differential regulations mechanisms.12, 19
The afferent limb of this loop reflex mechanism involves mechanoreceptors acti‑
vated by distension of the arterial wall. An increase in BP activates those receptors, 
inhibiting cardiac, renal and vasomotor sympathetic efferents, restoring BP to previ‑
ous values, and so helping to damp short‑term BP fluctuations.8, 9 This system may 
also be reset, through neural and humoral mechanisms, still largely unexplored, allow‑
ing higher BP values without reduction in reflex sensitivity, for example, circulating 
and brain derived angiotensin II can reset these reflex mechanism.8, 9 External, chronic 
electrical activation of this baroreceptor was associated to a reduction of neurohor‑
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monal indicators of sympathetic activity, namely NE and angiotensin II and with a pre‑
sumed increase in survival,7, 20 but apparently had little influence on long‑term control 
of BP.8, 21
Besides its nearness in the carotid bifurcation, the “road” into the brain, there is 
a close interaction between baroreceptors and chemoreceptors in the control of sym‑
pathetic activity, whereby the baroreflex activation is inhibitory and the chemoreceptor 
reflex is excitatory. Besides this contra regulatory action, there is a facilitator effect 
between them, whereby a reduced baroreceptor activity will enhance the chemore‑
ceptor response.7, 18 These reciprocal sensory modulation, exerted by baroreceptors 
and chemoreceptors, are beneficial in states of circulatory collapse and shock. When 
severe hypotension and hypoxia coexists, they mutually enhanced sympathetic drive 
and ventilation helping to overcome the crisis.
role of sympAtHetic nerve system on renAl function
the role of kidneys in long‑term regulation of BP, is mandatory in any discus‑
sion addressing this subject. The pressure‑natriuresis relationship described several 
years ago by Guyton,22 established that any increase in sodium retention produced 
an initial blood volume expansion, increasing cardiac output and therefore BP. The 
resulting peripheral tissues overperfusion leads to an increase in peripheral resis‑
tance, returning cardiac output towards normal. Accordingly, a reset of the pressure 
natriuresis relationship, establishing a new BP homeostatic set‑point, inevitably lead 
do HTN, regardless of the cause of the resetting. But we need to address the fact, not 
known at the time, that volume expansion also promotes atrial stretch and activation of 
baroreceptors located there, and subsequently to a selective inhibition of renal SNS 
activity.12, 19
Renal sympathetic nerve terminals innervate the three major renal neuroeffectors, 
directly influencing renal tubular function, glomerular flow rate (GFR) and renal blood 
flow, with a clear impact in all major components of renal function. Renal sympathetic 
efferents are in direct contact with the peritubular basement membrane, of all renal tubu‑
lar segments (α1A‑drenoreceptors), as well as the juxtaglomerular granular cells affect‑
ing renin secretion (β1‑adrenoreceptors) and renal arteries (α1A‑drenoreceptors). This 
control is frequency dependent, with increases in renin secretion rate without changes 
in urinary sodium excretion, renal blood flow and GFR at low frequencies. At slightly 
higher frequencies, the increase in renin secretion is associated with an increase in 
tubular sodium reabsorption, still without changes in renal blood flow and GFR.12 Much 
higher frequencies will decrease GFR and renal blood flow, maximizing renal ability 
to reabsorb sodium and water. Besides, additional neurophysiological renal studies 
support the existence of functionally specific renal sympathetic nerve fibers for each 
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neuroeffector, making the overall system more powerful and precise, in controlling the 
body sodium contends and thus BP.12 
We can assume that the coupling of regulation of total body fluid volume to 
arterial blood pressure, depends on kidney’s ability to excrete sodium in such a way 
as to achieve sodium internal balance in face of varying sodium intake, through the 
Guyton’s pressure natriuresis mechanism.22 Any defect on the kidney’s ability to main‑
tain this balance results in an increase in arterial pressure. The observation in various 
animal experiments,12 that renal denervation prevents or delays the onset of HTN, 
implies that an increase in renal sympathetic activity, may be a final common pathway 
required for a defective renal sodium excretion, leading to development and mainte‑
nance of HTN.
HumAn sympAtHetic nerve system Assessment
Until the early 70s, the most commonly used method to assess SNS activity, 
was blood measurements and urine excretion rates of NE and its derivate, a gross esti‑
mation of whole‑body sympathetic activity at best.23 Meanwhile, new methodologies 
emerged for measuring sympathetic nerve firing rates in subcutaneous nerves and for 
assaying the concentration of sympathetic transmitters in plasma.
Microneurography, a technique reported first by Hagbarth24, provided a tool 
to study sympathetic nerve firing in subcutaneous tissue and skeletal muscle vessels, 
through tungsten electrodes inserted in the skin. It records burst of nerve activity, syn‑
chronous to heart‑beat, generated by sympathetic efferent nerves. Highly reproducible 
and closely related to sympathetic traffic directed to other structures, it can be repeated 
over time, although painful, it allows the assess of interventions effects and direct quan‑
tification of sympathetic nerve traffic and vasomotor tone.
The spillover technique, a measurements of sympathetic NE transmitter 
release, first applied by Esler et al25, this isotope dilution method calculates the clear‑
ance and spillover of NE, using an infusion of tritium labelled NE administered intra‑
venously. The close relationship between the sympathetic nerve fibres firing rate of 
an organ and the rate of NE spillover into the venous effluent of that organ provides 
the rational for using measures of regional NE release as a surrogate of sympathetic 
tone in individual organs,26 allowing the assessment of regional SNS function in 
humans.
This technique was on the forefront in proving the concept that heart failure 
patients, had sympathetic overactivity rather than sympathetic denervation, as initially 
thought, and opened the way to the routine use of betablockers in heart failure.27 
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sympAtHetic nerve system over Activity
Besides its central role in cardiovascular homeostasis, controlling the vascular 
tone through vasoconstriction of small resistance arteries, the SNS also interferes and 
regulates numerous other physiological processes (Table 2). 
Table 2: Effects related to increased sympathetic nerve activity
Vascular
Smooth muscle cell hypertrophy and proliferation
Endothelial dysfunction and damage
Arterial stiffness
Posture blood pressure control impairment and syncope
Hypertension
Atherosclerosis
Cardiac
Myocyte hypertrophy
Left ventricle hypertrophy
Arrhythmia
Psychogenic heart disease 
Renal Effects
Renal artery vasoconstriction
Sodium and fluid retention
Microalbuminuria
RAAS activation
Metabolic Effects
Insulin resistance
Dyslipidemia
There is growing evidence that sustained chronic changes in SNS activity are 
involved in the pathogenesis of many diseases states, ranging from metabolism to 
psychological disorders, including ischemic heart disease28, chronic heart failure,29, 30 
HTN31‑33, kidney disease34, type II diabetes35, obesity35, metabolic syndrome35, obstruc‑
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tive sleep apnoea36, depression to inflammatory bowel disease.37, 38 A chronically over‑
active SNS is well known to worsen prognosis in patients with heart failure and end‑
stage renal disease39, 40.
Supported by accumulating scientific evidence41 is the fact that deleterious effects 
on vessels and myocardium, by an overactive SNS is independent of BP. Chronic SNS 
activation can cause hypertrophy and proliferation of vascular smooth muscles cells, as 
well as a direct trophic effect on cardiac myocytes with an increase on left ventricular 
mass (LVM) and wall thickness, without an increase in BP.41 The combined structural 
changes on the myocardium and the direct effect of an overactive SNS, is a major con‑
tribution to the high incidence of arrhythmias commonly seen in this patients.42 
Virtually all cardiovascular conditions and diseases, in which an increased adren‑
ergic drive is involved are also characterized by endothelial dysfunction.43 Nitric Oxide, 
one of the most important endothelial function mediators, is also an important neu‑
rotransmitter cooperating in the autonomic regulation of cardiovascular function, act‑
ing as a sympathetic‑inhibitory substance within the central nerve system44. Acute and 
chronic increases in SNS activity, through endothelial dysfunction and endothelial cell 
damage, have been proven to contribute to subsequent development of atherosclero‑
sis. 37, 41, 43
SNS overactivity has also been linked to the development of metabolic distur‑
bances, such as insulin resistance and dyslipidemia.45 Not only, an increased SNS 
activity can itself led to insulin resistance, particularly in hypertensive patients,45 but 
also elevations in circulating insulin levels, from insulin resistance in obese patients, can 
precipitate an increase in SNS activity leading to HTN.41, 45, 46. 
sympAtHetic nerve system And essentiAl Hypertension
From the 1930s, surgical sympathectomy appeared to be very efficacious in low‑
ering high BP and improving the clinical outcome in patients with severe HTN,47, 48 but 
its poorly tolerated side effects and high surgical risk led to his abandon, especially 
after the appearance of ganglion blockers, the first efficacious antihypertensive drug 
class.49
The critical role of SNS in the pathogenesis of HTN, other cardiovascular diseases 
and disturbances, is unquestionable, but the existing complex and clinically impractical 
methodology, to assess the activity of SNS in humans, makes it difficult to adequately 
establish a relationship between SNS activity and HTN in a particular patient, a major 
reason why the SNS was so neglected until now. 
A well‑known consequence of an overactive SNS is an increase in BP. Renal 
sympathetic nerve activity is pivotal in the pathogenesis of essential HTN, through influ‑
ences on renin release, sodium and water excretion, peripheral vasoconstriction, car‑
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diac contraction and venous capacitance.37 In previous studies, increased sympathetic 
outflow to kidneys were related to the magnitude of essential HTN.31, 33, 37, 50 Renal spill‑
over measurement, of sympathetic outflow to kidneys, in patients with HTN, revealed 
that more than 50% of them, had significant sympathetic hyperactivity.51 
resistAnt Hypertension
Treatment‑resistant HTN is defined as a BP persistently above 140/90 mm Hg 
and 130/80 mm Hg for patients with diabetes and renal disease, despite the prescrip‑
tion of three different antihypertensive drug classes, of complementary mechanism of 
action, at appropriate doses, preferably including a diuretic.52 Patients in this category 
might have pseudo‑resistance, that should be identified and differentiated from true 
resistance.
Pseudo‑resistance, comprising around 50% of patients claimed as having resis‑
tant HTN, includes those with inadequate treatment regimens, suboptimal adherence 
to medication and inadequate clinical BP measurements.53 
Several factors can lead to true resistant HTN, and must be addressed appropri‑
ately (Table 3).54 Inappropriate levels of aldosterone are seen in up to 20% of patients 
with resistant HTN, whether or not, an adenoma is present. On such patients, aldoste‑
rone antagonists may provide relevant additional BP reduction.54
Table. 3: Factors leading to resistant hypertension.
•  Obesity
•  Male gender
•  Older age
•  African‑American
•  Insulin resistance
•  Volume overload
•  Renal dysfunction
•  Exogenous drugs
Modified from: Masserli FH et al. Lancet 2007 Aug 18;370(9587):591-603
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The prevalence of resistant HTN has been reported to be between 5 and 30%. 
This prevalence differs accordingly to the hypertensive population being studied and 
the methods used in BP assessment, with higher percentage of patients with resistant 
HTN in cohorts from centres specialized in the treatment of HTN as compared to gen‑
eral community based cohorts.55‑57 Recent evaluations on the prevalence of resistant 
HTN, especially if 24‑hours ambulatory blood pressure measurement (ABPM) is used, 
points to rates less than 10% of all hypertensive patients.58
In Portugal, data from the PHYSA study involving 3720 adults patients, the prev‑
alence of HTN was 42%, of which 76.6% were aware of the fact, 74,9% were treated 
and only 42,5 had their BP values below the recommended thresholds.59 
Patients with resistant HTN, namely true resistant HTN exhibit a worst prognosis 
with a higher risk for cardiovascular events, when compared to hypertensive patients 
without resistant HTN.60, 61 
In face of the available clinical studies, patients considered to be good candi‑
dates for RDN should have severe true resistant HTN, defined as office systolic BP of 
at least 160mmHg BP of at least 160 systolic (150mmHg in type 2 diabetes). 62‑64 
renAl denervAtion
The finding that sympathetic renal activity was increased in spontaneous 
hypertensive rats, the animal model most used in essential HTN research, was 
of paramount for the role of renal SNS on HTN pathogenesis.65 In an experimen‑
tal model of HTN and obesity in dogs submitted to a high fat contend diet, RDN, 
not only prevented the appearance of HTN but also increased in 50% the urinary 
sodium excretion.66 In another animal model with chronic renal failure, sympathec‑
tomy prevented HTN and was associated to a decrease in the activity of the central 
adrenergic nucleus.67
Renal lesions induced by phenol injection, without changing the GFR, was 
linked to a sustained rise in HTN and NE release by the hypothalamus. RDN of 
those animals prevented the rise on BP.68 In different animal models, the effect of 
RDN has consistently showed the important role of renal SNS in the pathophysiol‑
ogy of HTN.
In humans, surgical sympathectomy exhibited a high efficacy in lowering high 
BP and improving the cardiovascular prognosis of patients with severe HTN.47‑49, 
69‑71 Its poorly tolerated side effects, such as: severe orthostatic hypotension, anhi‑
drosis, bowel disturbances and sexual dysfunction, led to its abandon. Neverthe‑
less, it has reinforced the important link between the SNS and the mechanisms 
controlling BP.
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clinicAl studies on cAtHeter bAsed sympAtHetic renAl 
denervAtion
Since 2009, several clinical studies were published describing the effect of cath‑
eter based RDN for the treatment of resistant HTN (Table 4). The Symplicity HTN‑172, 
a proof‑of‑principle study, was the first to evaluate the effects of RDN on patients with 
severe resistant HTN. One year after the procedure, the office BP decreased on aver‑
age 27 mmHg for the systolic and 17 mmHg for the diastolic, and this was sustained 
until 24 months of follow‑up, with 13% of non‑responders to RDN therapy73. A sub‑
group analysis targeting the renal and systemic sympathetic activity, revealed an aver‑
age reduction of 42% in renal NE spillover on these patients.73
The Symplicity HTN‑2 study,74 a multicenter clinical trial, randomized 106 patients 
with severe resistant HTN under medication to optimal antihypertensive medical ther‑
apy alone or in association with RDN, with the primary endpoint of changes on office 
BP at 6‑month follow‑up. The results revealed a significant decreased on office BP, in 
patients submitted to RDN, 32 mmHg on systolic BP and 12 mmHg on the diastolic 
(p<0.01), compared to an increase in 1 mmHg on systolic BP and a no change on 
diastolic BP (p=NS), observed in patients under optimal medical therapy alone. A 
subgroup analysis regarding ABPM measurements, revealed a similar behavior, a drop 
of 11mmHg on systolic BP and 7mmHg on diastolic BP, in the RDN group (p<0.001) 
compared to a drop of 3mmHg and 1mmHg respectively, in the medical therapy alone 
group (p=NS). The magnitude of the decrease in BP, between the RDN treated group 
and the optimal medical therapy alone group was maintained at 12 months follow‑up.73
Alongside its efficacy, RDN was a very safe procedure. On both studies, only 
minor vascular complications occurred, mainly at the puncture site, haematomas, 
pseudoaneurysms and one renal artery dissection during the diagnostic procedure, 
successfully treated with a stent, all without sequalae. Regarding renal function, no 
significant changes on GFR occurred during follow‑up. No major complications were 
identified during the follow‑up.62, 75
Using a different RDN device, the EnlightHTN I study64 also revealed a significant 
decrease in BP measured by office and by ABPM, at 6 months, with a remarkable 
safety profile.
The available published scientific data supports an excellent safety profile on 
short term, although the risk of renal artery stenosis on long term is still lacking.
The results from the simplicity HTN 1‑2 trials and EnlighHTN I trial were very prom‑
ising, nevertheless, their open control design made impossible to properly address the 
important bias made by the placebo effect on BP measurement, in either study groups. 
Some of those limitations were addressed in the Symplicity HTN3 Trial.76 
In the Symplicity HTN 3 clinical trial,77 a larger randomized study, to evaluate 
RDN for treatment of resistant HTN, the design included for the first time a sham con‑
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trol‑group. On the primary endpoint, the change on office systolic BP from baseline to 
6‑month follow‑up, between the RDN (n=353) and the sham control arm (n=171), the 
obtained average difference of ‑2.39mmHg between the 2 groups on office systolic 
BP, didn’t achieved statistical significance (95% CI: ‑6.89 to 2.12, p=0.26), with an 
average reduction of 14.1 mmHg on office systolic BP reduction in the RDN arm vs 11.7 
mmHg reduction in the sham control arm.
In the secondary endpoint, the change on the mean systolic BP from baseline to 
6‑month follow‑up, measured by ABPM, between RDN and the sham control arm, a 
statistically non‑significant difference of 1.96 mmHg (95% CI: ‑1.06 to 4.97, p=0.98) 
was achieved, with a systolic BP reduction of 6.8 mmHg in the RDN arm vs 4.8 mmHg 
reduction in the control arm, at 6‑month follow‑up.
The rate of major adverse events at 6 months, was very low, 1.4% in the RDN arm 
vs 0.6% in the sham control arm, much less than the 9.8% prespecified as the target 
for major safety events incidence. So, the primary safety endpoint was met, for a differ‑
ence of 0.8% (95% CI, ‑0.9 to 2.5; p=0.67).
Table 4: Main studies and trials about catheter based renal denervation. 
Study Symplicity-HTN 1 72 Symplicity-HTN 2 74 Symplicity-HTN 3 77 EnligHTN-1 64 RAPID 101
REDUCE HTN 
FIM102
Device
RF Single electrode
(Symplicity®)
RF Single 
electrode
(Symplicity®)
No renal 
denervation
RF Single electrode
(Symplicity®)
No renal 
denervation (sham)
RF multielectrode 
(EnligHTN®)
RF balloon 
(OneShot®)
RF balloon 
(Vessix®)
Total number of patients in study/patients 
in RDN arm
47 / 47 52 54 564 171 46 50 41
Randomized No Yes Yes No No No
Sham control No ‑ No ‑ Yes No No No
Blacks (%) 4* 2* 4* 2,2* NA 7.3
Mean baseline office Systolic BP (mmHg) 177 ±20 178 ±18 178±16 179±16 180±17 176 181.6 ± 20.8 183±18.1
Mean number BP drugs 4.7±1.5 5.2±1.5 5,3±1,8 5.1±1.4 5.2±1.4 4.1±0.6 4.9 5.1±1.7
Aldosterone blockers (%) NA 17 17 22.5 28.7 13 22 26.8
Office systolic BP change at 6 months 
(mmHg)
‑22 ‑32±23 1±21 ‑14.1±23.9 ‑11.7±25.9 ‑26 ‑20 ‑27.6
ABMP systolic BP reduction at 6 months 
(mmHg)
‑11** ‑11±15 ‑3±19 ‑6.8±15.1 ‑4.8±17.2 ‑10 ‑11 ‑8.5
Rate of responders, ≥10mmHg change in 
office systolic BP from baseline 
87% 84% 35% 58.3% 48.5% 80% 62 85%
RF: radiofrequency; NA‑ not available; **** Defined as non‑whites; Only 9 RDN responder patients had adequate ABPM at         baseline and longer than 30 days, follow‑up.
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These conflicting results between the Symplicity HTN 377 and the previous 
Symplictity studies, HTN‑172 and Symplicity HTN‑274, were intensely analysed and 
discussed. Many factors were identified has being potentially related to the unex‑
pected results. Among others, differences in the selected population with the inclu‑
sion for the first time of a large group of African American patients (24.8% of blacks 
on RDN arm and 29.2% on control arm), a population well known to be resistant to 
RAAS system blockers that could have a negative impact on RDN efficacy, indeed a 
subgroup analysis revealed a statistical significant difference favouring RDN arm, in 
non‑African‑American patients.
A likely technical procedural variability, due to the high number of recruiting 
centres in HTN‑3,77 with a low case load per operator, three procedures on average 
(most of them did their first and only case of RDN) were also implied. It may help 
to explain. the puzzling fact in HTN 377, of a smaller decrease in office systolic BP 
from baseline to 6 months in the RDN arm, about half of that observed in the RDN 
group in Symplicity HTN 274, despite similar baseline BP in the two studies. Such 
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discrepancy fired doubts, if the radiofrequency shots were properly delivered, in the 
renal arteries. 
A more aggressive antihypertensive therapy and the requirement that no changes 
could be made in the first 6 months after the procedure. Overall, the antihypertensive 
medication was more intensive than in previous studies, probably reflecting the more 
severe hypertensive patients included.
The presence for the first time of a sham procedure, in the control arm (a renal 
angiography was performed in all patients, before randomization) could eventually had 
increased the placebo effect.
The regression to the mean effect78, a more aggressive antihypertensive ther‑
apy allied to a bigger placebo effect, by the sham procedure may well explain the 
larger decrease in BP observed in the HTN 377 sham control‑group, compared with the 
much smaller decrease in the HTN 274 control group, and subsequently the lower than 
expected difference between the RDN‑treated and sham control groups, in HTN 377. 
Altogether, these facts may have played a major role on HTN 377 final results.
The inability to assess if renal SNS was in fact denervated by the procedure, 
because there is no test available able to do it, is a major limitation to this and to almost 
all the clinical studies performed until now.
Even though Symplicity HTN 377 follow‑up will continue as planed out to 5 years, 
the fact that patients were allowed to cross‑over from the sham‑control to the RDN arm 
at 6 month follow‑up, will make more difficult to drive significant conclusion on the long‑
term clinical results of RDN therapy, if not impossible, even to evaluate the long term 
impact of the sham placebo effect.
The Symplicity HTN 377 trial was a landmark study in the development of RDN 
treatment, driving the development of a new set of industry sponsored proof of concept 
trials, like the Spyral HTN ON‑MED and OFF‑MED trials.79 Such trials were designed to 
demonstrate the ability of RDN to influence BP in uncontrolled HTN, addressing some 
of the confounding factors identified from HTN‑377, such as drug changes, the patient 
adherence to drug therapy; the heterogeneity in studied population and the procedural 
variability. The recently published Spyral HTN OFF‑MED Trial80 addressed some of 
those non‑resolved issues from previous trials and proved the biological effect of RDN 
without the confounding factor of medication.
The Spyral HTN OFF‑MED Trial80 was an international, multicentre, randomized, 
blinded, sham controlled trial on RDN for the treatment of patients with HTN, in the 
absence of any antihypertensive medications. It was aimed to confirm the basic hypoth‑
esis that RDN therapy lowers BP in patients with HTN, without drug treatment, exclud‑
ing in such way the most important confounding variable in previous trials ‑ drug therapy.
Prior to randomization, patients had to undergo an antihypertensive medication 
washout period of three to four weeks. The trial was intended to isolate the effect of 
RDN on BP reduction as requested by both the US Federal Drug Administration and 
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the medical community. Key eligibility criteria included patient either on no antihyperten‑
sive medications or allowing discontinuation of drug therapy, or office systolic BP ≥ 150 
and < 180 mm Hg, or office diastolic BP ≥ 90 mm Hg or ABPM mean systolic BP ≥ 140 
and < 170 mm Hg. As on previous trials, patients with an ineligible renal artery anatomy, 
eGFR < 45 mL/min/1.73m2, type 1 diabetes mellitus or type 2 diabetes mellitus with 
HbA1C > 8.0%, and secondary causes of HTN were excluded. 
The device used was the Spyral Catheter© (Medtronic™, Santa Monica), a flexi‑
ble multi‑electrode catheter with a quadrantic vessel contact for simultaneous ablation 
in up to 4 electrodes, 90º apart, with a 60‑second simultaneous energy delivery, allow‑
ing renal branch treatment. The trial randomized 80 patients, 42 in the RDN group and 
38 in the sham control group. The primary efficacy endpoint was the BP reduction 
based on ABPM measurements, from baseline to 3‑month follow‑up, between RDN 
arm (n=38) and the sham control arm (n=42). At follow‑up, a reduction of 5.5mmHg 
on systolic BP (95% CI: ‑9.1 to ‑2.0, p=0.003) and of 4.8 in diastolic BP (95% CI: ‑7.0 
to ‑2.6, p=0,<0.0001) occured in the RDN group against a reduction of 0.5mmHg on 
systolic BP (95% CI: ‑3.9 to ‑2.9, p=0.76) and of 0.4 in diastolic BP (95% CI: ‑2.2 to 
‑1.4, p=0,65), in the sham control group. The blinding index was 0,65 at discharge and 
0,59 at 3‑months, indicating a proper blinding.
Once again, the RDN safety profile was outstanding, with no major procedural or 
clinical safety events observed throughout the 3‑months follow‑up: no deaths, no myo‑
cardial infarctions, no stroke, no major bleeding, no serum creatinine elevation greater 
than 40%, no embolic events, no vascular complications, no renal artery re‑interven‑
tions or hypertensive crisis.
The Spyral HTN OFF‑MED study80 allowed the biologic proof of principle for the 
efficacy of RDN, in mild to moderate hypertensive patients, in the absence of anti‑hy‑
pertensive medications, with a Clinically meaningful reduction of BP at 3 months, com‑
pared to the sham control group. As in previous trials, no major safety events occurred, 
despite a more complete denervation procedure that extended into the branches of 
renal arteries. Nevertheless, two major limitation need to be pointed out, the Spyral 
HTN OFF‑MED80 was a proof of concept trial, not powered for statistical significance; 
in addition, as in previous trials, there were no direct assessment of SNS activity before 
or after the procedure to verify the extend of nerve trafficking damages.
new devices for renAl denervAtion
A high expectations and enthusiasm was created in the medical community, driv‑
ing many device companies to develop new and improved technical solutions for RDN 
(Table 5).
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From predicable improvements of the original procedure to out of the box ideas, 
many innovations are being integrated in the new designs: a) alternative mechanisms 
of action, like ultrasound catheters and balloons with microinjection systems to deliver 
neurotoxins; b) simultaneous activation of multi‑electrodes, able to shorten significantly 
the procedural time and to increases reproducibility, guaranteeing that all quadrants 
are adequately denervated; c) radial artery access to reduce vascular complications, 
making the procedure less demanding, as manipulating renal catheters from a cra‑
neo‑caudal approach is generally easier and safer; d) radiofrequency catheters with 
bipolar electrodes and cooling systems, with their smaller precise electric field during 
Table 5: Catheter based sympathetic renal denervation devices.
Company Medtronic Medtronic St. Jude Maya/Covidien ReCor Medical Boston Scientific Terumo Cordis
Product Symplicity Flex™ Symplicity Spyral™ EnligHTN™ OneShot™ Paradise™ Vessix V2™ Iberis™ Renlane™
Catheter Size 6 F 6F 8F 9F 6F 8F 6F 6F
Energy Type Radiofrequency Radiofrequency Radiofrequency Radiofrequency Ultrasound Radiofrequency Radiofrequency Radiofrequency
Catheter design
Single electrode
Monopolar
Multielectrode (4)
Monopolar
Multielectrode
Monopolar
Multielectrode
Monopolar
Irrigated
Ultrasound Balloon 
with cooling
Multielecrode
Bipolar
 non‑compliant  
balloon
Single Electrode 
Monopolar
Multielectrode  
Monopolar
Over Wire No yes no yes yes yes   No no
Energy delivery time 2 min 1 min 1 min 2 min 5 min 30 sec 2 min 30 sec
Total treatment time 16‑24min 2 min 4 min 4 min Unknown 2 min 16‑24 min Unknown
Vessel Obstructtion No no no yes yes yes No no
Trials 
Symplicity HTN172
Symplicity HTN 273
Symplicity TN377
FIM103 EnligHTN‑164 RHAS101
PARADISE104
REALISE105
Reduce HTN102 ‑ RENABLATE I106
ABMP systolic BP reduction at 6 months 
(mmHg)
‑11** ‑11±15 ‑3±19 ‑6.8±15.1 ‑4.8±17.2 ‑10 ‑11 ‑8.5
Rate of responders, ≥10mmHg change in 
office systolic BP from baseline 
87% 84% 35% 58.3% 48.5% 80% 62 85%
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activation, they produces less heat and tissue burning, creating adequate nerve dam‑
age and much less pain and discomfort.
The absence of a method allowing intraprocedural assessment, of the degree 
of renal SNS damage and subsequent decrease in its activity, is a major limitation, 
of all devices under development. In such scenario, procedural success is difficult to 
determine and correlate with BP changes or HTN related target organ damages (TOD) 
response. Many efforts are being made in the search for a biomarker or physiologic 
test allowing a precise control over RDN procedure and renal sympathetic trafficking 
modulation.
Table 5: Catheter based sympathetic renal denervation devices.
Company Medtronic Medtronic St. Jude Maya/Covidien ReCor Medical Boston Scientific Terumo Cordis
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future indicAtions for sympAtHetic renAl denervAtion
The probable decrease on the overall SNS activity after RDN, may therefore make 
RDN, a valid alternative in clinical scenarios characterized by an increased SNS activity, 
other than resistant HTN. Some of these alternative applications, have already been 
explored with promising results.
The association between heart failure and an increased sympathetic drive is well 
known. Interestingly, cardiac and renal spillover of NE are more closely related with car‑
diovascular mortality than circulating catecholamine concentrations, although both are 
related to worst outcomes.27, 81 This provides evidence that reducing NE spillover from 
the kidney could have a beneficial symptomatic and prognostic effects.82, 83 
In animal models, RDN after myocardial infarction showed an improvement 
on sodium excretion84, increased cardiac output, improved renal blood flow85 and a 
down‑regulation of angiotensin AT1 receptors mediating maladaptive responses.86 In a 
multicentre study involving patients with resistant HTN treated by RDN, a subgroup with 
left ventricle (LV) dysfunction, with their anatomic and functional myocardial parameters 
assessed by magnetic resonance, had their ejection fraction and circumferential strain 
significantly increased, after RDN.87
In heart failure, the REACH pilot study provided evidence that RDN was able to 
improve the 6 min walk test results without affecting BP (average 120 mmHg at base‑
line).88 Ongoing clinical trials will provide further evidence on the potential of RDN, to 
influence the course and outcome of heart failure.
Type two diabetes and insulin resistance are other diseases with a strong asso‑
ciation with resistant HTN. About 50% of resistant HTN patients are considered to 
be insulin resistant, an increased risk for type II diabetes and since insulin resistance 
is dependent on sympathetic activity, it appears likely that it could also be a target for 
RDN.89, 90 In a pilot study, along with BP reductions, RDN improved fasting glucose, 
insulin, and C‑peptide concentrations as well as insulin sensitivity indices, in patients 
with resistant HTN and metabolic disease, suggesting that RDN might improve diabetic 
status on those patients.91 Witkowski et al. showed a decline in glycated hemoglobin 
concentrations after RDN.92 
Association between obstructive sleep apnea and resistant HTN is well known.92 
In 2011 Witkowski et al, published a pilot study on the effect of RDN in 10 patients 
with resistant HTN and obstructive sleep apnea. At 6 month after RDN, there was 
an improvement on apnea‑hypopnea indexes.92 In an experimental model, it has been 
shown that RDN reduces the post‑apneic BP rise, the renal hypoperfusion during 
apnea and activation of the RAAS system in the kidney.93, 94 The value of these findings 
is still controversial and confirmatory studies are needed.
In an animal model95 for obstructive sleep apnea and induced atrial fibrillation, 
RDN, decreased the atrium refractory period and the recurrence of atrial fibrillation,93 
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providing a better rate control.96 In another pilot trial, patients with resistant HTN and 
symptomatic paroxysmal or persistent atrial fibrillation, refractory to ≥2 antiarrhythmic 
drugs, were randomized to pulmonary vein isolation only or associated with RDN. At 
12‑month follow‑up, 69% of patients treated with RDN were free of atrial fibrillation in 
comparison with 29% of patients treated with pulmonary vein isolation only.97 These 
experimental findings support the potential usefulness of RDN on atrial fibrillation treat‑
ment. 
The scientific evidence supporting the pivotal role of SNS activity on the patho‑
physiology of ventricular arrhythmias is overwhelming. In an animal model of isch‑
emia‑reperfusion induced arrhythmias, RDN decreased the occurrence of ventricular 
arrhythmias and attenuated the rise in LV end diastolic pressure during LV myocardial 
ischemia, with no influence on infarct size, on ventricular contractility, on BP or on 
reperfusion arrhythmias.98 In small case series, of patients with dilated cardiomyopathy 
and electrical ventricular storm, RDN was able to reduce discharges from the implant‑
able cardioverter defibrillators and ventricular ectopies.99 Hoffmann et al.100 reported 
that RDN can be performed safely and effectively, as an adjunct to cardiac catheter 
ablation, in a hemodynamically unstable patient with ventricular storm after ST elevation 
myocardial infarction.
Even though preliminary findings, the biological plausibility underneath them and 
the promising results, will certainly rise the interest for RDN on those new clinical sce‑
narios.
conclusion
It seems now evident and well accepted, that an overactive sympathetic nerve 
system has a pivotal role in the pathophysiology of several diseases, besides essen‑
tial hypertension. All those clustered conditions like depression, mental stress, hyper‑
tension, diabetes, obesity, sleep apnea, metabolic syndrome, ischemic heart disease, 
heart failure and chronic kidney failure, have all a common “missing link”, the forgotten 
hyperactive sympathetic system. In this new era, with newer tools to control and treat 
effectively the sympathetic hyperactivity, it seems that this system will have finally, the 
long‑deserved attention.
The inability to effectively treat hypertension is due in part to a lack of understand‑
ing over the fundamental mechanism involved in blood pressure control. A complex mix‑
ture of hormonal, neural and intrinsic factors, all acting together, in different time scales 
and different feedbacks control pathways, and it seems unlikely, that any of the current 
treatment approaches is targeting altogether, the main factors that lead to hypertension. 
In patients with hypertension, catheter based renal denervation is a truly innovative 
approach to treat hypertension. This technique was able to significantly reduce blood 
22
SYMPATHETIC RENAL DENERVATION FOR RESISTANT HYPERTENSION
pressure, as well as sympathetic nerve activity and norepinephrine spill over, with high 
safety standards. Those achievements are well documented on several international 
multicentre trials.
Alongside with its proven efficacy in blood pressure reduction, its plausible ability 
to improve insulin resistance, diabetes, left ventricular mass and proteinuria, a cluster of 
known risk factors acting altogether in the pathophysiology of atherosclerosis, may act 
as an added value to be consider at any time a strategy is chosen to treat hypertension.
Nevertheless, there are still, important limitations that need to be properly 
addressed in the future, like the impossibility to determine if the denervation procedure 
was effective, or which patients have a suitable phenotype to renal denervation, or what 
are the proper endpoints to define as successful a treatment strategy for hypertension, 
just blood pressure reduction or it should include other endpoints such as improvement 
in target organ lesions and other known risk factors.
Certainly, much has to be done and will be done, in the next years, but for sure 
a new window has been open not only to address hypertension but most of all, to 
address sympathetic system dysfunction.
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summAry
In the last fifty years, albeit all efforts, anti-hypertensive drugs and the large scien-
tific evidence supporting their use, the number of hypertensive patients with controlled 
blood pressure remains very low. True drug resistance and low treatment adherence 
from patients are major causes for such failure. In addition, some of the underlying 
mechanisms that play a major role in the pathophysiology of hypertension were not 
properly addressed until recently.
The recent development of newer catheter-based devices to tackle sympathetic 
hyperactivity, through the denervation of renal sympathetic nerves, opened newer per-
spectives to be explored in current clinical practice.
Current drug treatment-based strategies, with their different drugs, targets and 
mechanism of action, interacting with each other, makes the final biological results, 
more difficult to track and to account as a direct effect of a specific mechanisms of 
action. Contrary, device-based strategies, such as renal denervation, acts solely by 
interfering with the renal input and output of sympathetic nerve traffic, making possible 
to better identify human biological responses as a solely consequence of such inter-
ference.
Until now, the prevailing theory is that a chronic rise in blood pressure has a per-
sistent direct negative impact on specific organs, namely the heart, the arterial walls 
and the kidneys, driving the mechanisms for damaging the left ventricle (hypertrophy, 
diastolic dysfunction) and the kidneys (proteinuria and kidney failure). In such setting, 
drug trials commonly used as surrogates off drug-treatment efficacy, changes in office 
blood pressure or in 24-hour ambulatory measurement. Very rarely, they add other 
endpoints such as the impact on target organs damages of hypertension. Contrary, 
the aim of this project is to evaluate in patients with severe drug resistant hyperten-
sion, refractory to drug treatment, the impact of renal denervation beyond changes on 
blood pressures, looking for changes on hypertension related target organ damages, 
such as on left ventricle function and morphology and on renal function, both as 
surrogate markers of treatment efficacy, a midpoint for the reduction of major clinical 
events.
The purpose of this chapter is to list and discuss possible unmet medical needs, 
in todays, hypertension treatment strategies, that may justify the need to newer treat-
ment approaches, such as renal denervation, since this treatment strategy might 
become a better alternative either alone or combined to drug treatment, for patients 
with hypertension.
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limitAtions of previous tHerApeutic strAtegies on blood 
pressure control
HTN has a well‑established and strong association with myocardial infarction, heart 
failure, stroke and end‑stage renal disease, making it the leading global risk factor for car‑
diovascular mortality.1, 2 Effective BP lowering consistently reduces overall cardiovascular 
risk3. Still the rates of adequate BP control remains suboptimal, despite the large amount of 
available antihypertensive drugs and the strong scientific evidence supporting their use4. 
As previously described, resistant HTN is defined as a BP persistently above 
140/90 mmHg or 130/80mmHg for patients with diabetes or chronic renal disease, 
under treatment with at least three antihypertensive drugs, of different classes of 
complementary mechanism of action (one of which must be a diuretic), on adequate 
doses.5 With a prevalence ranging from 5% to 30% of treated hypertensive patients it 
is an important cause for lack of success in BP control 5. These patients exhibit a worst 
prognosis, with higher risk for cardiovascular events, when compared to hypertensive 
patients without resistant HTN.6
The blame for such low rates on BP control is multifactorial. Poor adherence to 
treatment, due to drug intolerance, social and cultural reasons are important, but inade‑
quate treatment management or powerless therapy strategies are also to be blamed.7
From the two known main systems that control human BP, almost all efforts are 
targeted to the water and salt homeostasis control mechanisms, through agents bloc‑
king the RAAS axis or through diuresis, or occasionally, as second line, using agents 
that promote vascular dilatation. The role of the sympathetic system, though well known 
for a long time, was forgotten. The reason for such attitude resides in one hand, in the 
inability to measure and grade SNS activity and on the other hand, in the lack of tools 
to treat or modulate it, until now.
limitAtions of previous studies on renAl denervAtion
Compelling evidence from mid nineteen century8 and more recent clinical and 
animal models8‑12 consistently proved that RDN is efficacious as a treatment approach 
for resistant HTN, sustaining the important role of SNS system in the pathophysiology 
of HTN. 13,14,15
The recent development of a safe catheter‑based technique to decrease the renal 
sympathetic nerve traffic by radiofrequency ablation, opened a new range of possibi‑
lities including a second line of treatment for HTN, especially in patients with severe 
treatment‑resistant HTN.9, 11, 16 Alongside with its efficacy, RDN is a safe procedure with 
only minor vascular complications, mainly at the puncture site. There were no significant 
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changes on GFR during follow‑up9, 11, 16, although the risk of renal artery stenosis on 
long term is still lacking. 
Still, there are many limitations to establish RDN as a treatment of choice for HTN:
a) Identification of Resistant Hypertension. There is no reliable way to 
identify and select true resistant HTN patients for RDN treatment, mostly 
because office systolic HTN is a too simplistic criterion to properly identify 
true resistant HTN patients. In‑addition, the evaluation of drug‑treatment effi‑
cacy is frequently misleading, either due to patient non‑adherence to treat‑
ment or to inadequate or suboptimal treatment strategies. 5, 17
b) Blood pressure measurement. The recent routine use of ABPM for BP 
evaluation and longer run‑in treatment phases before patients’ selection, 
may partially overcome some of such limitations. ABPM is more robust than 
office BP measurement. It allows its recording in the entire day, with sub‑
jects engaged in their daily lives, including sleep and morning rise, avoiding 
the bias made by transient rise in BP measurements in response to medical 
environment and masked HTN, making ABPM values more reproducible, 
closer to the real BP load prevailing in patient’s daily life.17, 18 It is especially 
important in the evaluation of resistant HTN, allowing the precise definition 
of its diagnosis and excluding a significant number of patients initially wron‑
gly labelled as resistant hypertensive patients.19‑21 
ABPM has been proved to be better related to prognosis and to HTN rela‑
ted TOD.22, 23 In addition, there is significant scientific evidence, that chan‑
ges in ABPM values after treatment are superior to those obtained in office, 
to predict the effect of treatment on clinically relevant HTN related TOD 
and on its progression, such as LV hypertrophy or proteinuria.23‑25 There is a 
consensus on the superiority of ABPM to other measurements modalities, 
to determine eligibility criteria and assessment of treatment effects.17 
An important aspect of ABPM in the evaluation of a HTN treatment‑effects, is 
that BP lowering either with drugs or devices are much less pronounced when 
evaluated by ABPM than by office measurements.26 In the HTN 1 and 2 trials, 
the magnitude of the BP decrease after RDN, was 30 to 40% less in ABPM 
than in office measurements.9‑11 A possible explanation for such discrepancy 
may be that ABPM includes night‑time values, usually lower than day‑time. 
c) Patient selection. Another limitation of previous studies on RDN, regards 
the fact that they were aimed to patients with, the so called, treatment resis‑
tant HTN, defined as a BP persistently above 140/90 mmHg, under treat‑
ment with at least three antihypertensive drugs, of different classes, on ade‑
quate doses (one of which is a diuretic). The investigators were not obliged 
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to frame the drug treatment strategies during the studies, in order to reduce 
its interference in the final BP results, making more difficult to isolate the 
real RDN treatment‑effect from the broad variation induced by drug‑treat‑
ment changes.9‑11 A possible solution, besides framing by protocol the drug‑
treatment choices and changes, is to use RDN to treat patients with severe 
resistant HTN, under maximal tolerated drug treatment. It has never been 
evaluated before, to the best of our knowledge. 
Such task imposes the challenge of selecting patients with true resistant dru‑
g‑treatment HTN to maximal tolerated drug‑treatment regimens, meaning the 
failure of current best practice drug‑treatment strategies. The advantage of 
such strategy is that all patients are on maximal tolerated drug therapy. Assu‑
ming there are no remaining therapeutic options, there will be naturally less 
variation regarding changes on drugs ant treatments strategies, between 
patients. Such strategy will better help to isolate the RDN effect on BP con‑
trol, from the broad treatment variation effects that occurred in previous stu‑
dies, overcoming some of the limitations pointed‑out in previous studies.9‑11 
d) Operator experience. On previous RDN studies, there was a large dif‑
ference in experience and proficiency between RDN operators, introducing 
variability in the procedure and potentially affecting the final results.9‑11 The 
use of a restricted number of a high proficiency operators could overcome 
such limitation.
e) Endpoint selection. Previous RDN studies used as clinical endpoints, 
essentially changes in BP measurements, before and after treatment, usually 
office BP measurements and more recently, for the reasons previously dis‑
cussed, ABPM measurements. The effects on HTN related TOD, like chan‑
ges on LV structure and function or changes in renal function like proteinuria, 
were not included previously as surrogates of RDN treatment efficacy. We 
may‑say so, that they had never been tested before as surrogate markers of 
RDN treatment impact per se.
tArget orgAn dAmAge – beyond blood pressure control
HTN changes in left ventricular function and structure. Long‑standing HTN 
is known to be linked to myocardial hypertrophy, diastolic dysfunction, left atrial enlar‑
gement, atrial or LV arrhythmias, heart failure and ultimately myocardial infarction and 
stroke, but sympathetic drive is also implicated in cardiac and vascular remodeling.27‑30 
Of utmost importance, is the fact that LV hypertrophy is one of the most sig‑
nificant markers of HTN related TOD and it has been associated with an increase 
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rate of cardiovascular events, including death, independently of BP values.31‑33 So, any 
treatment able to positively change cardiac remodeling, with or without changes in 
BP values, may potentially have a favorable impact on the cardiovascular prognosis of 
patients with long‑standing HTN. 
Classically, on most studies involving HTN patients, LV hypertrophy was identi‑
fied by EKG. However, its sensitivity and accuracy to detect LV hypertrophy is at most 
moderate. Echocardiography is superior to EKG for many reasons: it can quantify LV 
hypertrophy indexed to body surface area and it can give specific and accurate infor‑
mation on LV function systolic and diastolic.34
HTN related proteinuria. Renal dysfunction, namely microalbuminuria is an 
early marker of renal damages in hypertensive patients.35 In several studies, microal‑
buminuria was observed in 17% to 46% of patients with HTN, being higher in resis‑
tant HTN.35‑38 In addition, microalbuminuria seems to be a potent “nephrotoxin” and a 
powerful predictor of cardiovascular morbidity and mortality in patients with resistant 
HTN, independent of traditional cardiovascular risk factors.37, 39, 40 Its reduction with 
HTN treatment is associated with favourable impact in cardiovascular events, rein‑
forcing the need for an early and aggressive control of BP in patients with resistant 
HTN.37, 39
Sympathetic system effects on HTN related TOD. Another powerful argu‑
ment to include HTN related TOD as markers of RDN treatment success, relies in the 
recently published results from small proof‑of‑concept studies, on RDN, showing other 
positive clinical results besides HTN, such as an increase on sodium renal excretion, 
independent of renal function and antihypertensive medications41; an improvement on 
LV mass and diastolic function42, 43; an enhancement on glucose metabolism in patients 
with resistant HTN and metabolic disease, alongside with BP reduction44, all implying 
that an overactive SNS may have a more important role in the pathophysiology of many 
disease states, than previously expected.
Indeed, a chronic SNS activation can cause hypertrophy and proliferation of vas‑
cular smooth muscles cells as well as a direct trophic effect on cardiac myocytes, 
increasing LV mass and wall thickness, even without an increase in BP.45 This structural 
changes on the myocardium and the direct effect of an overactive SNS have a direct 
contribution to the high incidence of arrhythmias, commonly seen in these patients.46 A 
chronically overactive SNS is linked to a worst prognosis in patients with heart failure 
and end‑stage renal disease. 47, 48
redefinition of tHerApeutic success of Hypertension
In HTN patients, the primary goal of treatment is to prevent major clinical compli‑
cations, cerebral, cardiovascular and renal, usually associated to long term uncontrol‑
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led HTN. To evaluate the long‑term impact of RDN on each one of these major clinical 
adverse events, trials with large number of patients and very long follow‑ups are requi‑
red. The shear cost of such studies, make them unreasonable to use in a catheter‑ba‑
sed treatment for HTN.
An alternative could be the use of surrogate endpoints, moving for a 2nd step 
towards a more robust clinical evaluation of HTN treatment efficacy (Fig. 1). 
Figure 1: Different approaches to assess HTN treatment efficacy.
Chronic high BP causes morbidity and mortality. A treatment that decreases BP 
as bean related to a reduction in morbidity and mortality. In such a context, BP changes 
after treatment, was established as the most frequently used surrogate endpoint for 
HTN treatment success, either measured on medical office, at home or using ABPM.
Other surrogates for subclinical disease, like HTN related TOD are also known to 
be powerful risk factors for major clinical events, and can act as valid proxies to major 
disease, but have been scarcely used.49
Because the beneficial changes in HTN related TOD are thought to have a 
significant positive effect on morbidity and mortality, in the absence of such hard 
clinical events, the use of intermediate endpoints, as changes in LV function and 
structure and in renal function, like the sensitive microalbuminuria, can provide 
valuable insights beyond BP changes, on the potential impact of RDN in the long‑
term.50, 51 
The combined use of a physiological measure, like BP, and surrogates of sub‑
clinical disease, like heart and kidney changes, to evaluate and grade the success of 
RDN treatment for severe resistant HTN, has never been tested before, to the best of 
our knowledge. 
A possible advantage of such approach relies in the fact that BP as a solely 
endpoint to evaluate the HTN treatment success, doesn’t fully capture the global 
effect of treatment on other important clinical adverse events. For example, antihyper‑
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tensive drugs have multiple effects besides lowering BP, some of which may not be 
reflected on BP changes. In fact, there seems to be no direct relationship between 
changes in BP and in concomitant changes in HTN related TOD. We can raise the 
hypothesis, that after RDN treatment, there will be patients with positive changes in 
BP values and in subclinical TOD, but also, there will be patients with changes in BP 
and HTN related subclinical TOD, in opposite directions. How frequent they are and 
what implications they have for the overall prognostic scenario of HTN, are presently 
still unknown.
Another difference to previous studies is the use of more robust surrogates of 
RDN efficacy. As previously mentioned, ABPM measurement is more robust than office 
evaluation to assess BP control and also proved to be better related to prognosis and 
to HTN related TOD.22 
The inclusion of HTN related TOD evaluation after RDN, as a surrogate mar‑
ker of RDN efficacy, is an additional difference. Although mentioned in previous 
studies, they were not assumed as efficacy endpoints of RDN treatment rather 
as “secondary effects”. On contrary, in the present study and due to their impor‑
tant role on HTN prognostic impact and different response to different treatment 
strategies, changes on LV function, structure and proteinuria, should be by their 
own rights, surrogates of RDN efficacy in the treatment of patients with resistant 
HTN.34, 50‑52
We foresee in the future, antihypertensive treatments strategies focused in 
the prevention of HTN related TOD, beyond BP control, introducing cardioprotec‑
tive therapies, like LV hypertrophy or proteinuria improvement, independently of 
BP reduction. 
In summary, the following arguments will support the search for subclinical organ 
damage in patients with chronic severe HTN, resistant to maximal tolerated antihyper‑
tensive therapy, submitted to RDN. They will be assumed as surrogate markers of RDN 
impact in such patients. 
 ■ HTN related TOD have been shown to have an independent prognostic 
impact, irrespectively of whether it involves the structure or heart function, 
the brain, the kidney or the vessels.50, 51, 53 
 ■ Resistant or refractory HTN is strongly associated with specific TOD. Simi‑
larly, TOD, particularly renal and cardiovascular may worsen the resistance 
to treatment of HTN.35, 38
 ■ Growing scientific evidences supports the concept that a chronic increased 
in SNS activity, is involved in the pathogenesis of HTN,54, 55 kidney disease,56 
type II diabetes,57 obesity including metabolic syndrome.57 Such effects are 
mediated by the chronic increase in BP, but also by direct negative effects 
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of SNS, in the cardiovascular system and metabolic disarrays, which are 
independent of BP changes.58
 ■ Recent studies and registries revealed that RDN, beside lowering BP, had 
positive effects in HTN related TOD. In patients with severe HTN, it was 
associated to improvements in LV hypertrophy, diastolic function34, 42, 59 and 
microalbuminuria.52, 58 These changes were independent from BP lowering 
effects.34, 42, 52, 59
 ■ Some studies had analysed the impact of RDN on HTN related TOD, not as 
endpoints of RDN efficacy, rather as “secondary effects”, but few if none, 
had assessed simultaneously the effect of RDN on BP and multiple HTN 
related TOD, in the same set of patients.
conclusion
Based on the arguments previously discussed and to clarify the therapeutic role 
of sympathetic nerve system modulation by renal denervation, through the application 
of radiofrequency energy inside the renal arteries, we assumed to be of scientific rele‑
vance, to evaluate in patients with severe resistant hypertension, under maximal tole‑
rated antihypertensive medication, the impact of renal denervation on a composite of 
endpoints including: changes on blood pressure assessed by office and 24 hours 
ambulatory blood pressure measurement and also on changes in target organ dama‑
ged, assessed through the surrogate markers: changes in left ventricular structure and 
function, renal function and proteinuria.
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summAry
The aim of this study is to evaluate the impact of renal denervation, by radiof-
requency application inside the renal arteries, on blood pressure and on markers of 
hypertension related target organ damage, such as changes on left ventricle function 
and structure and on renal function, in patients with severe resistant hypertension 
under maximal tolerated antihypertensive medication. 
To achieve such purpose, a longitudinal, prospective observational study was 
adopted. All selected patients were submitted to renal denervation and followed by a 
dedicated team, under a prespecified protocol. Office blood pressure, 24 hours ambu-
latory blood pressure measurement, left ventricle structure and function assessed 
through transthoracic echocardiography, renal function and determination of urinary 
albumin creatinine ratio were evaluated before and at one year after renal denervation.
Aims of present study
The aim of this study was to evaluate in patients with resistant HTN under maximal 
tolerated antihypertensive medication, the impact of RDN on BP and on HTN related 
TOD, assessed through the surrogate markers, LV function and mass, renal function 
and proteinuria.
Contrary to previous studies, that included patients with resistant HTN defined 
has having uncontrolled HTN under at least three antihypertensive medications, inclu‑
ding a diuretic on “adequate doses”, in this study, the aim was to include patients 
under maximal tolerated antihypertensive medication, and only after the HTN medical 
team assumed drug treatment failure in controlling BP, the patients were candidates 
to RDN. This RDN treatment strategy has never been tested before, to the best of our 
knowledge.
Another difference to previous studies was the use of more robust surrogates of 
RDN efficacy. As previously mentioned, ABPM measurement is a more robust evalua‑
tion of BP control, than office BP, and proved to be better related to prognosis and to 
HTN related TOD.1 
The inclusion of HTN related TOD evaluation after RDN, as a surrogate marker of 
efficacy, was another difference. Although mentioned in previous studies, they were not 
assumed as efficacy endpoints of RDN treatment, rather as “secondary effects”. On the 
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contrary in the present study and due to their important role on HTN prognosis, they 
were assumed as surrogate markers of RDN efficacy (Fig. 2).
Renal function and proteinuria
LV 
Hypertrophy
Blood 
Pressure
Figure 2: Impact of RDN on blood pressure and on target organ damage  
– left ventricle mass and renal function/proteinuria.
specific objectives of present study
Primary objective:
 ■ To evaluate the impact of RDN on systolic BP reduction, assessed by ABPM 
at 12 months follow‑up after RDN.
Secondary objectives:
 ■ To evaluate the impact of RDN on office systolic BP reduction, measured at 
12‑month follow‑up after RDN.
 ■ To evaluate the impact of RDN on LV mass, assessed by echocardiography 
at 12 months follow‑up.
 ■ To evaluate the impact of RDN on urinary albumin to creatinine ratio (ACR), 
at 12 months follow‑up.
Secondary safety objectives:
 ■ Rate of RDN procedure vascular access complications.
 ■ Deterioration of renal function assessed by changes in blood creatinine, 
blood urea and eGFR, at 12‑months of follow‑up.
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study teAm
For the purpose of this study, an RDN-Team was established including interven‑
tional cardiologists (who perform the procedure), imaging cardiologists (responsible 
for the echocardiogram) and nephrologists (running the hypertension outpatient clinic). 
From a historical perspective, the HTN Outpatient Clinic at Hospital de Santa Cruz was 
already managed by the Nephrology Department. In such context, it was decided to 
implement a specific outpatient clinic for resistant HTN, for the evaluation and follow up 
of patients proposed and submitted to renal denervation (Fig. 3). 
The mission of this RDN‑team was to analyse and discuss all patients with resis‑
tant HTN, evaluated in the dedicated HTN Outpatient clinic, to properly select the 
patients to RDN and to follow them after the procedure. The team has regular monthly 
meetings to discuss patient eligibility for RDN and the follow‑up results.
Figure 3: RDN – Team involving the Cardiology, Nephrology and Anesthesiology Departments. 
study design And pAtients selection
The RDN Registry. By protocol, all patients submitted to RDN in Hospital de 
Santa Cruz, are included in an ongoing single centre dedicated prospective registry. 
This registry (the RDN Registry) records all data obtained in the pre‑RDN evaluation 
phase, in the procedure and at follow‑up, including demographic, anthropometric and 
clinical variables, as well as medication, laboratory values and echocardiogram results. 
All obtained data, at baseline and at follow‑up are stored in an electronic database. 
Procedure data and safety endpoints are also recorded, as they happen or are known 
by the Renal Team. Pre‑specified outpatient visits are scheduled at 1‑6‑12 month, and 
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yearly after on. In these visits, a pre‑specified set of tests were performed, and all effi‑
cacy endpoints were recorded.
The resistant HTN protocol evaluation, the RDN procedure and the data collec‑
tion were all approved by the CHLO Ethical Commission. Dedicated informed consent 
is requested to all patients. 
Patient selection. Since its beginning, the Renal Team decided that only 
patients with resistant HTN should be considered for RDN. Resistant HTN was defi‑
ned according to international standards as BP > 140/90 mmHg in a patient with at 
least three antihypertensive drugs, of different classes (one of them must be a diuretic) 
on adequate doses.16 In all patients, secondary HTN had to be ruled out. Remaining 
inclusion criteria (Table 6) were drawn from simplicity HTN2 trial3 with the following 
major changes: the inclusion of patients with resistant HTN despite maximum tolera‑
ted antihypertensive drug therapy, with no limit to number, type or dose, as much as 
they were safe and tolerated by the patients. That strategy diverged from the one follo‑
wed by Simplicity HTN2 trial, as he included patients with resistant HTN by classical 
definition, meaning that drug treatment was not used up‑to its reasonable and clinical 
limits as we did. Our strategy was to perform RDN on top of maximal tolerated drug 
treatment. Another major change was to use ABPM instead of standard office BP 
measurements as the surrogate for drug treatment efficacy and BP control, because it 
is more robust than office BP measurements and its better linked with HTN long term 
prognosis.1, 4
Dimension of study population. The population dimension needed to appro‑
priately assess the impact of RDN on BP and on HTN related TOD, was calculated 
assuming the following criteria: data analysed from a single centre, single arm prospec‑
tive registry, single sided superiority test, assuming an expected reduction of 2 mmHg 
on the ABPM systolic BP measurement, as a surrogate for HTN success (value used as 
a secondary endpoint in Symplicity HTN 3 trial5), with a pre‑procedure average ABPM 
systolic BP of 149mmHg and a standard deviation of 18mmHg (data derived from a 
preliminary analysis of 31 patients submitted to RDN already included in the RDN regis‑
try) with an type one error of 2,5% (single sided) and a potency of 80%, the minimal 
number of patients needed were 28.
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Table 6: Inclusion criteria for catheter based renal denervation.
Clinical criteria
• age ≥ 18 years
• Severe resistant HTN in patients with at least ≥3 anti HTN drugs  
(including a diuretic) on maximal tolerated doses and 
– ABPM Systolic BP ≥ 135 mmHg 
• Patients with eGFR >30ml/min/1.73m2
Anatomic criteria
• Both renal arteries:  
– ≥ 3mm diameter of a main renal artery
– Less <50% stenosis and no previous intervention
• Anatomy documented by any of the following methods:
– Computed Tomography angiography
– MR angiography 
– Invasive renal angiography 
Exclusion criteria
• Type 1 Diabetes
• Unstable or terminal diseases
• Pregnancy
• Secondary HTN
• Recent major surgery
• Recent active bleeding
• Unable to give informed consent
renAl denervAtion procedure
RDN is an invasive procedure performed primarily through the femoral arteries, 
exceptionally, it may be performed by radial arteries. After selective cannulation of renal 
arteries, using dedicated catheters, an angiography is performed on each artery. A 
dedicated radiofrequency catheter is then inserted inside the renal artery and adequa‑
tely positioned (Fig. 4).
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Figure 4: Evaluation by CT angiography scan of right (A) and left (B) renal artery,  
and angiography, displaying the ablation catheter (E) in the right renal artery (C)  
with its ablation tip (D) positioned in the lower artery wall near the ostium.
A radiofrequency generator was connected to the catheter and radiofrequency 
was delivered to the artery wall accordingly to a proprietary protocol that considers 
the time, the temperature and impedance. If any of pre‑specified criteria values were 
surpassed, the radiofrequency application switched‑off automatically. The aim, was 
to apply multiple radiofrequency shots in a 360‑degree spiral circle inside the artery, 
avoiding unnecessary damages in the artery endothelium by multiple shots in the 
same spot. The EnligHTN® (St. Jude Medical, USA) and the OneShot® (Medtronic™, 
Santa Monica; California) devices, can apply simultaneously, multiple shots in different 
angles.
The systems used in the present study were Symplicity® Flex device (Medtronic™, 
Santa Monica; California) – Fig. 5, a single point by point radiofrequency applying sys‑
tem; the EnligHTN® device (Abbott Vascular™, Santa Clara, California) – Fig. 5, a 
multipoint radiofrequency applying system, and the OneShot® system (Medtronic™, 
Santa Monica; California), also a multipoint radiofrequency system. They all use a simi‑
lar radiofrequency applying protocol, aimed to improve efficacy by delivering the appro‑
priate amount of energy to vessel walls, and consequently to decrease nerve traffic in 
the renal SNS.
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Symplicity TM EnligHTNTM
Figure 5: The most frequently used devices used in RDN along the study. 
Being a painful procedure, anaesthesiology backup was needed. Weight adjus‑
ted propofol and remifentanyl were used to control the pain. Unfractionated heparin 
was used during the procedure to achieve an activated clotting time > 250 seconds. 
Saline iv was used as needed. At the end of the procedure and whenever possible, the 
femoral artery access was closed using a percutaneous closing device: Angio-Seal® 
(St. Jude Medical, USA), to minimize the risk of vascular access complications and to 
patient comfort (Fig. 6).
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Figure 6: An overview of the cathlab setup during an RDN procedure.
All listed, likely procedure related complications, were recorded (Table 7), with a 
special attention to complications related to the vascular access site. The definitions 
were depicted from those used in HTN 3 trial.5
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Table 7: Possible complications of catheter based renal denervation.
MAJOR 
complications
Kidney related 
complications
Insertion site 
complications
Minor complications 
Death Chronic loss kidney function Long standing local pain Hypotension
Severe bleeding Transient loss of kidney function Pseudoaneurysm Orthostatic hypotension
Emboli Kidney perforation Arterio‑venous fistula Hypertension
Life threatening 
arrhythmias Renal artery perforation Infection Vomiting
disturbances Renal artery occlusion Bleeding Nausea
Renal artery stenosis Retroperitoneal bleeding Contrast related
Renal artery aneurism Vessel perforation Procedure medications related
Vessel dissection Electrolyte disturbances
metHodology Assessment of specific objectives
pAtients follow-up. After the procedure, patients were followed in the HTN 
outpatient’s clinic. A prespecified set of visits to the HTN Outpatient clinic, were sche‑
duled as previously mentioned, without precluding the need for further visits if clinically 
driven, to achieve BP control or manage drug treatment side effects.
At one year, all patients were evaluated to assess prespecified efficacy endpoints. 
On those visits, BP was measured, medication was reviewed and adjusted as nee‑
ded. All data and changes in medication were recorded. Standard physical evaluation, 
anthropometrics, blood and urine analysis, ABPM measurements, echocardiogram 
results, were also recorded in each patient case report file.
A major change compared to previous studies, was the routine use of ABPM to 
assess BP values, instead of the commonly used office BP measurements. As a sur‑
rogate for RDN efficacy, ABPM is more robust than office BP measurements and its 
better linked to HTN long‑term prognosis as previously mentioned.1, 4
blood pressure meAsurements And definition of responders. Office BP readings 
were taken in a seated position with an oscillometric semiautomatic sphygmomanometer 
Omron HEM‑907 monitor (Omron Healthcare, USA), after 5 min of rest, according to 
the European Guidelines for the Management of Arterial Hypertension.6 At baseline, BP 
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was measured in both arms and the arm with the higher BP was used for all subsequent 
readings. Averages of the triplicate measures were calculated and used for analysis. 
Twenty‑four hours ambulatory blood pressure measurements were taken with 
an ABM monitor (Spacelabs Healthcare, USA), according to the current European 
Society of Hypertension Guidelines6. 
Blood pressure responders to RDN treatment were defined as those which had 
a reduction on office systolic BP of ≥5 mmHg at one year follow‑up or a reduction ≥ 2 
mmHg in ABPM systolic BP, according to the Symplicity HTN3 trial criteria7.
urinAry Albumin to creAtinine rAtio determinAtion. As recommended8, ACR was 
used as a marker of kidney damage. Urinary concentration of albumin and creatinine 
were measured separately by nephelometry and the Jaffé method respectively, using 
first morning void spot samples.9 This value is expressed in mg/g and it is equivalent 
to the 24 hours value expressed in mg/day. All laboratory testing was performed by a 
central laboratory.
The Modification of Diet in Renal Disease (MDRD) Formula: eGFR (mL/min/1.73 
m2) = 186 x (sCr/88.4)‑1.154 x (Age)‑0.203 x (0.742 if female) x (1.212 if of African 
descent) (SI units), was used estimate eGFR.
Urine spot samples to obtain ACR values were acquired before RDN (at baseline) 
and at 12 months follow‑up. 
Contrary to BP changes with RDN, regarding ACR changes and to the best of 
our knowledge, there is no specified standard definition to consider a patient as being 
a responder to RDN. In such setting, it was assumed that any decrease in ACR at one 
year after if RDN was consider a responder to RDN. 
trAnstHorAcic ecHocArdiogrApHy. Comprehensive two‑dimensional and Doppler 
transthoracic echocardiographic studies were performed at baseline and at one‑year fol‑
low‑up, in all patients, using a VIVID 7 ultrasound system (General Electric Healthcare). All 
echocardiographic recordings were stored in a digital format on a dedicated workstation 
for off‑line subsequent analysis. The studies were performed by one of two experienced 
operators, while analyzed and interpreted by another operator, not involved in the images 
acquisition. They were all blinded to patients’ clinical, BP status and sequence of images.
Left ventricular size was evaluated by both linear (using M‑mode 2D guided dia‑
meters obtained perpendicular to the LV long axis) and volumetric (using the biplane 
method of disks summation from tracings of the blood‑tissue interface in the apical four‑ 
and two‑chamber views), according to accepted recommendations from the American 
Society of Echocardiography and the European Association of Cardiovascular Imaging 
10. LV ejection fraction was calculated using the following formula: EF = (EDV − ESV)/
EDV, with LV volume estimates obtained by the biplane method of disks.
Assessment of LV mass (LVM) was performed by the linear method using the 
Deveraux cube formula11 (LV mass = 0.8×1.04[(IVS + LVID + PWT)3 −LVID3]+0.6g), 
with 2D guided M‑mode measurements obtained at end‑diastole from the parasternal 
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approach perpendicular to the LV long axis measured at the level of the mitral valve 
leaflet tips. LV hypertrophy was considered present when LV mass exceeded 115 g/m2 
for men and 95 g/m2 for women.
We also calculated the relative wall thickness (RWT) measured as twice the pos‑
terior wall thickness divided by LV end‑diastolic diameter and determined the LV ana‑
tomical pattern in each participant. Normal LV mass and RWT were defined as normal 
LV anatomy, normal LV mass and RWT >0.42 as concentric LV remodeling, increased 
LV mass and RWT >0.42 as concentric LV hypertrophy and increased LV mass in the 
presence of RWT <0.42 as eccentric LV hypertrophy 12. Left atrial size was evaluated 
using M‑mode 2D guided diameters and area, when the left atrium chamber was at its 
greatest dimension (end of LV systole). 
LV diastolic function was assessed by pulsed‑wave Doppler examination of mitral 
inflow and Doppler tissue imaging of the mitral annulus. Peak velocities of early (E) and 
late (A) trans‑mitral flow and deceleration time were determined, and the ratio E/A was cal‑
culated. Doppler tissue imaging with pulsed‑wave Doppler at the level of septal and lateral 
mitral annulus was used to measure e’ velocities. The average of septal and lateral mitral 
annulus e’ peak velocities, were used to calculate the E/e’ ratio. The Valsalva maneuver 
was performed to distinguish normal from pseudo‑normal patterns. Spectral recordings 
were obtained at a sweep speed of 100 mm/s at end‑expiration, and each measurement 
was averaged over multiple cardiac cycles to account for inter‑beat variability. 
Grade 1 diastolic dysfunction (impaired relaxation) was defined by the presence 
of an E/A ratio <0.8, a deceleration time >200ms and E/e′ ratio <8 in the presence of 
an enlarged left atrium. Moderate (pseudo‑normal, grade 2) diastolic dysfunction was 
defined as a mitral E/A ratio >0.8 and <1.5 that decreases by 50% during the Valsalva 
maneuver, E/e’ ratio 9 to 12 and e’<8 cm/s. Finally, severe (grade 3) diastolic dys‑
function corresponds to restrictive LV filling defined by E/A ratio >2, deceleration time 
<160ms, and average E/e’>13. All subjects with impaired LV relaxation, pseudo‑normal 
or restrictive filling patterns were defined as having LV diastolic disfunction 13.
Based on previous studies, a patient was assumed as a responder to RDN, if a 
5% reduction in the LV mass was achieved one year after the RDN procedure.14 
stAtistics
Continuous variables are reported as mean ± standard deviation. Variables’ nor‑
mal distribution was tested with the Kolmogorov‑Smirnov test and/or Q‑Q Plot visual 
assessment. Discrete variables are expressed as frequencies and percentages. Varia‑
bles with a normal distribution were compared between baseline and at one‑year follo‑
w‑up, using a paired Student t test or a Wilcoxon matched‑pairs test if without a nor‑
mal distribution. Discrete variables are expressed as frequencies and percentages (in 
brackets). A p value <0.05 was considered as statistically significant. Linear regression 
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analysis was used to calculate the correlation between the change on blood pressure, 
the change on echocardiographic parameters and on ACR values.
Statistical Package for the Social Sciences®, V.21.0 (IBM SPSS Modeler, Chi‑
cago, IL) and Medcalc® V.6.0 is used for data processing and statistical analysis.
definitions of otHer used vAriAbles
Height and weight were measured with the participant in light clothing without shoes.
Body mass index (BMI) was calculated as weight in kilograms divided by the 
square of height in meters
Diabetes was diagnosed if at least one of the following criteria was present: a 
fasting plasma glucose level ≥126 mg/dL (7.0 mmol/L), non‑fasting glucose of ≥200 
mg/dL (11.1 mmol/L) or an abnormal glucose tolerance test.
Obesity is a BMI greater than or equal to 30 and equal for both sexes.
Dyslipidemia defined according to the ESC guidelines.15 Measured in a blood sam‑
ple obtained under 12 hours of fasting condition and calculated, as in most studies, using 
Friedewald’s formula (unless Triglycerides are elevated >4.5 mmol/L or more than ∼400 mg/
dL). In patients with low risk for cardiovascular disease (<1% CV risk score) dyslipidemia 
was assumed present if Low Density Lipoproteins > 190mg/dL (4.9mmol/L). In patients with 
high risk for cardiovascular disease (>1% CV risk score) or if known cardiovascular disease, 
dyslipidemia was assumed if Low Density Lipoproteins > 100mg/dL (>2.5mmol/L).
Smoking defined as smoking daily or smoking on some days (National Cancer 
Institute).16
Sleep apnea defined as a documented spontaneous breathing cessation lasting 
more than 10 seconds, during sleep (European Respiratory Society).17 
Coronary artery disease defined as any of the following: conﬁrmed myocardial 
infarction, coronary angiography showing more than 50% narrowing of at least 1 major 
coronary artery, diagnosis of classic angina pectoris, or concordant abnormalities on 
electrocardiography, echocardiography, or radionuclide scans from stress test findings 
concordant for ischemia.
Any vascular disease defined as any documented sign of clinical meaningful 
arterial obstructive disease outside coronaries. Documented either by brachial ankle 
index significant changes or by any imageology test showing significant artery narrowing.
etHicAl ApprovAls
The present study was submitted and approved by the Ethical Commission from 
Nova Medical school on September 1st, 2015 and by the Ethical Commission from the 
Centro Hospitalar de Lisboa Ocidental (CHLO) on July 11, 2011.
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summAry
From 318 patients with suspected resistant hypertension, evaluated between 
2011 and 2015 in a dedicated outpatient clinic, 65 were confirmed as having resistant 
hypertension and later submitted to renal denervation, of which 31 patients had a com-
plete 12 months follow-up data at the time of the present analysis and are reported here.
At 12-months follow-up there was a statistically significant decrease in office and 
24-hour ambulatory blood pressure values, with 84% of patients considered responders to 
renal denervation regarding systolic blood pressure and 71% for diastolic blood pressure.
There was also a statistically significant decrease in left ventricle mass, mea-
sured by transthoracic echocardiography, with an improvement in left ventricle mass, 
from 152.3g/m2 to 135.7g/m2 (p<0.001). Five patients (16%) were not responders 
in left ventricle mass reduction to renal denervation.
Regarding renal function, assessed through urinary albumin to creatinine 
ratio, there was also a significant decrease at one year, from 25.9mg/g to 14.8mg/g 
(p=0.007), with no significant changes in estimated glomerular filtration rate. Such 
significant decrease was maintained, regardless of being diabetics or not.
No clear linear correlations were found, between changes in blood pressure, 
after renal denervation, and changes in either left ventricular mass or urinary albumin 
to creatine ratio, both surrogates of hypertension related target organ damages.
There were no major complications related to the renal denervation procedure.
study populAtion
Between July 2011 and April 2015, a total of 318 patients with presumed resis‑
tant HTN were evaluated in a dedicated outpatient HTN clinic as probable candidates 
for RDN. From those, 253 patients were excluded after an extensive clinical evaluation, 
the majority of which due to pseudo‑resistance, after controlling their BP with further 
treatment adjustment (n=139). Secondary HTN (n=31), unfavorable renal anatomy 
(n=22), renal dysfunction with an eGFR below 30ml/min/1.73m2, considered at the 
time, the lowest safety limit for RDN (n=85), and patients refusal for RDN(n=41), were 
also reasons for excluding patients from the RDN program.
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The remaining 65 patients were considered good candidates and were submitted 
to RDN. Those patients entered a prospective registry aimed do evaluate in a standar‑
dized fashion, safety and the outcomes of RDN on a set of prespecified endpoints, 
including changes on BP and on HTN related TOD. (Fig. 7)
From these 65 patients treated with RDN, it was possible to obtain the complete 
clinical and technical data at one‑year follow‑up, including ABPM measurements, trans‑
thoracic echocardiogram and ACR values, in 31 consecutive patients that were the 
final population included at the time of this analysis.
Figure 7. Flowchart of patient selection.  
From the total number of patients evaluated in the outpatient HTN clinic (n=318),  
31 patients with ABPM monitoring, transthoracic echocardiography (TTE) and complete data 
at 12‑months follow‑up, were select for the analysis.
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The mean age of selected study population, was 65±7 years, 48% were males 
(n=15), all Caucasian. Concerning traditional cardiovascular risk factors, obesity was 
present in 68% of the patients (mean body mass index 32±6 Kg/m2), type 2 diabetes 
in 71%, dyslipidemia in 68% and active smoking in one patient (3.2%). Coronary artery 
disease was present in 10 patients (32%) and any vascular disease in 11 (36%). 
The mean eGFR at baseline, was 76.4±24.7 mL/min/1.73m2. Five patients had 
chronic kidney disease defined as having an eGFR < 60 mL/min/1.73m2.
Baseline, median ACR was 25.8 (IQR 9.0‑574.0) and 15 patients (48,4%), had 
an ACR > 30 mg/g.
Patient’s demographic and clinical characteristics at baseline, are shown in Table 8.
Table 8: Patient’s demographic and clinical characteristics at baseline.
Demographic and clinical variables
Age (years) 65±7
Male (%) 15 (48.4)
Caucasians (%) 31 (100)
Weight (kg) 86±16
Height (m) 1.65±0.1
BMI (kg/m2) 31.8±5.5
Obesity (%) 21 (67.7)
Atrial fibrillation (%) 1 (3.2)
Previous stroke (%) 2 (6.5)
Type 2 Diabetes (%) 22 (71)
Dyslipidaemia (%) 21 (67.7)
Smoking (%) 1 (3.2)
Sleep apnea (%) 5 (19.1)
eGFR (ml/min/1,73m2) 76.4±24.7
Chronic kidney disease* (%) 5 (16.1)
Hypertension > 10 years (%) 28 (90.3)
Coronary artery disease (%) 10 (32.3)
Any vascular disease (%) 11 (35.5)
*Chronic kidney disease (eGFR <60 ml/min/1,73m2)
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The majority of patients (90%) had HTN lasting for more than 10 years, treated 
with a median of 5.8 anti‑hypertensive agents from a median of 5.5 different pharma‑
cological classes. Almost all patients were treated with calcium antagonists, 96.8% 
(n=30), 87% with diuretics including 74% with spironolactone, 61% with ACE inhibi‑
tors, 61% with ARB inhibitors, 84% with beta‑blockers and 71% with a sympatholytic 
drug (Table 9).
Table 9: Antihypertensive medication at baseline.
Baseline
Mean number of antihypertensive drugs 5.8±1.1
Mean number of classes 5.5±0.9
ACE inhibitors 19 (61.3)
ARBs (%) 19 (61.3)
Beta‑blockers (%) 26 (83.9)
Calcium channel blockers (%) 30 (96.8)
Diuretics (%) 27 (87.1)
Spironolactone (%) 23 (74.2)
Sympatholytic (%) 22 (71)
Aliskirene 4 (12.9)
renAl denervAtion procedure
RDN was performed using standard approved percutaneous catheter systems. 
All of them have similar radiofrequency applying proprietary protocols, aimed to be effi‑
cacious in the amount of energy delivered at each point and to be safe avoiding severe 
damage to vessel endothelium and walls. 
Their difference was in the number of radiofrequency points applied simultane‑
ously. The Symplicity® Flex system (n=25) is a single, point by point, radiofrequency 
applying system. The EnligHTN® (n=4) and OneShot® (n=2) catheter are simultane‑
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ous multipoint radiofrequency applying systems. In all of them, radiofrequency has to 
be applied in multiple equidistant points, in a 360º a spiral fashion, using the standard 
technique, as previously reported.
The median number of radiofrequency applications per artery and per patient are 
revealed in table 10.
Table 10: Procedure characteristics of catheter based renal denervation.
RDN Procedure
Median number of applications right renal artery 5.1±1.3
Median number of applications left renal artery 5.7±1.1
Median number of applications per patient 10.8±2.3
impAct on blood pressure
At baseline, average office systolic BP and diastolic BP was 176±24 mmHg 
and 90±14 mmHg, respectively, with an average heart rate of 73±11 bpm. The ABPM 
measurements revealed the following average values: 150±20 mmHg for systolic 
BP, 83±10 mmHg for diastolic BP with an average pulse pressure of 67±18mmHg 
(Table 11).
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Table 11: Results of blood pressure and heart rate measurements at baseline and 
one‑year follow‑up.
Baseline One-year P
Office systolic BP (mmHg) 176±24 149±13 < .001
Office diastolic BP (mmHg) 90±14 79±11 < .001
Heart rate (bpm) 73±11 70±11 .261
ABPM systolic BP (mmHg) 150±20 132±14 < .001
ABPM diastolic BP (mmHg) 83±10 74±9 < .001
ABPM pulse pressure (mmHg) 67±18 58±13 .001
ABPM mean pressure (mmHg) 105±9 95.3±8.4 < .001
ABPM heart rate (bpm) 67.6±9.1 65.5±9.5 .090
ABPM systolic BP responders (%)* ‑ 26 (83.9) ‑
Office systolic BP responders (%)** ‑ 22 (71) ‑
Bpm: beats per minute; *ABPM systolic BP responders: a decrease of 2mmHg between baseline  
and one‑year follow‑up; **Office systolic BP responders: a decrease of 10mmHg between baseline 
and one‑year follow‑up.
Overall, at one‑year follow‑up, there was a statistically significant reduction on 
office systolic BP (176±24 to 149±13mmHg, p<0.001), on diastolic BP (90±14 to 
79±11mmHg, p<0.001), on ABPM systolic BP (150±20 to 132±14 mmHg, p<0.001) 
and on ABPM diastolic BP (83±10 to 74±9 mmHg, p<0.01) (Fig. 8). 
Figure 8. BP results one year after RDN. There was a statistically significant decrease  
in both systolic and diastolic BP, in office and ABPM measurements. 
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A significant decrease was also found in the average 24‑hours pulse pres‑
sure, measured by ABPM, an important surrogate of TOD, that decreased on 
average 9 mmHg, from 67±18 to 58±13 mmHg (p= 0.001) alongside with the 
average 24 hours BP in ABPM, from 105±9 to 95.3±8.4 mmHg (p<0.001), 
(Fig. 9).
Figure 9. A statistically significant decrease on 24‑hourse average Pulse Pressure  
and on Mean BP, measured by ABPM. 
Those results were found, despite the significant reduction in the number of both 
antihypertensive drugs and classes in use at one year: 5.8±1.1 to 5.0±1.2 (p=0.002) 
and 5.5±0.9 to 4.9±1.1 (p=0.015) respectively (Table 12).
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Table 12. Antihypertensive medication at baseline and at one‑year follow‑up.
Baseline One year p
Mean number of antihypertensive drugs 5.8±1.1 5.0±1.2 0.002
Mean number of classes 5.5±0.9 4.9±1.1 0.015
ACE inhibitors 19 (61.3) 17(54.8) 0.688
ARBs (%) 19 (61.3) 18 (58.1) 1.0
Beta‑blockers (%) 26 (83.9) 27 (87.1) 1.0
Calcium channel blockers (%) 30 (96.8) 21 (67.7) 0.012
Diuretics (%) 27 (87.1) 24 (77.4) 0.727
Spironolactone (%) 23 (74.2) 26 (83.9) 0.453
Sympatholytic (%) 22 (71) 19 (61.3) 0.508
Aliskirene 4 (12.9) 0 0.046
At follow‑up, 22 from the total of 31 patients (71%) were considered office 
systolic BP responders and 26 (84%) ABPM systolic BP responders, based on a 
decrease of more than 10mmHg on office systolic BP and 2mmHg on ABPM systolic 
BP.
impAct on left ventricle structure And function
Transthoracic echocardiographic studies were performed at baseline and at one‑
year follow‑up in all patients and stored in digital format on a dedicated workstation for 
off‑line subsequent analyses. The exams were all performed by one of two experienced 
operators, while the analysis and interpretation were done by another operator, not 
involved in the images acquisition, all blinded to patient’s BP status and sequence of 
tests. The echocardiographic execution and interpretation protocols are mentioned in 
detail in the Methods chapter.
The echocardiographic data values obtained at baseline and at one‑year follow‑
‑up, for heart structure and function, are enlisted in Table 13. 
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Table 13. Transthoracic echocardiographic parameters at baseline and at one‑year 
follow‑up.
Baseline One-year p
Heart structure
LVEDV (mL/m2) 93.3±18,2 110.9±27.4 .004
LVESV (mL/m2) 35.8±12.6 38.2±3.1 .121
IVSTd (mm) 13.4±1.9 13.1±2.4 .616
PWTd (mm) 11.7±1.6 11.8±1.7 .620
LVEDD (mm) 48.7±5.8 47.8±5.4 .230
LVESD (mm) 28.9±5.7 27.9±6.5 .296
LV mass/BSC (g/m2) 152.3±32.4 135.7±33.9 <.001
Left atrium size/BSC (cm/m2) 32.8±8.3 34.1±6.2 .227
Function
LVEF Simpson (%) 64.5±9.2 67.7±9.1 .001
Stroke volume (ml) 81.7±14.9 102.7±16.7 .075
Mitral valve E Vmax (cm/s) 73.6±15.2 73.2±16.4 .881
Mitral valve A Vmax (cm/s) 88.3±16.5 86.0±21 .469
Mitral valve E/A ratio 0.84±0.21 0.86±0.20 .574
Mitral valve E deceleration time (ms) 224.9±49.4 247.3±50.5 .015
Mitral valve lateral E’ (cm/s) 7.2±1.8 7.3±2.1 .417
Mitral valve lateral E/e’ ratio 11.0±3.3 10.5±3.5 .228
After RDN, there was a significant improvement on LV end diastolic volume 
index, from 93.3±18.2 at baseline to 110.9±27.4 ml/m2 at one year (p<0.001), and 
on the LV ejection fraction, from 64.5±9.2% to 67.7±9.1% (p=0.001), as depicted 
from Figure 10. 
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Figure 10: Statistically significant changes on LV end diastolic volume and function,  
one year after RDN. 
Regarding LV mass index, an important endpoint of HTN related TOD, there was 
a significant decrease (152.3±32.4 to 135.7±33.9 g/m2, p<0.001) one year after 
RDN, shown in Figure 11.
Figure 11: Statistically significant changes on LV mass index, one year after RDN. 
Assuming the cutoff value of 5% decrease in LV mass at one‑year after the pro‑
cedure, a responder definition to RDN, 65% of patients (n=20) were considered res‑
ponders to RDN.
Reduction on LV mass reached statistical significance in ABPM systolic BP res‑
ponders (n=26), from 148±32 to 133±29g/m2 (p<0.001). In non‑responders (n=5), 
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LV mass also decreased from 166±23 to 129±15g/m2 (p=0.05), although not rea‑
ching statistical significance certainly due to sample size. (Fig. 12)
Figure 12. Comparison of LV mass changes at baseline and one‑year follow‑up,  
according to BP responders (n=19) and non‑responders (n=5) to RDN.
The changes on LV mass index were in line with those observed in BP measure‑
ments, Office and on ABPM (Fig. 13).
Figure 13. RDN results one year after RDN, on BP (both office and ABPM)  
and on LV mass index, with significant reductions in all parameters. 
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It seems, from the scatter‑plot graphic (Fig. 14), a cross analysis relationship 
between changes on LV mass index and on ABPM systolic BP, one year after RDN, for 
the entire population, that there is not significantly linear correlation, between those two 
variables, as depicted by the very low r2 values obtained.
Figure 14. Cross analysis relationship between LV mass index  
and ABPM systolic BP changes at one‑year follow‑up.
However, a note should be taken, on the large variability observed in the LV mass 
index changes, after RDN, that may eventually account for the lack of linear correlation 
between changes in BP and in LV mass index. (Fig. 15) 
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Figure 15. Left ventricle mass changes (g/m2) at baseline and one after RDN,  
for responders (gray line) and non‑responders (dark line).
Transthoracic echocardiography at baseline revealed LV hypertrophy (LV mass 
index > 115 g/m2) in 27 patients (87%), with a mean LV mass of 152±32 g/m2. 
According to the international standard definitions provided in the previous chap‑
ter, the large majority of patients had concentric hypertrophy (74%), with only 3% 
presenting a normal pattern. There were no significant changes in the geometric 
distributions patterns with RDN until one‑year follow‑up, eventually due to the small 
sample size or a short follow‑up. The distribution among different geometric patterns 
is shown in Figure 16.
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Figure 16. Comparison of different LV geometric patterns at baseline and one year after RDN.
Average left atrium size, changed after RDN, from 32.8±8.3 to 34.1±6.2cm/
m2 (p=0.227), a non‑significant change, 15 patients (48.4%) had a left atrium size ≥ 
34cm/m2. 
For the entire population, after RDN, E/A ratio changed from 0.84±0.21 
to 0.86±0.2 (p=0.574), E‑wave deceleration time changed from 224.9±49.4 
to 247.3±50.5ms (p=0.015) and E/e’ ratio changed from a baseline of 11±3.3 to 
10.5±3.5 (p=0.228) at one‑year, a very mild reduction not reaching statistically signif‑
icance. Overall, according to previous mentioned criteria, LV diastolic dysfunction was 
diagnosed in 29 patients (93.5 %), 11 of them (37.9%) had grade 1 diastolic dysfunc‑
tion and 18 patients (62.1%) a pseudo‑normal pattern. There were no patients with a 
restrictive filling pattern. Once again, there were no statistically significant changes 
in each diastolic function group from baseline to one year after RDN. (Fig. 17) Two 
patients, were in atrial fibrillation. 
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Figure 17. Analysis of LV diastolic function at baseline and one year after RDN.  
The percentage of patients in each diastolic function group  
(Normal, Impaired relaxation, pseudo normal and restrictive) is depicted.
impAct on AlbuminuriA And renAl function
All changes in renal function and ACR, from baseline to one year after RDN, can 
be depicted from Table 14. 
Table 14: Changes in renal function one year after catheter based renal denervation.
Baseline One year P
eGFR (ml/min/1,73m2)
ACR*
ACR in ABPM BP responders *
ACR in ABPM BP non‑responders*
ACR in ABPM Dippers*
ACR in ABPM non‑Dippers*
ACR in diabetic patients*
ACR in non‑diabetic patients*
73.6±25.1
25.8 (9.0‑574.0)
25.6 (8.7‑382.8)
165.0 (8.8‑1423.5)
20.8 (6.8‑290.0)
62.3 (9.1‑852.3)
48.9 (9.1‑1116.3)
25.4 (5.2‑68.6)
72.5±25.1
14.8 (4.5‑61.0)
15.9 (4.4‑55.0)
13.6 (5.7‑1417.0)
9.4 (3.7‑41.1)
20.8 (9.3‑197.1)
23.1 (4.3‑123.8)
10.9 (3.4‑20.8)
0.711
0.007
0.009
0.345
0.028
0.096
0.028
0.066
* (mg/g)
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There were no changes on the average eGFR from baseline (76.4 ± 24.7 mL/
min/1.73m2) to one year after RDN (72.5 ± 25.1mL/min/1.73m2, p=0.711). Five 
patients had chronic kidney disease defined has having an eGFR < 60 mL/min/1.73m2. 
Baseline median ACR was 25.8 (IQR 9.0‑574.0) and 15 patients (48,4%), had 
an ACR > 30 mg/g. One year after RDN, ACR decreased to a median value of 14.8 
mg/g (IQR 4.5‑61.0 mg/g), a statistically significant decrease in the ACR one year after 
RDN (p=0.007), with some extreme out layers.
A note for the lower dispersion of ACR at one‑year, assessed through the obser‑
ved changes in the interquartile range from baseline (IQR 9.0‑574.0) to one year after 
RDN (IQR 4.5‑61.0 mg/g). (Fig. 18) 
Figure 18. Decrease in the median ACR after RDN. 
The distribution of patients across the different classes of urinary albumin excre‑
tion, also demonstrates a favourable effect (Fig. 19). Interestingly, a significant reduc‑
tion in the percentage of patients with an ACR >300mg/g between baseline and one‑
year, was also found (Fig. 19).
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Figure 19: ACR changes after RDN, according to different ACR subgroups.  
A decrease in the percentage of patients with an ACR >300mg/g and an increase in patients 
with normal urinary albumin excretion one year after RDN.
Considering any ACR reduction as a responder to RDN, 77.4% (n=24) of patients 
were responders. When the ACR results were split according to ABPM systolic BP res‑
ponder status, a significant reduction in ACR [from 25.6 mg/g (IQR 8.7‑382.8 mg/g) 
to 15.9 mg/g (IQR 4.4‑55.0 mg/g), p=0.009] was found in ABPM responders group, 
to RDN. In the ABPM non‑responders group to RDN, a trend in ACR decrease [from 
165.0mg/g (IQR 8.8‑1423.5 mg/g) to 13.6 mg/dl (IQR 5.7‑1417.0 mg/g), p=0.345] , 
was also found, although non‑statistically significant (Fig. 20).
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Figure 20: Results of ACR one year after RDN, according to ABPM systolic BP responder 
subgroups. A significant reduction in the median values of ACR on BP‑responder’s subgroup, 
and a numerically decrease also in non‑responders.
The same analysis, performed regarding ABPM dipper status at baseline, obtai‑
ned similar results, a statistically significant decrease in ACR, in patients with a dipper 
ABPM response (20.8 IQR: 6.8‑290 to 9.4 IQR: 3.7‑41.1mg/g, p=0.028), in line with 
those achieved on ABPM responder’s status. (Fig. 21). 
Figure 21: Results of ACR at 1 year after renal denervation according to ABPM Dipper 
status at baseline. There was a significant reduction in the median values of ACR  
in the Dippers subgroup, and a numerically decrease in non‑dippers.
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Patients with diabetes had a higher median baseline ACR value, with statistically 
significant decrease one year after RDN, from 48.9 (IQR 9.1‑1116.3) to 23.1 mg/g 
(IQR 4.3‑123.8) a p=0.028. A trend in ACR decrease was also found in non‑diabetic 
patients, from 25.4mg/g (IQR: 5.3‑68.6mg/g) to 10.9 mg/dl (IQR: 3.4‑20.8 mg/g) a 
p=0.066, although not statistically significant, probably due to the small sample sub‑
group (n=9). (Fig. 22).
Figure 22: Results of ACR one year after RDN, according to Diabetic status.  
A significant reduction in the median ACR in patients with diabetes, and a numerically 
decrease in the smaller subgroup of patients without diabetes. 
Overall, for the entire population, there were no linear correlation relationship bet‑
ween ACR and ABPM systolic BP changes at one‑year, as depicted by the low r2 
values in the scatter‑plot graphic (Fig. 23) 
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Figure 23. Crosse analysis relationships between ACR and ABPM systolic BP changes  
at one‑year follow‑up.
relAtionsHips between ABPM blood pressure meAsurements, 
ACR And lv mAss index After renAl denervAtion
Since the beginning of modern physiology, in the twentieth century, it has been 
recognized a direct linear relationship between chronic higher BP and the severity of 
damages found in organs, known to have a special sensitivity to HTN (TOD), such as 
the kidneys, the heart and the arterial system. In line with such context, one of the main 
purposes of this study was to analyses possible linear relationships between detected 
changes in BP, and changes on selected surrogates of TOD, namely changes on LV 
mass, changes on renal function and on ACR, after RDN. 
In the cross analysis combining the observed simultaneous changes on ABPM 
systolic BP, on LV mass index and on ACR, one year after RDN, there seems to be no 
linear relationship between changes either in ABPM systolic BP, LV mass index and 
ACR, for the entire population, as depicted by the very low r2 values obtained and the 
scatter plots. (Fig. 24). 
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Figure 24: Cross analysis of correlation between changes in average systolic BP on ABPM, 
ACR and LV mass one year after RDN.
Regarding the response rate to RDN to any of the selected endpoints, in the cross 
analysis combining the observed simultaneous changes on ABPM systolic BP, on LV 
mass index and on ACR, one year after RDN, it seems uncommon to find patients that 
do not respond to RDN in both analysed surrogates (upper right quadrant). Frequently 
they will respond to both (inferior left quadrant), more evident in the ABPM‑systolic BP 
vs ACR relationship (Fig. 25).
BPM SBP vertical line set at 2mmHg for responder in ABPM systolic BP reduction.
ACR horizontal line set at 0 mg/g for responder in ACR reduction.
LV Mass vertical and horizontal line set to 5% reduction in LVM.
Figure 25: Cross analysis of responders one year after RDN,  
to ABPM systolic BP, LV Mass and ACR.
We must consider the presence of some extreme out layers in the ACR distribu‑
tion, which may bias the relationship with the other endpoints. If we exclude these ACR 
out layers values from the analyses, the same conclusion may be drawn, as in previous 
graphics, (Fig. 26). 
83
CHAPTER 3: RESULTS
Figure 26: Cross analysis of responders one year after RDN,  
excluding ACR extreme out layers (those with ACR >1500).
We also looked specifically to the proportion of responders to RDN, from all 
patients (n=31), in any of the selected endpoints, isolated or in combination with each 
other (Fig. 27). 
Figure 27: Rate of of responders to RDN at one year, regarding the studied endpoints, 
according to predefined cutoffs: >2mmHg decrease in average ABPM systolic BP, > 5% 
decrease in LV mass and any decrease in ACR value. 
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From that analysis, it seems that there is some consistency among them. All 
patients showed a response to RDN in at least one endpoint, according to the prede‑
fined cutoffs, either a decrease on ABPM systolic BP, or on LV mass or on ACR. Less 
patients had responded to RDN in all endpoints, but still a clinically significant amount, 
42% (n=13),.
Looking for the proportions of responders to each isolated endpoint, the values 
seems to leverage around 65% to 77%, with lesser responders regarding LV mass 
(65%) and equal proportions in ABPM average systolic BP and ACR values (77%). 
Nonetheless, all patients with severe resistant HTN, once submitted to RDN, respon‑
ded at least to one important known surrogate of a major clinical event, HTN, proteinu‑
ria or myocardial hypertrophy.
The small patient’s sample in this study make‑it impossible to achieve statistical 
significance
The reason for such puzzling discrepancies is presently unknow. It may represent 
a different sensitivity to RDN, of underlying mechanisms driving myocardial hypertro‑
phy, BP rising or proteinuria, or eventually, it may be related to a different role of SNS 
activity in their underlying mechanism. But at present, it is still an open question.
sAfety of renAl denervAtion
An important concern of the RDN procedure was safety. There were no major 
complications events, namely death, serious bleeding, emboli or life‑threatening arrhy‑
thmias.
No kidney related complications occurred during the study, such as chronic or 
transient loss of kidney function, kidney perforation or renal artery perforation, occlu‑
sion, dissection, stenosis or pseudoaneurysm.
Concerning the vascular site access, there were 3 mild hematomas spontaneou‑
sly resolved, and 1 femoral pseudoaneurysm treated with surgery. All of them without 
any permanent sequelae. There were other minor events such as symptomatic hypo‑
tension (one patient), orthostatic hypotension (one patient) both easily controlled with 
drug adjustment. No other minor complications such as contrast related, electrolyte 
disturbances or with procedure related medications.
A major concern regarding the renal impact of RDN, was changes in renal func‑
tion, namely GFR. There were no significant changes in creatinine as in eGFR as depic‑
ted from Figure 28.
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Figure 28: Changes in the median values of eGFR,  
between baseline and one year, after RDN.
In summary, renal denervation was a very safe procedure. Even considering, that 
those patients were frequently obese (68%), some of them severely obese (9 patients, 
29%, with a BMI>35kg/m2), which significantly increases the risk of femoral access 
complications, the overall rate of clinically relevant access vascular complications, 
demanding special attention, was very low, 3% (1 patient), managed without any per‑
manent sequalae. 
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summAry
In the present chapter, a comprehensive discussion of the main results of the 
thesis is provided. The main findings of our study, at one-year follow up, were: 1) RDN 
in patients with severe resistant hypertension was associated with significant reduction 
on both office and 24-hours ambulatory blood pressure measurements; 2) There was 
a significant reduction on left ventricle mass index, a recognized marker of hyperten-
sion related target organ damage; 3) There was a significant decrease in the median 
urinary albumin to creatinine ratio, and in the percentage of patients with an urinary 
albumin to creatinine ratio >30mg/g, observed both in blood pressure responders 
and non-responders, without changes in estimated glomerular filtration rate; 4) there 
were no linear relationships among the changes observed after renal denervation, in 
the three studied endpoints: ABPM systolic blood pressure; Left ventricle mass index 
and urinary albumin creatinine ratio. These 4 main findings are discussed in separate 
subchapters.
The initial results with RDN were very promising 1‑3, but the simplicity HTN‑34 fai‑
led to meet its primary efficacy endpoint, raising doubts about the real biological effect 
of this catheter based treatment on HTN. The unexpected negative results of HTN‑3, 
were extensively discussed and many possible explanations for the results were poin‑
ted out, clinical, patient selection, extensive changes in medication during the study 
and procedure related, mostly regarding the low number and inadequate pattern of 
radiofrequency applications.5
The results from the recent studies, Spyral HTN off‑med6 and Radiance Solo 
Trial7, helped to clarify some of the doubts raised by Symplicity HTN‑3 Trial. These 
randomized blinded trials, with sham controlled arms, in hypertensive patients without 
drug treatment showed a significant decrease on systolic and diastolic ABPM BP in 
patients submitted to RDN when compared to the sham‑controlled group, providing the 
scientific evidence for an isolated clinical meaningful effect of RDN on HTN.
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Almost all trials performed to date used as a marker for RDN efficacy, the sin‑
gle endpoint of changes in BP from baseline. However, its well known in the medi‑
cal community, the close relationship between HTN and damages in some specific 
organs – HTN target organs damages.8‑11 Such damages have a close relationship with 
patients ‘prognosis.12‑16
The aim of these study was to evaluate in an integrated approach, the impact 
of RDN in BP and in specific damages on organs known to be targets of HTN long‑
term harmful effect. Such impact was assessed through the simultaneous evaluation of 
changes on BP and on the LV structure, function and on kidney function. Up‑to‑date, to 
the best of our knowledge, it’s the first time such approach has been performed.
At one year after RDN, the main findings of our study were: 1) RDN in patients 
with severe resistant HTN was associated with significant reduction in both office and 
ABPM BP; 2) There was a significant reduction in LV mass index, a recognized marker 
of HTN related TOD; 3) There was a significant decrease in the median ACR, and in 
the percentage of patients with an ACR >30mg/g at one‑year follow up; observed both 
in BP responders and non‑responders, without changes in eGFR; 4) There were no 
linear relationships among the changes observed after renal denervation, in the three 
studied endpoints: ABPM systolic blood pressure; Left ventricle mass index and urinary 
albumin creatinine ratio. 
Each one of these results, due to their clinical relevance will be discussed in a 
separate subchapter.
impAct on blood pressure
Renal denervation has been associated with a significant reduction on both office 
and ABPM BP in many trials1, 17, 18 and registries.19 Our findings seems to be in line 
with such results, revealing a statistical and also clinical meaningful drop on office and 
ABPM BP at one year after RDN, with an average reduction on office systolic BP of 
27 mmHg (from 176±24 to 149±13mmHg, p=<.001) and 11 mmHg on diastolic BP 
(from 90±14 to 79±11mmHg, p<.001). Although in a smaller degree, similar results 
were obtained in ABPM measurements: an average decrease of 18mmHg on systolic 
BP (from 150±20 to 132±14mmHg, p=<.001), 9 mmHg on diastolic BP (from 83±10 
to 74±9mmHg, p<.001) and 5mmHg on average (67±18 to 58±13mmHg, p=0.001) 
on ABPM pulse pressure, an important clinical surrogate of HTN related TOD. This 
favorable impact on BP also meant a readjustment in the number of antihypertensive 
drugs prescribed, with a reduction in the number of drugs in use at one year after RDN, 
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from 5.8±1.1 to 5.0±1.2 (p=0.002) and in the number of drug classes, from 5.5 to 
4.9±1.1 (p=0.015).
The rate of responders to RDN after one year, were 83.9% considering a drop of 
10mmHg in office systolic BP and 71% considering a drop of 2mmHg in ABPM. Those 
results are all in line with most of the previous and more recently published trials and 
studies.1, 6, 7, 17, 20‑22
Symplicity HTN‑2 study,17 the first randomized trial to show a BP reduction at six‑
month follow‑up after RDN, reported an average reduction of 32 mmHg on systolic BP 
and 12 mmHg on diastolic BP, but other trials like Prague‑15,23 DENERHTN22 and the 
more recent trials,6, 7, 21 showed a more modest but still consistent decrease in BP, more 
in line with those obtained in this study.
Off notice is the low percentage of patients with true severe resistant HTN, which 
were considered suitable by our RDN‑Team for RDN. From a total of 318 patients, 
with suspected resistant HTN evaluated in a dedicated HTN outpatient clinic, only 
65 were considered eligible for RDN, a ratio of 5 to 1 (20%). The main reasons for 
exclusion were adequate BP control after drug adjustments (n=139, 44%), severe 
renal dysfunction with a eGFR <30mL/min (n=85, 27%), and the identification of 
secondary causes of HTN (n= 31, 10%), accounting together for more than 80% of 
the refusals.
The HTN treatment strategy adopted in this study of maximum tolerated drug 
treatment, before recommending RDN, may eventually had an influence in the final 
results. In addition, the number of patients treated with spironolactone in this study 
(74,2% at baseline and 83.9% at one year) was much higher in comparison with 
some previous published studies.4, 17, 24 Such disparity mean that such drugs are more 
tolerable than previously noticed, but also, that the patients selected to RDN were 
most probably true resistant hypertensive. DenerHTN trial22 used spironolactone in 
79% of patients with resistant HTN submitted to RDN, similar to this study and achie‑
ved similar results on ABPM BP decrease, reinforcing the concept that RDN on top 
of optimal anti‑hypertensive therapy decreases BP even further. Interestingly, one 
predictor of HTN decrease with RDN, in HTN 3 trial5, was previous treatment with 
spironolactone.
The use of spironolactone may have had an influence on the final results, not only 
as a predictor of HTN decrease with RDN, but also by its direct effect on LV hypertro‑
phy25, 26 and on proteinuria,27‑29 opening an argument on the possible synergistic effect 
of RDN on top of optimal anti‑hypertensive drug treatment including spironolactone.
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A limitation of this registry was the absence of control of drug taking by the 
patients, by serum or urine testing. A previous study, assessing adherence to HTN 
drug therapy through measurement of serum antihypertensive drug levels, revealed that 
34.5% had no detectable drugs in circulation and that 65.5% met criteria for nonadhe‑
rence to drug treatment.30 In the more recent Spyral HTN‑ON MED trial21, 37.5% of 
patients had incomplete or non‑adherence to drug therapy, with a high variability along 
the study, even knowing that they were under close scrutiny and drug testing. Such limi‑
tation can also make a case for the synergistic effect of RDN and drug therapy, as the 
long‑term effects of the former are not depend on patient’s will and can therefore limit 
the negative impact of patients non‑adherence on HTN treatment, with its ”always‑on 
effect”.21
In this background, it is difficult to be certain whether the impact of RDN on BP 
levels is due to the intervention itself, or to a possible better compliance to therapy, or 
even a placebo effect, so care should be used in translating these results to clinical 
grounds, until newer studies and results are published.
Another important issue is that sympathetic activity may vary along the day, 
from patient to patient, and in different stages of HTN. It is therefore crucial to mea‑
sure sympathetic activity, ideally before and after RDN, to identify objective para‑
meters able to predict the response to RDN, to enable better selection of patients 
with greater potential to respond and to identify possible non‑responders, avoiding 
unnecessary procedures and risks. Until then, the combined use of a safer techni‑
que as RDN with drug treatment, may overcome such limitation, as drugs can still 
exert their effect on those hypertensive patients with unidentified normal sympathe‑
tic activity.
Finally, our results come from a registry with a very rigorous selection process of 
patients for RDN, perceived from the high number of antihypertensive drugs (median 
5.8), the wide use of spironolactone, the high baseline office and ABPM BP as depic‑
ted from the patient selection flowchart, with an almost 5 to 1 proportion between 
patients that were evaluated and selected. It is worth mentioning that an median of 5.8 
drugs were higher than those reported by other similar studies31, 32 (ranging from 4.3 in 
the study of Schirmer SH et al31 to 4.7 in the study of Brandt MC et al.32).
Considered to be a more accurate evaluation of treatment impact on BP, ABPM 
was used in all patients.33 Lastly, our results were evaluated one year after RDN, a sig‑
nificantly longer follow‑up than those reported by some previous studies, who evaluated 
patients at 6 months follow up.31, 32, 34
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impAct on left ventriculAr structure & function
Left ventricle hypertrophy is one of the most important markers of HTN related 
TOD and has been associated with an increased rate of cardiovascular events and 
death, independently of BP values12‑14. With this rational, this study pursued to evaluate 
the impact of RDN on LV structure and function, at one‑year follow‑up.
In this study, a significant reduction on LV mass was noticed, in line with pre‑
vious studies that also used transthoracic echocardiography 31, 32 or cardiac magnetic 
resonance 34. Brandt MC et al32 in a study including 46 patients, using transthoracic 
echocardiogram, found that RDN was associated with a significant reduction in LV 
mass index and improvements in mitral valve lateral E/E ,´ indicator of LV filling pressure. 
In another small study using a similar methodology, Schirmer SH et al 31 assessed the 
impact of RDN on LV hypertrophy by echocardiography and were able to document 
that in patients with resistant HTN, the observed reductions in LV mass were similar 
across terciles of baseline systolic BP, suggesting that the pathophysiology behind LV 
hypertrophy could be related to a direct effect of SNS hyperactivity, not dependent on 
BP or heart rate. But, it is worth mentioning that in the present study, the use of drugs, 
was on average 5.8, higher than 4.3, reported by Schirmer et al31 and 4.7, reported by 
Brandt MC et al 32. 
In this registry a linear correlation between LV mass and ABPM systolic BP chan‑
ges at one‑year, was not found, who suggests that LV hypertrophy reduction after RDN 
might be affected by other mechanisms beyond BP reduction. Previous studies35 des‑
cribed that for similar BP reductions, different pharmacological agents had a diffe‑
rent impact on LV hypertrophy. In one interesting study, for the same magnitude of BP 
reduction, a greater regression in LV hypertrophy was achieved with a drug combina‑
tion that targeted simultaneously the neuroendocrine activity (both the RAAS and the 
SNS activity).36 
A recent cardiac magnetic resonance study 37 evaluating the impact of RDN on 
LV structure, in hypertensive patients, observed that the reduction on LV mass, besides 
the reduction in myocyte hypertrophy was also associated to an absolute reduction 
on collagen content and diffuse interstitial myocardial fibrosis, helping to clarify the 
possible mechanisms underlying the LV mass reduction observed in previous studies. 
In another study, using cardiac magnetic resonance imaging, Mahfoud F et al 34 also 
verified that at 6‑months follow‑up, RDN was associated with a significant reduction in 
LV mass index, an improvement in LVEF and a reduction in LV circumferential strain, a 
surrogate of diastolic function.
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Taken together, these studies are consistent with the favorable impact of RDN 
in LV mass regression and improvement in several markers of diastolic function. In our 
study, we also found a significant reduction in LV mass but there were no significant 
changes in transthoracic echocardiogram parameters of diastolic function. In addition, 
we didn’t find any reduction in left atrial volume index. There was a small but signifi‑
cant increase in LVEF and LVEDV, which could be explained, at least partially, by the 
numerically lower heart rate at one‑year follow‑up documented on office and on ABPM 
recordings. This small increase in LVEF is in line with some 32, 34 but not all of previous 
studies 31.  
The lack of a linear correlation found in this study, between the observed changes 
in BP and the observed changes in LV mass, raises some doubts on the assumption, 
that a sustained high systemic arterial BP and the consequential increased after‑load 
is the main stimulus promoting concentric hypertrophy on LV cardiomyocytes.38‑40 Our 
results and those from previous studies are not in line with such hypothesis.
An alternative explanation, for such a lack of correlation, may rely in the fact that 
an increased SNS activity is responsible, in different degrees, for a rise in BP by well‑
‑known mechanisms,41‑43 and also for an increase in LV mass by either a direct stimulus 
on cardiac myocytes,44 or indirectly through the activation of RAAS axis, a well‑known 
promoter of LV hypertrophy.45 
In such a scenario, an approach with drug‑agents blocking the RAAS axis com‑
bined with RDN reducing the SNS activity, may well be much more efficacious in redu‑
cing BP and the overall impact of HTN related TOD, with a better improvement of 
cardiovascular risk and prognosis of hypertensive patients, instead of simply pursuing 
the reduction of BP either with drugs or RDN. This reinforces the concept that solo 
changes in BP may not be the best surrogate of efficacy, in assessing overall RDN 
impact on the prognosis of patients with severe resistant HTN.
impAct on renAl function
Concerning the impact of RDN on renal function, the main findings of our study 
were: 1) a significant decrease in the median ACR and in the percentage of patients 
with an ACR >30mg/g, between baseline and one year after RDN; 2) a reduction in 
ACR observed in both BP responders and non‑responders; 3) there were no changes 
on eGFR.
The ACR is a well‑recognized marker of long term HTN damaging impact on 
renal function, who has been linked to unfavourable cardiovascular outcomes in 
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several studies.46‑48 In a recent study, Ott C et al49 found a significant reduction 
on ACR at 6‑months follow‑up, in 59 patients with resistant HTN (average ABPM 
systolic BP of 156mmHg, treated with an average of 5.5 drugs). In contrast with 
the previous study, we also included patients with normal (<30mg/g) baseline ACR 
and therefore our median values are lower than those reported by Ott C et al.49 
Even with this mixed population of different ACR baseline profiles, with half of them 
having a normal urinary albumin excretion (51.6% with ACR <30mg/dl), a mean age 
of 65 years, an average baseline ABPM systolic BP of 150mmHg and a treated with 
median number of 5.8 drugs per patient, our results are very similar to the study of 
Ott C et al.49 Even though, we included a higher percentage of patients with type 
2 diabetes (71%), compared to the 51% in the study from Ott C.49 Another single 
centre study, recently published, Verloop et al 50 achieved only a modest decrease 
in HTN after RDN, and failed to demonstrate any significant decrease in both LV 
mass (by cardiac magnetic resonance) and urinary albumin excretion. These results 
are in contrast with others in previous studies and with our owns. To understand 
such discrepancy, some differences in the selected population should be taken 
in to consideration. In the study of Verloop et al50, the mean age was lower (58 
years) and so was the median of 4 antihypertensive drugs, as opposed to 5.5 in the 
study of Ott C et al49 and 5.8 in our study, so was the much lower prevalence of 
diabetes (only 15%) and the fact that the authors didn’t excluded patients with an 
eGFR<45ml/min.
One interesting observation in our study is the fact that the reduction on ACR was 
also found in BP non‑responders, although not reaching statistical significance, proba‑
bly due to the small sample size of this subgroup. This raises the question of whether 
RDN, by reducing sympathetic hyperactivity, might have a positive direct effect on glo‑
merular endothelium function, independently of the hemodynamic effect derived from 
the BP reduction, since there is a close relationship between urinary albumin excretion, 
glomerular endothelium dysfunction and glycocalyx damaging. 47, 51 
We may raise the hypothesis, if a modulation of SNS through RDN will posi‑
tively affect endothelial dysfunction, a common denominator in cardiovascular and 
renal disease, normally associated to an increased SNS activity.52 If so, such a 
favourable impact on endothelial dysfunction may affect, in different degrees, BP 
and glomerular function and ultimately have a favourable impact in the overall car‑
diovascular risk, which is the ultimate‑goal for these patients, independently of BP 
changes per se.
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These results are in line with those found for LV mass index and taken together 
reinforces the concept that solo changes in BP may not be the best surrogate of effi‑
cacy for the overall impact of RDN on the prognosis of patients with severe resistant 
HTN.
These favourable results of reduction on ACR and on LV mass index, found in 
this study, should be interpreted in the context of the high cardiovascular risk of these 
patients with resistant HTN, 11, 53 if proven to be consistent, such reductions are expec‑
ted to contribute significantly to lower the overall cardiovascular risk, commonly asso‑
ciated to severe resistant HTN, although at the present, there is no published studies 
on the prognostic impact of RDN in major clinical outcomes.
relAtionsHips between cHAnges on blood pressure  
And on tArget orgAn dAmAge
One aim of this study was to analyse in the entire population, the relationships 
between changes in BP and on surrogate markers of HTN related TOD, by the simul‑
taneous evaluation of the RDN impact, at one year, on BP, LV function and structure 
and on renal function. To pursuit such task, a cross analysis of BP, ACR and LV mass 
responders to RDN was performed, looking for the presence of linear correlations and 
their responder status distribution in the scatter plots graphics.
The following results were found. When depicted alone, the rate of responders 
to each one of the selected endpoints, showed some consistency, ranging from 64% 
on LV mass to 77% on ABPM systolic BP and ACR. When combined, the rate of 
responders, decreased significantly, still, almost half of the patients (41%) responded 
simultaneously to all endpoints (ABPM systolic BP; LV mass and ACR) and all of them 
responded at least to one endpoint.
Such discrepancy between the rate of responders to a single endpoint or to a 
combined set, could be related to a lack of a linear relationship between them. When 
we analysed the relationships between changes on BP, on LV mass and on ACR, no 
linear correlation was found between them. Such results don’t come as a surprise, as 
they were previously reported in other studies. 44, 54‑57
As previously mentioned, it is understood that LV and proteinuria are direct 
consequences of long‑term chronic mechanical stress of high BP, on the LV myo‑
cardial and arterial walls, eventually causing endothelial dysfunction, and changes of 
glomerular permeability to proteins.58, 59 57, 60, 61 In such model, it is perceived, that the 
correction of HTN, with a sustained drop on BP, will have a negative feed‑back on the 
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HTN mechanical stress over the cardio‑renal system, thus, a positive effect either on 
LV mass or in the ACR, which should be proportional to the degree of BP decrease. 
In such “mechanical” context, it is expected to find a certain linear relationship bet‑
ween the degree of BP decrease after RDN and the degree of improvement in the 
HTN related TOD, LV mass index and ACR values. That was not the case in this study 
with RDN.
The lack of any linear correlation between the decrease in BP, achieved after 
RDN, and the changes in HTN related TOD, assessed through LV mass and ACR 
changes, raises doubts if other factors, besides high BP mechanical trauma, are also 
implicated in the underlying mechanisms of HTN related TOD, such as LV hypertrophy 
and glomerular endothelial dysfunction.44, 56, 62, 63 In this case, isolated changes in BP 
may not be sufficient to alter the stimulus (or may not be the prime stimulus) driving 
myocardial hypertrophy or glomerular endothelial dysfunction.
If this hypothesis is confirmed, then any HTN treatment strategy, aiming only BP 
decrease, may not be sufficient to achieve the ultimate goal of reducing long‑term HTN‑
‑related TOD and the ultimate goal of preventing major clinical events affecting HTN 
patients.
A possible alternative, to be tested in future studies, is a treatment strategy 
aiming, in simultaneous, the sympathetic‑endocrinal system (SNS and RAAS axis), 
known to have a pivotal role in BP control and eventually in HTN aetiology. If such 
approach proves to be more efficacious in the control of HTN and in the preven‑
tion of TOD, then current strategy of using only drug treatment as a first option to 
HTN treatment, must be changed for a combined initial approach of RDN and drug 
treatment.
Off course, other studies and trials are strongly needed to prove such concepts 
and to increase our understanding on the full scope of RDN impact in the cardiovascu‑
lar and renal systems.
procedure sAfety
One of the most important results of this study was procedure safety. There were 
no major complications, clinical or kidney related, such as chronic or transient loss 
of kidney function and there was no change in eGFR at one year after RDN. Some 
minor events, like symptomatic hypotension (one patient), orthostatic hypotension (one 
patient), were easily controlled with drug adjustment. 
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The only concern in this study were complications related to femoral access site: 
3 mild hematomas spontaneously resolved, and 1 femoral pseudoaneurysm treated 
with surgery during the hospital stay (1 in 31 patients, 3,2%). All of them without any 
permanent sequelae. We should consider, however, the high‑risk population for femo‑
ral access procedures. Obesity (BMI>30kg/m2) was present in 68% of patients and 
severe obesity (BMI>35kg/m2) in 29% (9 patients), who makes femoral access par‑
ticularly risky. Overall the rate of clinically relevant, access vascular complications nee‑
ding special attention, were very low, considering the single case of pseudoaneurysm 
successfully managed without sequalae.
In previous studies,1, 4, 6, 7, 20, 21, 64 the rate of serious complication related to RDN 
were also very low, ranging from 0 to 13%, in line with this study, although in this study, 
the BMI was higher than in previous studies (31.8 vs 30.6kg/m2), the patients were sic‑
ker, with more antihypertensive drugs, including spironolactone, all of them with severe 
HTN resistant to drug treatment and 71% were diabetics, all predictors of vascular 
access complications.65 
In the future, the standard use radial access, will decrease even further the rate 
of complications,66 allowing the treatment of more complex and higher risk patients. Of 
notice is the fact that, this research group performed the first case of RDN by radial 
access,67 that will became the standard access route, once dedicated radial devices 
become available. 
study limitAtions
This study has several limitations that must be acknowledge. It is a single center 
prospective registry, with a small sample size population, making difficult to draw defi‑
nitive conclusions on RDN safety and efficacy and to identify predictors for non‑res‑
ponders.
Routine assessment of renal artery during follow‑up, to identify local vascular 
complications, was not systematically performed in all patients, preventing a full asses‑
sment of long‑term renal artery safety, after radiofrequency ablation.
There was no control group and no blinding for the patients and the physicians 
performing either the follow‑up or the echocardiogram, although the important outcome 
measurements, ABPM and ACR values, were performed by cardiac and laboratory 
technicians unware of treatment status. 
There were changes on antihypertensive drug therapy during follow‑up, which 
can interfere with BP, LV mass and ACR measurements. Nevertheless, in our study the 
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mean number of drugs was reduced at follow‑up, meaning that, the reduction obtained 
with RDN could have been underestimated in this real‑world setting.
Patients adherence to drug therapy was assessed only by questionnaires during 
prescheduled clinical visits. It was not verified with validated techniques such as urine 
and blood testing.
Cardiac resonance was not used and could have provided a more accurate 
evaluation of LV mass and function changes. 
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conclusions
In this single center, non‑blinded, prospective registry involving patients with 
severe resistant hypertension, refractory to drug therapy, renal denervation by means of 
radiofrequency, was associated with a significant reduction in blood pressure by office 
and 24 hours ambulatory measurements. In addition, there was a significant decrease 
in left ventricular mass, evaluated by transthoracic echocardiogram, and a significant 
decrease in the median urinary albumin to creatinine ratio, without changes in estimated 
glomerular filtration rate, at 12‑months follow‑up, after renal denervation. There was also 
a reduction in the percentage of patients with a pathological urinary albumin excretion. 
All those changes occurred, despite a reduction on antihypertensive drug treat‑
ment, prescribed during the 12 months of follow‑up.
Interestingly, our results revealed an absence of any linear correlation between 
changes in blood pressure and changes in the selected surrogates of hypertension 
related target organ damage, namely left ventricular mass and urinary albumin to crea‑
tine ratio. In the absence of an objective measurement of sympathetic activity before 
and after renal denervation, it is difficult to establish a causality effect between the level 
of blood pressure and the level of changes in the left ventricular mass or urinary albumin 
to creatine ratio, an important limitation for renal denervation.
Another important result from our registry was that renal denervation proved to be 
a very safe procedure. Without clinically relevant complications, namely major vascular, 
renal or cardiovascular complications, until 12 months of follow‑up.
Thus, renal denervation appears to be a valid option for patients with resistant 
hypertension, with important clinical benefits beyond improved blood pressure con‑
trol. Nevertheless, randomized studies with larger populations samples are required to 
assess the impact of this intervention on major clinical events in the long‑term.
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summAry
The arrive of newer device-based treatments, will certainly change the field of 
hypertension management, perhaps its diagnosis and underlying pathophysiology. 
Results of previous and undergoing studies and trials, had already changed clinical 
practice. The routine use of 24-hour ambulatory blood pressure management as stan-
dard for hypertension assessment and management is one of them. The important 
problem of patient adherence to treatment will become central in planning hyperten-
sion treatment strategies, especially with drugs, and probably will make device-based 
renal denervation, a first choice with its “always on treatment effect”. Patient prefer-
ence will also play a role in future clinical decision-making.
Still, there are many ongoing challenges for renal denervation. The identification 
of underlying mechanism beyond non-responsiveness to RDN, is a priority. It may be 
related to the technical procedure, a limitation that can be overcome with techno-
logical improvements, newer devices and a better knowledge on renal nerves map-
ping and trafficking. Proper patient selection will also be of utmost importance since 
patients with low or normal renal nerve trafficking, may not need the renal denerva-
tion, avoiding unnecessary risks. To overcome such limitation, a reliable technology, 
capable of assessing renal sympathetic activity before and after the procedure, to 
validate its efficacy, is much needed. Only then will be possible to better understand 
the underlying pathophysiology and possibly enlarge the scope of sympathetic renal 
denervation, to treatment of other diseases closely related to an increased sympa-
thetic activity.
new cHAnges in Hypertension mAnAgement
One of the first conclusions coming from RDN trials and studies, performed until 
now, was the pivotal role of ABPM measurements in HTN management, in the diagnos‑
tic phase, allowing a better definition of resistant HTN, but also in the assessment of 
treatment efficacy. ABPM became the central testing in HTN management overshado‑
wing office assessment.1 
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Another issue, that surfaced with RDN studies and trials, was patient adherence 
to drug treatment. Even in trials were patients were strongly advised to comply with 
medication, and were told in advance that they were under closed surveillance with 
periodical drug testing for compliance, 15% failed to comply, with no reasonable justi‑
fication.2, 3 Low patient’s compliance to drug treatment will certainly imply a redefinition 
of resistant hypertension, as the most important cause for resistant HTN may be the 
lack of patient’s adherence to treatment.
These unresolved issues became more relevant in face of the hypothesis of a 
“single shot” treatment for HTN, that is “always on”, and is not dependable on patient 
will and future compliance.
The recently published Spyral HTN‑Off Med trial2 started a new strategy for the 
initial treatment of HTN, a device‑based strategy, instead of a drug‑based treatment. 
This was the first time that a device‑based treatment for essential HTN was tested as 
a first‑choice strategy. The long‑term success of such a strategy will depend, ultima‑
tely, on the answer to some important questions on RDN: Is BP control sustainable 
in the long‑term? Which side effects can we expect? Are there additional pleotropic 
effects? 
The new active role of patients, in the clinical decision process, regarding HTN 
management, is another important issue, raised by the Spyral HTN‑Off Med Trial.2 The 
patient will have the power to co‑decide with his physician, witch treatment he wants as 
a first choice for the initial treatment of its HTN: a device based or a drug based. This 
new role may come along with a more prominent patient expectation on HTN treatment. 
Until now, with drug treatment, patients expected HTN control. With a more invasive, 
complex and single shot procedure, they may expect HTN cure with no additional needs 
for drugs and no side effects, an evidence that at the present is still lacking. 
These new tools for HTN treatment, will also mean newer treatment options: HTN 
device‑based treatment only, drug treatment only, as first choices or low dose drugs 
combined with device treatment.
The long‑standing efficacy is still to be demonstrated. Many open question 
remains: will it fades with time? Will there be a place for a redo procedure? If so, 
What will be the added efficacy? What about complications or side effects of a 
repeated procedure. Will it maintain the very favourable safety profile of RDN as 
described so far?
Another pending question, is: Which patients will be non‑responders to RDN? 
Why some patients are non‑responders? Is it related to the device or to the techni‑
que? Is there a patient phenotype more adequate for a device, for a drug approach, 
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both or for a specific device? Their identification in advance would be very useful, 
not only because it will avoid unnecessary procedures and risks, but also because 
it will improve treatment success, patient safety and confidence, and ultimately, 
outcomes. 
Higher efficacy in HTN treatment is expected alongside higher complexity. Until 
then more studies and trials are needed to provide proper scientific evidence to support 
such new strategies.
new side effects
Until now, all published studies and trials on RDN had in common a very high 
safety profile for all tested devices. Nevertheless, published results were all in the shor‑
t‑term.4‑10 It is possible, with longer follow‑ups, that the safety profile may change, with 
higher or newer complications or side effects. Long‑term renal artery stenosis is still a 
concern, although rarely reported so far. A sustainable decrease in SNS activity, after 
RDN, may have unpredictable and newer side effects, demanding our constant watch‑
fulness to promptly identify them and provide the proper solution.
The more recent trials2, 3 still reveals a high variability in HTN response to RDN. 
A significant proportion of patients, around 20 to 30%, on average, didn’t showed a 
decrease in BP after RDN. They were tagged as non‑responders. But, even though 
some of them didn’t showed significant changes in BP after RDN, others, rather sho‑
wed an increase in BP after RDN. Such behaviour may be related to the complex patho‑
physiology of HTN or to the intrinsic variability of BP response to RDN. But, it may also 
be a potential side effect of RDN, a paradoxal increase in HTN after RDN. 
Such concern, strongly supports the need for markers of SNS activity, simple, 
reliable, reproductible, applicable on real time and able to verify SNS activity before and 
after RDN, allowing the online assessment of its efficacy.11
The medical community must be on continuous alert and prepared to deal pro‑
perly with such unwanted events. Such environment is not totally new for interventional 
cardiologists, since the extensive experience in dealing with other previous devices, 
has teach them how to deal with such surprises and use them as an opportunity to 
improvement. 
109
CHAPTER 5: FUTURE RESEARCH OPPORTUNITIES
new indicAtions And future clinicAl cHAllenges
Since SNS has a direct interference in a broad range of systems in the human 
body, initiating or stopping many different actions in different tissues and organs, 
through distinct receptors, it is largely expectable that trafficking modulation of sympa‑
thetic renal nerves, namely the renal afferent ones may have more generalized effects 
besides BP changes.12‑14
Sustained chronic change in sympathetic activity is involved in many different 
diseases, from metabolic to psychological disorders, including ischemic heart disease,15 
heart failure,16, 17 kidney disease,18 type 2 diabetes,19, 20 obesity,19, 20 obstructive sleep 
apnoea21 and inflammatory bowel disease22, issues previously reviewed in the introduc‑
tion chapter.
Among such a pleiades of effects, it will not be a surprise, if newer pleotropic 
effects arise from sympathetic activity modulation provided by RDN. After RDN, the 
expected overall decrease on SNS drive, may have a significant impact in other clinical 
scenarios characterized by SNS hyperactivity. Small proof of concept studies, have 
already showed promising results.
The association between heart failure and increased sympathetic drive is well 
known. Interestingly, cardiac and renal spillover of norepinephrine are more closely 
associated with mortality than circulating catecholamine concentrations, both related 
to worst outcomes.23, 24 This provides the evidence that reducing NE spillover from the 
kidney, by RDN, could have a beneficial symptomatic and prognostic effect.25, 26 
In animal models, RDN after myocardial infarction showed an improvement on 
sodium excretion27, increased cardiac output, improved renal blood flow28, and a down‑
‑regulation of angiotensin AT1 receptors mediating maladaptive responses.29 In a mul‑
ticentre study on patients with resistant HTN treated by RDN, a subgroup of patients 
with LV dysfunction, with their anatomic and functional myocardial parameters asses‑
sed by cardiac magnetic resonance, had their LVEF and circumferential strain signifi‑
cantly increased.30 The REACH pilot study, in heart failure, provided evidence that RDN 
was able to improve the 6 minutes walking test results, without affecting BP (average 
120 mmHg at baseline).31 
Type 2 diabetes and insulin resistance have a strong association with resistant 
HTN. About 50% of resistant HTN patients are considered to be insulin resistant, 
increasing the risk for type 2 diabetes and, since insulin resistance is dependent on 
sympathetic activity, it appears likely that it could also be a target for RDN.32, 33 Small 
studies revealed that, along with BP reductions, RDN improved fasting glucose, sus‑
tainable decline in glycated hemoglobin concentrations, insulin and C‑peptide con‑
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centrations, as well as insulin sensitivity indices in patients with resistant HTN and 
metabolic disease, suggesting that RDN might improve the diabetic status, in those 
patients.34, 35
Obstructive sleep apnea and resistant HTN are a well‑known association35, ano‑
ther possible target for RDN. In 2011, Witkowski et al published a pilot study on the 
effect of RDN in 10 patients with resistant HTN and obstructive sleep apnea. At 6‑mon‑
ths, there was an improvement on apnea‑hypopnea indexes.35 An experimental model, 
revealed that RDN was able reduce the post‑apneic BP rise, renal hypo perfusion 
during apnea and activation of the renin–angiotensin system in the kidney.36, 37 
Regarding atrial fibrillation, an epidemic affecting millions of patients worldwide, 
it was shown in a recent pilot trial,38 that patients with resistant HTN and symptomatic 
paroxysmal or persistent atrial fibrillation, refractory to ≥2 antiarrhythmic drugs, rando‑
mized to pulmonary vein isolation only or in association with RDN, at 12‑month follow‑
‑up, 69% of patients submitted to RDN were free of atrial fibrillation, compared to 29% 
of patients treated with pulmonary vein isolation only, supporting a potential usefulness 
of RDN on AF treatment. 
In ventricular arrhythmias, the scientific evidence supporting the fundamental role 
of sympathetic activity on their origin is overwhelming. In an animal model of ischemia/
reperfusion‑arrhythmias, RDN decreased the occurrence of ventricular arrhythmias/
fibrillation and attenuated the rise in LV end diastolic pressure during LV ischemia, 
without influencing infarct size, changes in ventricular contractility, BP and reperfu‑
sion arrhythmias.39 In other small case series, involving patients with dilated cardiomy‑
opathy and an electrical ventricular storm, RDN was able to reduce discharges from 
the implantable cardioverter defibrillators and ventricular ectopias.40 Hoffmann et al.41 
reported that RDN can be safely and effectively performed, as an adjunct to cardiac 
catheter ablation, in a hemodynamically unstable patient with ventricular storm after ST 
elevation myocardial infarction.
The value of these findings is still controversial and confirmatory studies are nee‑
ded. 
The impact of RDN and changes on SNS activity in other diseases, and human 
systems disarrangements, outside the cardiovascular field, is still to be addressed. But 
the underlying pathophysiological evidence supporting their deep interconnecting rela‑
tionships is overwhelming.
New horizons have been opened in the understanding on how SNS disarran‑
ges may drive disease, alongside with new and better tools to track and treat those 
changes. Altogether, they will certainly push the development of newer collaborations 
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between medical groups, from different fields of knowledge, not usually involved in the 
endovascular field.
A future challenge, will be the establishment of RDN efficacy in the reduc‑
tion of major clinical endpoints in patients with HTN (the 3rd step): death, stroke, 
acute coronary syndromes, heart failure and kidney dysfunction. Only then, it will 
be possible to safely assume that RDN is at least as efficacious as drugs in HTN 
treatment. If that becomes a reality, it is reasonable to assume that RDN may be the 
first choice for HTN initial treatment strategy. The challenges facing such endeavor, 
are mostly economical. The trials needed to prove such benefits, will require large 
numbers of patients and longer follow‑ups, making them hugely expensive, but una‑
voidable!
Assessment of sympAtHetic nerve system Activity
There are still a considerable number of important issues, regarding RDN, that 
were not properly addressed until now, or even at all. One of them is how to properly 
measure RDN efficacy in respect to the decrease in renal SNS activity after RDN. A 
methodology capable of quantifying renal SNS activity before and after RDN, able to be 
used in clinical practice, safe, comfortable and reliable, is still lacking.
Until now, the scientific bases validating RDN, are clinical. Meaning the favorable 
impact of RDN on surrogates of an increased SNS activity: HTN; myocardial hyper‑
trophy or renal disfunction. Some small studies in animals and humans used NE renal 
spill‑over and smooth muscle tonus, as a proof of concept that RDN decreases SNS 
activity. But, such tests are not feasible to a broader daily clinical use.
A marker for SNS activity, simple, reliable, reproducible, applicable on real time, 
leading to a better pathophysiological understanding of what is happening after RDN, 
is much needed.11 It will help to explain possible side effects, the lack of efficacy in 
certain patients (non‑responders) driving for a better patient selection, and it will 
track possible renal nerve regrowth in the long term. It will help to validated RDN, 
to understand non‑responder patients, to improve the technique and devices. Most 
of all, it will enlarge the scope of RDN as a new treatment strategy for other disea‑
ses, known to be related to SNS hyperactivity. It will also serve as an important tool 
to understand the pathophysiology of other diseases, and eventually establish their 
relationship to SNS disarrangements, for example, the broad field of psychosomatic 
diseases.
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finAl remArks
There are urgent unmet medical needs to address by the academic, scientific 
and medical community. The latest published trials had shown very promising results 
on RDN efficacy. The enthusiasm arousing from such results may tempt the medical 
community to start using RDN solely based on the trials clinical indications, and skip 
other fundamental questions, but those answers are much needed to a better unders‑
tanding of how SNS disarrangements affects human health. Such understanding will 
become of utmost importance and will provide the much‑needed support to prevent 
and treat diseases at earlier stages.
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Abstract There is a marked contrast between the high prevalence of hypertension and the
low rates of adequate control. A subset of patients with suboptimal blood pressure control
have drug-resistant hypertension, in the pathophysiology of which chronic sympathetic hyper-
activation is signiﬁcantly involved. Sympathetic renal denervation has recently emerged as
a device-based treatment for resistant hypertension. In this review, the pathophysiological
mechanisms linking the sympathetic nervous system and cardiovascular disease are reviewed,
focusing on resistant hypertension and the role of sympathetic renal denervation. An update
on experimental and clinical results is provided, along with potential future indications for this
device-based technique in other cardiovascular diseases.
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Desnervac¸ão renal para hipertensão arterial resistente
Resumo A elevada prevalência da hipertensão está em claro contraste com a sua ainda
insuﬁciente taxa de controlo. Um importante subgrupo destes doentes apresenta uma hiperten-
são resistente aos fármacos, na qual a hiperativac¸ão crónica do sistema nervoso simpático
tem importantes implicac¸ões ﬁsiopatológicas. Recentemente, a desnervac¸ão simpática renal
emergiu como um tratamento de intervenc¸ão para a hipertensão arterial resistente. No pre-
sente artigo, são revistos os mecanismos ﬁsiopatológicos subjacentes à interac¸ão entre o
sistema nervoso simpático e as doenc¸as cardiovasculares, com particular enfâse na hipertensão
∗ Corresponding author.
E-mail address: paraujogoncalves@yahoo.co.uk (P. de Araújo Gonc¸alves).
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arterial resistente e no papel da desnervac¸ão simpática renal. É igualmente feita uma
atualizac¸ão dos resultados de estudos experimentais e clínicos, bem como de potenciais futuras
indicac¸ões desta técnica de intervenc¸ão noutras doenc¸as do foro cardiovascular.
© 2014 Sociedade Portuguesa de Cardiologia. Publicado por Elsevier España, S.L.U. Todos os
direitos reservados.
List of abbreviations
BP blood pressure
CI conﬁdence interval
eGFR estimated glomerular ﬁltration rate
SNS sympathetic nervous system
RAAS renin-angiotensin-aldosterone system
RDN renal denervation
RF radiofrequency
Introduction
Hypertension is the leading global risk factor for cardiovas-
cular mortality, accounting for more than ninemillion deaths
worldwide in 2010.1 Its close association with myocardial
infarction, heart failure, stroke, end-stage renal disease and
cardiovascular death is well established, with 54% of stroke
and 47% of ischemic heart disease worldwide attributable to
high blood pressure (BP).2 Effective BP lowering has consis-
tently been shown to reduce overall cardiovascular risk,3 but
rates of adequate BP control remain suboptimal, despite the
wide range of antihypertensive drugs available and strong
evidence supporting their use. A recently published study
conﬁrmed that rates of BP control in European countries are
low, with only 37% of treated hypertensive patients achiev-
ing recommended BP values.4
The blame for such low rates cannot be attributed only
to poor treatment. Resistant hypertension has a prevalence
ranging from 15% to 30% of treated hypertensive patients,5
and is an important cause of failure of BP control. Most
importantly, these patients exhibit a worse prognosis, with
a higher risk for cardiovascular events, compared to hyper-
tensive patients without resistant hypertension.6
In recent decades, the renin-angiotensin-aldosterone sys-
tem (RAAS) has been the central focus of hypertension
treatment and management. The availability of safe, effec-
tive and evidence-based drugs that block this system has
meant that the role of other systems, particularly the auto-
nomic nervous system, has been neglected.
The sympathetic nervous system (SNS) and its possible
role in the pathogenesis of hypertension is receiving increas-
ing attention. The aim of this review is to provide an update
on the current understanding of the role of the SNS in blood
pressure control and its implications for sympathetic renal
denervation (RDN).
The sympathetic nervous system
and cardiovascular disease
The development of open surgical sympathectomy in the
1930s highlighted the role of the SNS in severe hyperten-
sion, since it appeared to be effective in lowering high BP
in patients with severe hypertension.7,8 However, the proce-
dure was abandoned due to its poorly tolerated side effects
and high surgical risk, especially after the appearance of
ganglionic blockers, the ﬁrst effective antihypertensive drug
class.9
The recent development of a new device-based approach
to treat severe resistant hypertension, through RDN, focused
attention on the already well-known role of the SNS in ini-
tiating and maintaining high BP in patients with essential
hypertension.10,11
Assessment of the sympathetic nervous system
in humans
The major reason that the SNS has been so neglected is not
because there are doubts concerning its critical role in the
pathogenesis of hypertension and other cardiovascular dis-
eases, but because it has been difﬁcult to study and test this
relation, due to the complex and clinically impractical meth-
ods used for assessing the SNS in humans. Until the early
1970s, the most common techniques were measurements of
blood levels and urine excretion rates of norepinephrine and
its derivatives, which provide a gross estimate of whole-body
sympathetic activity at best.12 Since then, new methods
have emerged for measuring sympathetic nerve ﬁring rates
in subcutaneous nerves and for assaying plasma concentra-
tions of sympathetic transmitters.
Microneurography, a technique reported ﬁrst by Hagbarth
and Vallbo,13 provided a tool to study nerve ﬁring in sub-
cutaneous sympathetic nerves in skin and skeletal muscle
vessels. It is based on recording bursts of nerve activity,
synchronous with the heartbeat, generated in skeletal mus-
cle vascular efferent nerves, through tungsten electrodes
inserted in the skin. It is highly reproducible and closely
related to sympathetic trafﬁc directed to other structures
and can be repeated over time, allowing assessment of
the effects of interventions, direct quantiﬁcation of sym-
pathetic nerve trafﬁc regulating vasomotor tone, and study
of instantaneous reactions to rapid stimuli.
The spillover technique for measurement of norepi-
nephrine release, ﬁrst applied by Esler et al,14 is an
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Table 1 Effects of increased sympathetic nerve activity.
Vascular
Smooth muscle cell hypertrophy and proliferation
Endothelial dysfunction and damage
Arterial stiffness
Impairment of postural blood pressure control
and syncope
Hypertension
Atherosclerosis
Cardiac
Myocyte hypertrophy
Left ventricular hypertrophy
Arrhythmia
Psychogenic heart disease
Renal
Renal artery vasoconstriction
Sodium and ﬂuid retention
Microalbuminuria
RAAS activation
Metabolic
Insulin resistance
Dyslipidemia
RAAS: renin-angiotensin-aldosterone system.
isotope dilution method that calculates the clearance and
spillover of norepinephrine, using an intravenous infu-
sion of tritium-labeled norepinephrine. The relationship
between the sympathetic nerve ﬁber ﬁring rate of an organ
and the rate of norepinephrine spillover into the venous
efﬂuent of that organ provides the rationale for using
measures of regional norepinephrine release as a surro-
gate for sympathetic tone in individual organs,15 enabling
assessment of regional sympathetic nervous function in
humans.
This technique was central to the demonstration that
heart failure patients had sympathetic overactivity rather
than sympathetic denervation, as thought at the time, and
opened the way to the routine use of beta-blockers in heart
failure.16
Sympathetic nervous system overactivity
Besides its central role in cardiovascular homeostasis, by
controlling vascular tone through vasoconstriction of small
resistance arteries, the sympathetic system also affects and
regulates numerous other physiological processes (Table 1).
There is growing evidence that sustained chronic changes
in sympathetic activity are involved in the pathogenesis
of many disease states, from metabolic to psychologi-
cal disorders, including ischemic heart disease,17 chronic
heart failure,18,19 hypertension,20--22 kidney disease,23 type
2 diabetes,24 obesity,24 metabolic syndrome,24 obstruc-
tive sleep apnea,25 depression26 and inﬂammatory bowel
disease.27 A chronically overactive sympathetic system is
linked to a worse prognosis in patients with heart failure
and end-stage renal disease.28,29
Sympathetic nervous system overactivity
and cardiovascular disease
There is growing evidence that the deleterious effects on
blood vessels and myocardium of an overactive SNS are inde-
pendent of increased BP.30 Chronic SNS activation without
an increase in BP can cause hypertrophy and proliferation
of vascular smooth muscle cells as well as having a direct
trophic effect on cardiac myocytes, increasing left ventri-
cular (LV) mass and wall thickness,30 while BP reduction
after catheter-based RDN has been shown to lead to a sig-
niﬁcant reduction in LV mass and improvement in diastolic
function.31
These structural changes in the myocardium and the
direct effects of an overactive SNS contribute to the high
incidence of arrhythmias commonly seen in patients with
hypertension.32
The link between mental stress, psychiatric illness and
cardiovascular disease, although best established for heart
disease consequential to acute mental stress and depressive
illness, has been much more difﬁcult to establish.26 Acute
mental stress can trigger sympathetic outﬂow to the heart
and adrenal secretion of epinephrine. In patients with pre-
existing atherosclerosis, not only can increased epinephrine
cause ventricular arrhythmias (especially in the presence of
coronary artery stenosis), but the attendant BP surge can
ﬁssure coronary plaques and promote platelet aggregation,
predisposing to thrombosis.26 Takotsubo (stress) cardiomy-
opathy is a good example of extreme acute activation of car-
diac sympathetic outﬂow to the heart,26 as are panic attacks
accompanied by coronary spasm and cardiac arrhythmias.33
In patients with depressive illness, chronic cardiac sympa-
thetic outﬂow is at almost the same level as seen in patients
with heart failure, and is accepted as a primary cause for
heart disease, associated with a worse prognosis.
The sympathetic nervous system
and atherosclerosis
The pivotal role of endothelial impairment in the devel-
opment of atherosclerosis and in future cardiovascular risk
is well established. Less known is the interaction between
the SNS and endothelial function. Virtually all cardiovascu-
lar risk factors and diseases in which increased adrenergic
drive is involved are also characterized by endothelial
dysfunction.34 Nitric oxide (NO), one of the main mediators
of endothelial function, is also an important neurotransmit-
ter, involved in the autonomic regulation of cardiovascular
function, and acts as a sympathoinhibitory substance within
the central nervous system.35 Acute and chronic increases in
SNS activity, through endothelial dysfunction and endothe-
lial cell damage, have been shown to contribute to the
subsequent development of atherosclerosis.26,30,34
SNS overactivity has also been linked to the develop-
ment of metabolic disturbances such as insulin resistance
and dyslipidemia.36 Not only can increased SNS activity in
itself lead to insulin resistance, particularly in hyperten-
sive patients,36 but also elevated circulating insulin levels
due to insulin resistance in obese patients can precipitate
an increase in SNS activity, leading to hypertension.30,36,37
There is abundant evidence that statins, through their
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numerous pleiotropic effects, reduce and even normalize
excessive SNS activity, improving LV function and arterial
baroreﬂex sensitivity.26,30,34
Sympathetic nervous system function and heart
failure
The observation that norepinephrine concentrations were
reduced in the failing heart suggested the existence of
sympathetic denervation,38 despite the increased concen-
trations in peripheral venous plasma commonly found in
patients with heart failure,39 indicating overall increased
SNS activity except in the heart. Later studies conﬁrmed
very high levels of norepinephrine spillover from the heart
in heart failure, up to 50 times the normal range in untreated
patients,26 demonstrating high sympathetic tone in the
failing heart. This was later explained by a reduction in
the concentration of beta-1 adrenoreceptors in the failing
myocardium, due to downregulation of these receptors by
increased sympathetic activity in the failing heart.26
This increased sympathetic activity in the peripheral
circulation and kidneys leads to adverse effects, causing
vasoconstriction, increasing cardiac work, and promoting
sodium retention and ventricular overﬁlling. The strong
link between the level of sympathetic activity in heart
failure, progressive ventricular deterioration, the develop-
ment of ventricular arrhythmias, sudden death and reduced
survival26 provided the rationale for the subsequent use of
beta-blockers in heart failure.40
Sympathetic nervous system function and essential
hypertension
A well-known consequence of an overactive SNS is an
increase in BP. Previous studies showed not only that sympa-
thetic outﬂow to the kidneys was increased, but that the
extent of the outﬂow was also related to the degree of
essential hypertension.20,22,26,41 Regional measurements of
norepinephrine spillover to the kidneys support this concept,
and indicate that more than 50% of cases of essential hyper-
tension present signiﬁcant sympathetic hyperactivation.42
Renal sympathetic nerve activity is pivotal in the pathogene-
sis of essential hypertension, through its inﬂuence on renin
release, sodium and water excretion, peripheral vasocon-
striction, cardiac contraction and venous capacitance.26
The safety and efﬁcacy of BP lowering achieved recently
with RDN has led to renewed interest in the role of sympa-
thetic activity in the pathogenesis of essential hypertension.
Correct identiﬁcation of sympathetic hyperactivation in
patients with essential hypertension can lead to better
selection of patients for RDN treatment.
Resistant hypertension
Data from the PAP study involving 5023 adult patients
showed that the prevalence of hypertension in Portugal was
42%, of whom only 46.1% were aware of the fact, 39% were
taking medication and only 11.2% had BP values below the
recommended thresholds.43
Table 2 Evaluation of patients with resistant hypertension
considered to be potential candidates for renal denervation.
1st step
Exclusion of pseudoresistance (by 24-hour ABPM)
Exclusion of secondary causes
Search for conditions that maintain high BP values
2nd step
Modiﬁcation of antihypertensive treatment
(optimization of dosages and combinations; use
of aldosterone blockers if possible)
Reassessment of BP control with 24-hour ABPM
3rd step
Assessment of renal artery anatomy (CT, MRI
or invasive angiography; Doppler ultrasound)
Assessment of renal function (eGFR ideally
>45 ml/min/1.73 m2)
ABPM: ambulatory blood pressure monitoring; BP: blood pres-
sure; CT: computed tomography; eGFR: estimated glomerular
ﬁltration rate; MRI: magnetic resonance imaging.
Not all patients with uncontrolled hypertension are con-
sidered to be resistant, as there are several factors that
can contribute to lack of control, including inadequate
treatment regimens (type and/or dosage of drugs), poor
adherence to medical therapy, and undetected secondary
causes of hypertension. A diagnosis of resistant hyperten-
sion should therefore only be made after ruling out other
factors.
Resistant hypertension has been deﬁned as BP values
above 140/90 mmHg (or >130/80 mmHg in patients with
diabetes or chronic kidney disease) in patients treated with
three or more antihypertensive drugs at appropriate doses,
including if possible a diuretic.44 In an alternative deﬁnition,
patients with target BP values can be considered to have
resistant hypertension if they need to take at least four dif-
ferent antihypertensive drugs; this is known as controlled
resistant hypertension.45 The prevalence of resistant hyper-
tension has been reported as 5--30%,46--48 the ﬁgure varying
according to the hypertensive population being studied,
with higher percentages in cohorts from centers specializing
in the treatment of hypertension compared to community-
based cohorts.
At the present time, and in the light of the available
clinical studies, patients considered to be good candidates
for RDN should have more severe treatment-resistant hyper-
tension, deﬁned as ofﬁce systolic BP of at least 160 mmHg
(150 mmHg in type 2 diabetes).49--51
Renal denervation
Assessment of a potential candidate for RDN should follow
several steps (Table 2) designed to select candidates
expected to beneﬁt from this intervention. According to
a recent European Society of Hypertension (ESH) position
paper on RDN,52 it is recommended that patients should
undergo careful assessment in centers that have consider-
able experience in dealing with hypertension (ideally ESH
excellence centers).
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The ﬁrst step should be to exclude pseudoresistance,
secondary causes of hypertension and conditions that main-
tain high BP values. Pseudoresistance can be excluded by
24-hour ambulatory BP monitoring, which is recommended
not only for pre-RDN assessment but as good practice in
the assessment of all patients with hypertension.5,53 In
patients with severe resistant hypertension considered for
RDN, the initial assessment should also include investiga-
tion of possible secondary causes of hypertension, including
primary aldosteronism, renal artery stenosis, pheochromo-
cytoma, Cushing’s disease, hyperparathyroidism and aortic
coarctation, although some of these are very uncommon.44
Some conditions that can maintain high BP values should
also be treated when possible, such as severe obesity,
high salt and alcohol intake, concomitant use of drugs
that raise BP and the presence of obstructive sleep
apnea.
The second step should be the optimization of antihy-
pertensive treatment, including the use of diuretics and
aldosterone blockers, optimization of dosages and com-
binations, and reassessment of BP control with 24-hour
ambulatory BP monitoring (ABPM).
The third step should be assessment of renal artery
anatomy, as there are relative contraindications for RDN
related to the number of renal arteries (multiple main
arteries) and their diameter (ideally >4 mm) and length
(ideally >20 mm) as well as eGFR, which should be
above 45 ml/min/1.73 m2. Some of these are consid-
ered contraindications to RDN, because they were excluded
from RDN trials, but are regarded in clinical practice as
relative contraindications; some of these patients have
been treated with RDN and included in small studies and
registries.54--56
Experimental studies on renal denervation
The ﬁnding that renal sympathetic activity is increased in
spontaneously hypertensive rats, the animal model most
often used in investigation of essential hypertension, has
shone light on the role of the renal SNS in the patho-
genesis of hypertension.57 In an experimental model of
hypertension and obesity in dogs subjected to a high-fat
diet, RDN not only prevented the appearance of hyper-
tension but also increased urinary sodium excretion by
50%.58 In another animal model of chronic renal failure,
sympathectomy prevented hypertension and was associ-
ated with decreased adrenergic activity in the hypothalamic
nuclei.59
Renal lesions induced by injection of phenol cause a
sustained rise in BP and norepinephrine release by the
hypothalamus without changing eGFR. RDN of these ani-
mals prevented the rise in BP.60 In different animal models,
the effects of RDN have consistently shown the important
role of the renal SNS in the pathophysiology of hyperten-
sion.
In humans, surgical sympathectomy lowers high BP
and improves the cardiovascular prognosis of patients
with severe hypertension.7--9,61--63 Its poorly tolerated side
effects, which include severe orthostatic hypotension,
anhidrosis, intestinal disturbances and sexual dysfunction,
and its high surgical risk, have led to the technique being
abandoned. Nevertheless, it has proved the importance of
the SNS in BP control beyond doubt.
Clinical studies on percutaneous sympathetic
renal denervation
Symplicity HTN-1,11 a proof-of-principle study, was the ﬁrst
to evaluate RDN in patients with severe resistant hyper-
tension. One year after the procedure, mean ofﬁce BP fall
was 27 mmHg systolic and 17 mmHg diastolic, and was
maintained until 24 months of follow-up, with 13% non-
responders. A subgroup analysis assessing renal and systemic
sympathetic activity showed a 47% reduction in renal norepi-
nephrine spillover in these patients.64
In the Symplicity HTN-2 multicenter clinical trial,64,65
106 patients with severe resistant hypertension under
medication were randomized to optimal antihypertensive
medical therapy alone or to RDN plus optimal antihyperten-
sive medical therapy. The primary endpoint was change in
ofﬁce BP at six-month follow-up. A signiﬁcant fall in BP was
observed in patients who underwent RDN: −32 mmHg in
systolic BP and−12 mmHg in diastolic BP (p<0.01) compared
to an increase of 1 mmHg in systolic BP and no change
in diastolic BP (p=NS) in patients under optimal medical
therapy alone at six months following RDN. A subgroup
analysis of 24-hour ABPM data revealed a similar pattern, a
fall of 11 mmHg in systolic BP and 7 mmHg in diastolic BP in
the RDN group (p<0.001) compared to a fall of 3 mmHg and
1 mmHg on medical therapy alone (p=NS). The magnitude of
the difference in BP fall between RDN and optimal medical
therapy alone was maintained at 12-month follow-up.64
Alongside its efﬁcacy, RDN was a safe procedure. In both
studies, only minor vascular complications occurred, mainly
at the puncture site: hematomas and pseudoaneurysms (four
patients), one renal artery dissection during the diagnostic
procedure, successfully treated with a stent, and no major
complications. Regarding renal function, there were no sig-
niﬁcant changes in eGFR during follow-up.49,66
The recently published EnlightHTN I trial51 also revealed
a signiﬁcant fall in both ofﬁce BP and mean 24-hour ABPM
values at six months, with a good safety proﬁle.
The published data indicate that RDN has an excellent
short-term safety proﬁle, although data on the long-term
risk of renal artery stenosis are lacking. The results of the
Symplicity trials and EnlightHTN I are certainly promising,
but their open design meant that bias in BP measure-
ments, or even the extent of the placebo effect in treated
patients, could not be properly addressed. Some of these
limitations were addressed in the recently published ran-
domized SYMPLICITY HTN-3 trial.67,68 This was the ﬁrst
blinded sham-controlled study of RDN for treatment of
resistant hypertension. The primary efﬁcacy endpoint was
the mean change in ofﬁce systolic BP from baseline to six
months in the RDN arm (n=364) compared to the control
arm (n=171). At six-month follow-up, there was a differ-
ence of 2.39 mmHg in the change in systolic BP (−14.13±
23.93 mmHg in the RDN arm vs. −11.74±25.94 mmHg in the
sham procedure arm), which did not reach statistical signiﬁ-
cance (95% conﬁdence interval [CI]: −6.89 to 2.12, p=0.26).
The secondary efﬁcacy endpoint was the change in
mean 24-hour ambulatory BP at six months. A statistically
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non-signiﬁcant difference of 1.96 mmHg (95% CI: −4.97 to
1.06, p=0.98) was seen at six months (−6.75±15.11 mm Hg
in the RDN arm vs. −4.79±17.25 mm Hg in the control arm).
The rate of major adverse events at six months was
4% in the RDN arm vs. 5.8% in the control arm (p=0.37).
The primary safety endpoint (a composite of major adverse
events) rate was 1.4% in the RDN arm, less than the pre-
speciﬁed objective of 9.8%, reaching statistical signiﬁcance
(p<0.001).
These conﬂicting results between Symplicity HTN-368
and the previous Symplicity trials, HTN-111 and HTN-265
(Table 3), may be related to a different and more rigorous
design adopted in HTN-3, a different study population, more
aggressive antihypertensive medication, and the require-
ment that no changes in antihypertensive medication could
be made in the six months after the procedure. There was
also potential for procedural variability due to the large
number of centers involved in the HTN-3 study and a low
case load per operator, each performing only three proce-
dures on average (most performed their ﬁrst and only RDN
procedure for the trial). The inclusion for the ﬁrst time of
a large proportion of African-American patients (24.8% of
the RDN arm and 29.2% of the control arm), a population
known to be resistant to RAAS blockers, could have had a
negative impact on the efﬁcacy of RDN; a subgroup analy-
sis revealed a statistically signiﬁcant difference favoring the
RDN arm in non-African-American patients. Overall antihy-
pertensive medication was more intensive than in previous
studies, probably reﬂecting the more severe hypertensive
patients included. Regression to the mean may also at least
partially explain the differences.69 The presence for the ﬁrst
time of a sham procedure in the control arm (renal angiog-
raphy was performed in all patients before randomization)
may have diluted the expected placebo effect favoring the
treated group.
Puzzling ﬁndings in Symplicity HTN-3 include the smaller
decrease in ofﬁce systolic BP from baseline to six months
in the RDN arm, about half that observed in the Symplicity
HTN-2 RDN group, despite similar baseline BP in the two
studies, raising doubts as to whether RF energy was properly
delivered. A larger decrease in BP was also observed in the
HTN-3 control group compared to themuch smaller decrease
in the HTN-2 control group. These ﬁndings raise the question
of whether a less effective denervation procedure allied to
more aggressive medical therapy could have played a major
role in the HTN-3 results.
The fact that there was no measurement to conﬁrm that
the renal nerves were in fact denervated by the procedure,
because there is no test that can be easily performed in a
large trial, is a major limitation to this and to almost all of
these trials.
While the Symplicity HTN-3 follow-up will continue as
planned for up to ﬁve years, the fact that many patients
crossed over from the control arm to the RDN arm at
six months will make it more difﬁcult to draw signiﬁ-
cant conclusions concerning the long-term clinical results
of RDN therapy and to assess the placebo effect over
time.
Nevertheless, the Symplicity HTN-3 trial is a landmark in
the development of RDN treatment, signaling the start of its
reﬂection phase, in which new hypotheses generated by this
trial can be addressed.
Renal denervation: new devices
The high expectations and enthusiasm created in the medi-
cal device industry has led many companies to develop new
or improved technical solutions for RDN, some of which are
commercially available (Table 4).
From predictable improvements of the original proce-
dure to out-of-the-box ideas, many innovations are being
integrated in the new designs. These include alterna-
tive mechanisms of action, like ultrasound catheters and
balloons with microinjection systems to deliver neuro-
toxins. Simultaneously activated multi-electrodes not only
signiﬁcantly shorten procedural time but also increase
reproducibility, ensuring that all quadrants are adequately
denervated, while radial access reduces access site vascular
complications, and manipulating renal catheters by a cran-
iocaudal approach is generally less challenging and safer.
Pain control is also a challenge, as electric current, tissue
burning, and nerve damage, although essential components
of the procedure, all cause discomfort. The more recent
radiofrequency catheters with bipolar electrodes reportedly
reduce discomfort due to a signiﬁcantly smaller electric ﬁeld
during activation, but this is not yet clinically proven; the
absence of an acute procedural efﬁcacy endpoint is still a
major limitation. Procedural success is difﬁcult to determine
and to correlate with BP response. Efforts are being made
to ﬁnd a biomarker or physiological test that indicates acute
RDN success.
Sympathetic renal denervation: potential
future indications
The overall decrease in SNS drive through RDN may be a
valid alternative in clinical scenarios characterized by sym-
pathetic hyperactivity other than resistant hypertension.
A few of these alternative applications have already been
explored and show promising results.
The association between heart failure and increased sym-
pathetic drive is well known. Interestingly, cardiac and renal
norepinephrine spillover is more closely associated with
mortality than circulating catecholamine concentrations,
although both are associated with worse outcomes.16,70 This
suggests that reducing norepinephrine spillover from the
kidney could have beneﬁcial symptomatic and prognostic
effects.71,72
In animal models, RDN after myocardial infarction led
to improvement in sodium excretion,73 increased cardiac
output, improved renal blood ﬂow,74 and down-regulation
of angiotensin AT1 receptors mediating maladaptive
responses.75 In a multicenter study of patients with resistant
hypertension treated by RDN with anatomical and func-
tional myocardial parameters assessed by MRI, a subgroup
of patients with LV dysfunction had signiﬁcantly increased
ejection fraction and circumferential strain.76
The REACH pilot study in heart failure provided evi-
dence that RDN improved six-minute walk distances without
affecting BP (mean 120 mmHg at baseline).77 Other ongoing
clinical trials will provide further evidence on the potential
of RDN to inﬂuence the course and outcome of heart failure.
Type 2 diabetes and insulin resistance are other conditions
that have a strong association with resistant hypertension.
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Half of resistant hypertension patients are considered to be
insulin resistant, increasing the risk for type 2 diabetes, and
since insulin resistance is dependent on sympathetic activity
it appears likely that it could also be a target for RDN.78,79 In
a pilot study, along with reducing BP, RDN improved fasting
glucose, insulin, and C-peptide concentrations, as well as
homeostasis model assessment-insulin resistance indices in
patients with resistant hypertension and metabolic disease,
suggesting that RDN might improve diabetic status in these
patients.80 Witkowski et al. showed a decline in glycated
hemoglobin concentrations after RDN.81
The association between obstructive sleep apnea and
resistant hypertension is well known.81 In 2011 Witkowski
et al. published a pilot study on the effect of RDN in 10
patients with resistant hypertension and obstructive sleep
apnea. At six months there was an improvement in apnea-
hypopnea indices.81 In an experimental model, it has been
shown that RDN reduces post-apneic BP rise, renal hypoper-
fusion during apnea and RAAS activation in the kidney.82,83
The value of these ﬁndings is still controversial and conﬁrm-
atory studies are needed.
In an animal model84 of obstructive sleep apnea and
induced atrial ﬁbrillation (AF), RDN decreased the atrial
refractory period and AF recurrence,82 providing better rate
control.85 In a pilot trial, patients with resistant hyper-
tension and symptomatic paroxysmal or persistent atrial
ﬁbrillation refractory to ≥2 antiarrhythmic drugs were ran-
domized to pulmonary vein isolation alone or associated with
RDN. At 12-month follow-up 69% of patients treated with
RDN were AF-free, compared to 29% of those treated with
pulmonary vein isolation only.86 These experimental ﬁndings
indicate the potential usefulness of RDN in AF treatment.
The evidence for the fundamental role of sympathetic
activity in ventricular arrhythmias is overwhelming. In
an animal model of ischemia/reperfusion arrhythmias,
RDN decreased the occurrence of ventricular arrhyth-
mias/ﬁbrillation and attenuated the rise in LV end-diastolic
pressure during LV ischemia without inﬂuencing infarct
size, changes in ventricular contractility, BP or reperfusion
arrhythmias.87 In a small case series involving patients
with chronic heart failure and ventricular electrical storm,
RDN reduced discharges from implantable cardioverter-
deﬁbrillators and ventricular ectopies.88 Hoffmann et al.89
reported that RDN can be safely and effectively performed
as an adjunct to cardiac catheter ablation, in a hemo-
dynamically unstable patient with ventricular storm after
ST-elevation myocardial infarction. Although these are early
and preliminary ﬁndings, the underlying biological plausibil-
ity will certainly heighten interest in these potential future
applications of RDN.
Conclusions
It is now accepted that an overactive sympathetic system
has a pivotal role in the pathophysiology of several diseases
besides essential hypertension. Related conditions like
depression, mental stress, hypertension, diabetes, obesity,
sleep apnea, metabolic syndrome, ischemic heart disease,
heart failure and chronic renal failure, all have a common
link, the often neglected hyperactive SNS. In a new era with
new tools to control and treat sympathetic hyperactivity,
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perhaps this system will ﬁnally receive the attention it
deserves.
The inability to treat hypertension effectively is due in
part to a lack of understanding of the fundamental mecha-
nisms involved in BP control. There is a complex mixture of
hormonal, neural and intrinsic factors, all acting together,
over different time scales and with different feedback con-
trol pathways, and it seems unlikely that any of the current
treatment approaches is actually targeting the factors that
originally led to the rise in BP. Catheter-based RDN is a truly
innovative approach to treat hypertension by changing sym-
pathetic activity. In patients with resistant hypertension,
the technique has signiﬁcantly reduced BP as well as sympa-
thetic nerve activity and norepinephrine spillover, with high
safety levels. These achievements are well documented in
several international multicenter trials and registries. Along
with its proven efﬁcacy in BP reduction, it has the potential
to positively affect insulin resistance and diabetes, LV mass,
proteinuria and arrhythmias, as indicated by various small
proof-of-concept studies.
Nevertheless, there are still important issues that need
to be addressed in the near future, like the impossibility of
determining whether denervation was effective, what level
of denervation is needed to achieve clinical success, which
patients have an appropriate phenotype for RDN, and what
endpoints should be used to deﬁne RDN success (merely BP
reduction or reduction in target organ damage). Much needs
to be done and will be in the coming years, but a newwindow
has certainly been opened not only to address hypertension,
but most importantly to address SNS dysfunction.
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Abstract
Introduction: Increased activation of the sympathetic nervous system plays a central role in the
pathophysiology of hypertension (HTN). Catheter-based renal denervation (RDN) was recently
developed for the treatment of resistant HTN.
Aim: To assess the safety and efﬁcacy of RDN for blood pressure (BP) reduction at six months
in patients with resistant HTN.
Methods: In this prospective registry of patients with essential resistant HTN who underwent
RDN between July 2011 and May 2013, the efﬁcacy of RDN was deﬁned as ≥10 mmHg reduction
in ofﬁce systolic blood pressure (SBP) six months after the intervention.
Results: In a resistant HTN outpatient clinic, 177 consecutive patients were evaluated, of whom
34 underwent RDN (age 62.7±7.6 years; 50.0% male). There were no vascular complications,
either at the access site or in the renal arteries. Of the 22 patients with complete six-month
follow-up, the response rate was 81.8% (n=18). The mean ofﬁce SBP reduction was 22 mmHg
(174±23 vs. 152±22 mmHg; p<0.001) and 9 mmHg in diastolic BP (89±16 vs. 80±11 mmHg;
p=0.006). The number of antihypertensive drugs (5.5±1.0 vs. 4.6±1.1; p=0.010) and pharma-
cological classes (5.4±0.7 vs. 4.6±1.1; p=0.009) also decreased signiﬁcantly. Of the 24-hour
ambulatory BP monitoring and echocardiographic parameters analyzed, there were signiﬁcant
reductions in diastolic load (45±29 vs. 27±26%; p=0.049) and in left ventricular mass index
(174±56 vs. 158±60 g/m2; p=0.014).
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Conclusion: In this cohort of patients with resistant HTN, RDN was safe and effective, with a
signiﬁcant BP reduction at six-month follow-up.
© 2013 Sociedade Portuguesa de Cardiologia. Published by Elsevier España, S.L. All rights
reserved.
PALAVRAS-CHAVE
Hipertensão arterial
resistente;
Desnervac¸ão renal;
Hipertroﬁa
ventricular esquerda
Desnervac¸ão renal em doentes com hipertensão arterial resistente: resultados aos
seis meses de seguimento
Resumo
Introduc¸ão: O aumento da atividade do sistema nervoso simpático desempenha um papel pre-
ponderante na ﬁsiopatologia da hipertensão arterial (HTA). Recentemente foi desenvolvida uma
técnica de intervenc¸ão percutânea -- a desnervac¸ão renal (DNR) -- para o tratamento da HTA
resistente.
Objetivo: Avaliar a seguranc¸a imediata e a eﬁcácia da DNR aos seis meses na reduc¸ão da pressão
arterial em doentes com HTA resistente.
Métodos: Registo prospetivo de doentes com HTA essencial resistente submetidos a DNR entre
julho de 2011 e maio de 2013. A eﬁcácia da DNR foi deﬁnida pela reduc¸ão ≥10 mmHg da pressão
arterial sistólica (PAS), avaliada na consulta dos seis meses de seguimento.
Resultados: Numa consulta de HTA resistente avaliaram-se 177 doentes consecutivos, dos quais
34 (idade 62,7±7,6 anos; 50,0% homens) efetuaram DNR. Não ocorreram complicac¸ões vas-
culares, nomeadamente no acesso ou nas artérias renais. Nos 22 doentes com seguimento
completo aos seis meses, a taxa de respondedores foi 81,8% (n=18). A PAS na consulta diminuiu
em média 22 mmHg (174±23 versus 152±22 mmHg; p<0,001) e a diastólica 9 mmHg (89±16 ver-
sus 80±11 mmHg; p=0,006). O número de fármacos anti-hipertensores (5,5±1,0 versus 4,6±1,1;
p=0,010) e de classes farmacológicas (5,4±0,7 versus 4,6±1,1; p=0,009) também diminuíram
signiﬁcativamente. Dos parâmetros da monitorizac¸ão ambulatória da pressão arterial de 24 h
e ecocardiográﬁcos analisados, a percentagem de cargas diastólicas (45±29 versus 27±26%;
p=0,049) e o índice de massa ventricular esquerda (174±56 versus 158±60 g/m2; p=0,014)
diminuíram signiﬁcativamente.
Conclusão: Na populac¸ão estudada de doentes com HTA resistente submetidos a DNR, esta foi
uma intervenc¸ão segura e eﬁcaz na reduc¸ão da pressão arterial aos seis meses de seguimento.
© 2013 Sociedade Portuguesa de Cardiologia. Publicado por Elsevier España, S.L. Todos os
direitos reservados.
Introduction
Hypertension (HTN) is one of the main independent risk fac-
tors for global mortality.1 Its high prevalence and increasing
incidence, including among young adults, are a major public
health concern.2
Despite the many approved and recommended therapeu-
tic options, the rate of control of HTN is far from ideal.3
This was demonstrated by the PAP study on the prevalence,
awareness, treatment and control of HTN in Portugal,4 which
showed not only a high prevalence of HTN in individuals aged
18 and over (42.1%) but also a low rate of control (11.2%).
Although various factors contribute to poor control, in a sig-
niﬁcant number of cases HTN is resistant to drug therapy
and it is therefore essential to identify such patients given
their high risk of cardiovascular events.5--7 The limitations of
current drug therapies probably reﬂect the complex patho-
physiological mechanisms involved in the development and
persistence of HTN.8,9 Chronic activation of the sympathetic
nervous system is an important mechanism in resistant HTN,
and so a new interventional technique -- renal denerva-
tion (RDN) -- has been developed, consisting of endovascular
application of radiofrequency energy in the renal arteries to
modulate renal sympathetic activity.10,11
The safety and efﬁcacy of RDN were ﬁrst documented
in the Symplicity HTN-111 and Symplicity HTN-2 trials,12
and there is evidence that similar levels of blood pressure
(BP) reduction are maintained in the medium term.13,14 We
recently published our initial experience with this technique
to treat patients with resistant HTN.15
The aim of this study was to assess the safety and efﬁ-
cacy of RDN for BP reduction at six months in patients with
resistant HTN.
Methods
Study design and population
In this prospective registry of 177 consecutive patients eval-
uated in the resistant HTN outpatient clinic of a tertiary
center between July 2011 and May 2013, resistant HTN
was deﬁned as ofﬁce BP of ≥140/90 mmHg despite ther-
apy with at least three antihypertensive drugs (including a
diuretic) at maximum tolerated doses.16 Possible secondary
causes of HTN were excluded in all patients. Patients were
selected for RDN in joint meetings between the cardiolo-
gists and nephrologists responsible for patient assessment
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Patients excluded for RDN (n=143)
Patients assessed at
resistant HTN clinic
n=177
Patients undergoing RDN
n=34
Six-month follow-up
n=22
– HTN controlled after therapy adjustment (n=59)
– Secondary cause of HTN identified (n=20)
– Unfavorable renal anatomy for RDN (n=13)
– Patient refusal (n=6)
– Other (n=6)
– eGFR <45 ml/min/1.73 m2 (n=39)
Figure 1 Patient selection. eGFR: estimated glomerular
ﬁltration rate; HTN: hypertension; RDN: renal denervation.
in the HTN clinic. The procedures were approved by the
hospital’s ethics committee and patients’ informed consent
was obtained. The study design is summarized in Figure 1.
The criteria used in selecting patients for RDN were recently
published by de Araújo Gonc¸alves et al.15
After clinical and laboratory assessment in accordance
with the protocol, 34 patients were selected for RDN, of
whom 22 completed six-month follow-up. The ﬁnal anal-
ysis assessed the immediate safety of the procedure in
all patients and its efﬁcacy in the group with complete
six-month follow-up.
Clinical assessment and diagnostic exams
Renal artery angiography was performed in all patients
to assess anatomical suitability for RDN, and in 73.5%
(n=25) of those considered eligible, noninvasive com-
puted tomography angiography was performed prior to
RDN. The anatomical criteria were renal artery diam-
eter ≥4 mm and absence of signiﬁcant tortuosity or
>50% stenosis. Demographic variables, clinical history
and anthropometric data were recorded. Baseline assess-
ment prior to RDN included systolic (SBP) and diastolic
blood pressure (DBP) at the last consultation, transtho-
racic echocardiography, 24-hour ambulatory BP monitoring
(ABPM) and laboratory tests. Antihypertensive medica-
tion was also recorded, both the number of drugs
and pharmacological classes, divided into the follow-
ing categories: angiotensin-converting enzyme inhibitors,
angiotensin receptor blockers, direct renin inhibitors,
aldosterone antagonists, diuretics, beta-blockers, calcium-
channel blockers and alpha-blockers.
Renal denervation procedure
The procedure was performed via femoral access in all
cases except one in which the left radial artery was
used. After gaining vascular access, abdominal aortogra-
phy and selective renal artery angiography were performed.
Radiofrequency energy was applied in both renal arteries
using the following systems: Symplicity® (Medtronic, USA)
in 26 patients, EnligHTN® (St. Jude Medical, USA) in six, and
OneShot® (Covidien, USA) in two. The device is connected
to a radiofrequency generator that automatically programs
and controls impedance, temperature and duration of the
application, independently of the operator, on the basis of
the manufacturer’s protocols for each type of device. The
Symplicity® system performs 4--6 applications lasting 120
s each in both renal arteries, beginning in the most dis-
tal segment of the vessel, at intervals of around 5 mm and
in different quadrants of the arterial wall.11 EnligHTN® is a
multi-electrode system that provides multiple applications
without the need to maneuver the device; the procedure
also begins with the most distal electrode with four sequen-
tial applications lasting 90 s each, the ideal being two series
of four applications in each artery.17 The more recently
approved OneShot® system uses a guidewire and a single irri-
gated balloon-mounted spiral electrode that applies energy
for 120 s.18 All procedures were performed under seda-
tion with anesthesia support (propofol and remifentanil in
weight-adjusted doses) and anticoagulation with unfraction-
ated heparin for a minimum activated clotting time of 250
s. In all cases of femoral access, the access site was closed
using an Angio-Seal® (St. Jude Medical, USA). There were no
complications at the access site or in the renal arteries fol-
lowing RDN; there was one case of renal artery spasm and
stenosis on ﬁnal angiographic assessment, in a procedure
performed on an accessory renal artery with a diameter at
the lower recommended limit (4 mm).
Follow-up
To assess the efﬁcacy of RDN at six months, we used the
deﬁnition of responder used in validation studies of the tech-
nique: reduction in ofﬁce SBP of ≥10 mmHg at follow-up.
Ofﬁce DBP, number of antihypertensive drugs and phar-
macological classes, and 24-hour ABPM values were also
assessed at follow-up, as well as the following echocar-
diographic parameters: left ventricular mass index (LVMI),
left ventricular ejection fraction (LVEF), left atrial vol-
ume index, E/A ratio (E and A representing maximum early
and late mitral ﬂow velocities, respectively, by pulsed
Doppler), E wave deceleration time, and E/e� ratio (e� rep-
resenting mitral annular early diastolic velocity by tissue
Doppler).
The immediate safety of RDN was assessed on the basis of
complications related to the vascular access site (hematoma
or pseudoaneurysm) or to selective renal artery catheter-
ization or radiofrequency application (spasm, stenosis,
dissection, thrombosis or perforation).
Statistical analysis
The statistical analysis was performed using Statisti-
cal Package for Social Sciences® for Windows, version
19.0 (SPSS, Inc., Chicago, IL). Categorical variables were
expressed as frequencies (percentages in brackets) and
compared using Fisher’s exact test. Continuous varia-
bles were expressed as means ± standard deviation and
compared using the Student’s t test when appropriate.
Results with p<0.05 were considered statistically signiﬁ-
cant.
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Table 1 Baseline characteristics of the study population
(n=34).
n (%)
Demographic data
Age (years) 62.7±7.6
Male 17 (50.0)
Caucasian 32 (94.1)
Cardiovascular risk factors
BMI (kg/m2) 30.9±5.3
Obesity (BMI ≥30.0 kg/m2) 19 (55.9)
Diabetes 22 (64.7)
Dyslipidemia 23 (67.6)
Current smoking 1 (2.9)
Family history of CAD 2 (5.9)
Personal history
CAD 7 (20.6)
Peripheral arterial disease 4 (11.8)
Myocardial infarction 2 (5.9)
PCI 5 (14.7)
Stroke 3 (8.8)
Chronic renal failure 6 (17.6)
Obstructive sleep apnea 3 (8.8)
Pharmacological therapy
Number of drugs 5.8±1.0
Number of classes 5.5±0.8
Ofﬁce blood pressure
SBP (mmHg) 175±23
DBP (mmHg) 92±18
24-hour ABPM
Mean SBP (mmHg) 151±20
Mean DBP (mmHg) 85±16
Systolic load (%) 73±25
Diastolic load (%) 45±28
Transthoracic echocardiography
LV mass index (g/m2) 164±48
LV ejection fraction (%) 63±9
Left atrial volume index (ml/m2) 37±15
E/A ratio 0.9±0.4
E-wave deceleration time (ms) 239±65
E/e� ratio 12±4
GFR (ml/min/1.73 m2) 81.8±36.3
Serum creatinine (mg/dl) 1.1±0.4
ABPM: ambulatory blood pressure monitoring; BMI: body mass
index; CAD: coronary artery disease; DBP: diastolic blood pres-
sure; GFR: glomerular ﬁltration rate; LV: left ventricular; PCI:
percutaneous coronary intervention; SBP: systolic blood pres-
sure.
Results
Baseline characteristics of patients
The baseline characteristics of patients undergoing RDN are
shown in Table 1. Their mean age was 62.7±7.6 years,
50% were male (n=17) and most (94.1%, n=32) were Cau-
casian. Cardiovascular risk factors included obesity in 55.9%
(mean body mass index 30.9±5.3 kg/m2), type 2 diabetes in
64.7%, dyslipidemia in 67.6%, current smoking in 2.9%, and
family history of premature coronary artery disease (CAD)
in 5.9%. Personal history included vascular disease in any
territory in 32.4% (n=11) -- peripheral arterial disease in
11.8% (n=4), cerebrovascular disease in 8.8% (n=3), and CAD
in 20.6% (5.9% with previous myocardial infarction and 14.7%
with percutaneous coronary intervention). Three patients
(8.8%) had concomitant obstructive sleep apnea and their
elevated BP levels persisted despite home noninvasive ven-
tilatory support. Mean estimated glomerular ﬁltration rate
(eGFR) was 81.8±36.3 ml/min/1.73 m2; 17.6% had chronic
renal failure, deﬁned as eGFR <60 ml/min/1.73 m2. Mean
serum creatinine was 1.1±0.4 mg/dl.
At the last consultation prior to RDN, mean SBP and
DBP were 175±23 mmHg and 92±18 mmHg, respectively,
and mean heart rate was 71±18 bpm, while 24-hour ABPM
showed the following mean values: SBP 151±20 mmHg,
DBP 85±16 mmHg, mean arterial pressure 107±14 mmHg,
pulse pressure 68±16 mmHg, systolic load 73±25%, dia-
stolic load 45±28% and heart rate 69±12 bpm, with absence
of circadian rhythm in 57.1% of patients. Transthoracic
echocardiography revealed left ventricular (LV) hypertro-
phy in most patients (90.9%), with mean LVMI of 164±48
g/m2. Mean LVEF was 66±9%, and only four patients pre-
sented reduced LVEF (<55% by Simpson’s biplane method).
Mean left atrial volume index was 37±15 g/m2, E/A ratio
0.9±0.4, E-wave deceleration time 239±65 ms and E/e�
ratio 12±4. On average, patients were medicated with
5.8±1.0 antihypertensive drugs, from 5.5±0.8 pharma-
cological classes. The most commonly prescribed drug
classes were calcium channel blockers, used in 97.1%
(n=33), diuretics in 88.2% (n=30) and beta-blockers in 82.4%
(n=28). Both aldosterone antagonists and alpha-blockers
were prescribed in 70.6% (n=24), angiotensin receptor
blockers in 61.8% (n=21), angiotensin-converting enzyme
inhibitors in 52.9% (n=18) and renin inhibitors in 14.7%
(n=5).
Six-month follow-up
Of the 22 patients with complete six-month follow-up, 18
(81.8%) were considered responders (Figure 2). Of the four
non-responders, only one had higher BP after RDN than
the baseline value, while the other three showed reduc-
tions of less than 10 mmHg. Mean ofﬁce SBP decreased
by 22 mmHg, a statistically signiﬁcant reduction (174±23
vs. 152±22 mmHg, p<0.001), and mean DBP also fell sig-
niﬁcantly, by 9 mmHg (89±16 vs. 80±11 mmHg, p=0.006)
(Figure 3). Other parameters that changed signiﬁcantly six
months after RDN were diastolic load on 24-hour ABPM
(45±29% vs. 27±26%, p=0.049) and LVMI (174±56 vs. 158±60
g/m2, p=0.014). The echocardiographic parameters used to
assess systolic and diastolic function did not change signiﬁ-
cantly, nor did serum creatinine (1.0±0.3 vs. 1.0±0.4 mg/dl,
p=0.344) (Table 2). The number of antihypertensive drugs
(5.5±1.0 vs. 4.6±1.1, p=0.010) and pharmacological classes
(5.4±0.7 vs. 4.6±1.1, p=0.009) also decreased signiﬁcantly
after RDN. It was not possible to compare the different RDN
systems since patients treated by the OneShot® (n=2) and
EnligHTN® (n=6) systems had not completed the six-month
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Table 2 Ofﬁce blood pressure, pharmacological therapy, 24-hour ambulatory blood pressure monitoring and echocardiographic
parameters before and six months after renal denervation (n=22).
Before RDN After RDN p
Ofﬁce BP
SBP (mmHg) 174± 23 152± 22 <0.001
DBP (mmHg) 89± 16 80± 11 0.006
Pharmacological therapy
Number of drugs 5.5± 1.0 4.6± 1.1 0.010
Number of classes 5.4± 0.7 4.6± 1.1 0.009
24-hour ABPM
SBP (mmHg) 146± 18 141± 17 0.279
DBP (mmHg) 79± 10 77± 14 0.459
Systolic load (%) 66± 28 55± 30 0.209
Diastolic load (%) 45± 29 27± 26 0.049
Transthoracic echocardiography
LVMI (g/m2) 174± 56 158± 60 0.014
LVEF (%) 63± 5 65± 8 0.139
LA volume index (ml/m2) 35± 13 34± 12 0.470
E/A ratio 0.9± 0.3 0.8± 0.4 0.535
E-wave deceleration time (ms) 226± 60 217± 32 0.572
E/e� ratio 11.3± 2.8 11.4± 2.7 0.923
ABPM: ambulatory blood pressure monitoring; BP: blood pressure, DBP: diastolic blood pressure; LA: left atrial; LVEF: left ventricular
ejection fraction; LVMI: left ventricular mass index; RDN: renal denervation; SBP: systolic blood pressure.
follow-up period. However, their inclusion in the study did
enable the baseline characteristics of patients selected for
RDN to be described, and the immediate safety of the pro-
cedure to be assessed.
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Figure 2 Systolic blood pressure before and six months after
renal denervation (n=22). RDN: renal denervation.
Discussion
RDN proved to be safe in this group of patients with resistant
HTN, with no serious complications. There were no access
site complications such as pseudoaneurysm; one patient was
the ﬁrst published case of RDN via radial access.19 There
were no cases of renal artery dissection, thrombosis or rup-
ture, and only one case of spasm and stenosis, observed
at the end of the procedure performed on an accessory
renal artery with a diameter at the lower recommended
limit.
The safety of RDN was ﬁrst demonstrated in 2009 by
the Symplicity HTN-1 study,11 which enabled the technique
to be introduced into clinical practice. Nevertheless, the
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Figure 3 Mean change in ofﬁce systolic and diastolic blood
pressure at baseline and six months after renal denervation.
DBP: diastolic blood pressure; SBP: systolic blood pressure.
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studies in the literature involved small numbers of patients,
and follow-up periods are still too short to draw deﬁnitive
conclusions on the technique’s safety in the medium to long
term.
As well as demonstrating its safety, our study showed RDN
to be effective in reducing ofﬁce BP at six-month follow-
up, with a mean reduction in SBP of 22 mmHg; there was
a reduction in SBP of at least 10 mmHg in 82% of cases, as
well as a signiﬁcant fall in mean DBP (9 mmHg). Its impact
on ofﬁce BP also meant that the number of antihypertensive
drugs prescribed decreased signiﬁcantly.
The growing number of hypertensive patients and the
morbidity andmortality associated with poor BP control, due
in part to resistant HTN, point to the need for alternative
therapeutic approaches. It is estimated that around seven
million deaths and 64 million disability-adjusted life years
each year can be attributed to poorly controlled HTN.20 Lit-
erature reviews indicate that around 15% of hypertensive
patients may have resistant HTN,5,6 which occurs more fre-
quently in men, those aged >55 years, blacks, and those with
diabetes, obesity or chronic end-stage renal failure.5,6,8,9
Management of patients with resistant HTN is com-
plex; it is essential to rule out secondary causes of HTN,
optimize drug therapy and exclude white coat or other
pseudo-resistant forms of HTN prior to applying advanced
techniques such as RDN. The low percentage of patients
in a resistant HTN outpatient clinic who were considered
suitable for RDN in the present study demonstrates the com-
plexity of patient selection for this technique, the ratio of
the total number assessed to those considered eligible being
approximately 5:1 (19.2%).
Pharmacological therapy in HTN is mainly based on drugs
that act on the renin-angiotensin-aldosterone system, the
sympathetic nervous system being considered of secondary
importance. However, the role of sympathetic modulation
in HTN was demonstrated more than half a century ago.
An association has been shown between sympathetic ner-
vous system activation and different forms and stages of
HTN, including the earliest.21--24 In addition, the effect
of sympathectomy in reducing BP has also been demon-
strated, although this technique was abandoned due to
procedure-related complications and the subsequent devel-
opment of antihypertensive drugs.25--27 Recent advances in
miniaturized devices for radiofrequency ablation have made
percutaneous sympathetic denervation possible and have
renewed interest in intervention in the relationship between
sympathetic activity and HTN.
Our results are similar to those of previous studies
demonstrating the efﬁcacy of RDN in patients with resis-
tant HTN. The Symplicity HTN-2 study,12 the ﬁrst randomized
trial to show BP reduction at six-month follow-up, reported
a mean reduction of 32 mmHg in SBP and 12 mmHg in DBP.
In absolute terms, the reduction was greater than in our
study, but comparison between the results of the two stud-
ies is difﬁcult for various reasons: our sample was smaller
(approximately half); baseline BP levels were higher in Sym-
plicity HTN-212 (SBP 178 vs. 174 mmHg and DBP 97 vs.
89 mmHg), making a greater fall in BP more likely; and
particularly importantly, drug therapy was not maintained
throughout follow-up in our study population, which may
have affected our results. The above may also explain the
differences found in BP values on 24-hour ABPM: in contrast
to the Symplicity HTN-2 study,12 in which 24-hour ABPM
values fell signiﬁcantly six months after RDN, our study
found a statistically signiﬁcant reduction in diastolic load
only, even though mean SBP and DBP decreased (by 5 and
3 mmHg, respectively). Besides the short-term beneﬁts
demonstrated in the present study, the long-term efﬁcacy
of RDN has been reported in up to 36 months of follow-up.14
With regard to echocardiographic parameters, there was
a signiﬁcant reduction in LVMI, in line with the results
published by other groups.28 This ﬁnding is particularly
important since LV hypertrophy is a marker of subclinical
target organ damage and is associated with cardiovascu-
lar events.29 Furthermore, regression of LV hypertrophy as
a result of better HTN control has been shown to improve
prognosis.30 However, unlike in previous studies,28 our anal-
ysis found no signiﬁcant improvement in systolic or diastolic
function after RDN, probably due to the small sample size.
Some questions remain concerning the applicability of
RDN. Careful patient selection, thorough investigation of the
reasons behind nonadherence to drug therapy and exclu-
sion of white coat HTN are essential aspects that require
improvement. A recent study in 84 hypertensive patients
assessing adherence to therapy through measurement of
serum antihypertensive drug levels showed that 34.5% had
no detectable drugs in the circulation and that 65.5% met
criteria for nonadherence.31 Against this background, it is
difﬁcult to determine whether the impact of RDN on BP
levels is due to the intervention itself, possible improved
compliance with therapy, or even a placebo effect, as seen
in various areas of medicine. The Symplicity HTN-3 study,32
currently in progress, one endpoint of which is ABPM assess-
ment, will help to answer some of these questions. On the
other hand, sympathetic activity may vary from patient to
patient, and it is therefore crucial to identify objective
parameters that will predict the response to RDN, enabling
those with greater potential to respond to be selected
and possible non-responders to be identiﬁed. The number
of applications and the radiofrequency dose may in the
future be established on an individual basis, adapted to
the speciﬁc characteristics of each patient. Another ques-
tion concerns sympathetic nervous system activation in the
different stages of HTN. It is possible that sympathetic mod-
ulation in the early stages of HTN has a greater beneﬁcial
effect and can inﬂuence the natural history of the disease.
Finally, further studies are required to determine the impact
of RDN on morbidity and mortality in patients with resis-
tant HTN, as well as to validate the cost-effectiveness of
the technique, although preliminary data suggest that this is
favorable.33 The expectations surrounding RDN are reﬂected
by the fact that several endovascular intervention systems
are currently under development, clinical trials and reg-
istries of which will increase knowledge in this area and
answer some of the above questions, leading to improve-
ments in patient comfort and the procedure’s safety and
efﬁcacy, which are essential for more widespread adoption
of the technique.34
Limitations
The present study has certain limitations. Firstly, the study
population was small, which means it is not possible to draw
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deﬁnitive conclusions as to the efﬁcacy and safety of RDN,
make comparisons between the different RDN systems used
in terms of safety, or determine the demographic and clini-
cal proﬁle of patients who will not respond to RDN. The fact
that control renal artery angiography was not systematically
performed during follow-up prevented a full assessment of
the medium- to long-term safety of radiofrequency abla-
tion. It was also not possible to compare the efﬁcacy of
the various devices used, since all the patients with com-
plete six-month follow-up were treated with the Symplicity®
system. Lastly, changes were made in drug therapy during
follow-up, whichmay have inﬂuenced assessment of the efﬁ-
cacy of RDN, leading to underestimation of its effect on the
various parameters studied.
Conclusion
In this cohort of patients with resistant essential HTN,
RDN was safe and effective at six-month follow-up, with
signiﬁcant reductions in ofﬁce SBP and DBP and a signif-
icant decrease in the number of antihypertensive drugs
prescribed. In addition, RDN signiﬁcantly reduced LVMI, a
known marker of target organ damage. RDN thus appears to
be a valid option for patients with resistant HTN, with bene-
ﬁts beyond improved BP control. Nevertheless, randomized
studies with larger populations are required to assess the
impact of this intervention on clinical events in the long
term.
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Abstract
Background
Catheter-based sympathetic renal denervation (RDN) is a recent therapeutic option for
patients with resistant hypertension. However, the impact of RDN in left ventricular (LV)
mass and function is not completely established. Our aim was to evaluate the effects of
RDN on LV structure and function (systolic and diastolic) in patients with resistant hyperten-
sion (HTN).
Methods and Results
From a single centre prospective registry including 65 consecutive patients with resistant
HTN submitted to RDN between July-2011 and April-2015, 31 patients with baseline and 1-
year follow-up echocardiogram were included in this analysis. Mean age was 65±7 years,
48% were males, 71% had type 2 diabetes. Most had hypertension lasting for more than 10
years (90%), and were being treated with a median number of 6 anti-hypertensive drugs,
including 74% on spironolactone. At 1-year, there was a significant decrease both on office
SBP (176±24 to 149±13mmHg, p<0.001) and DBP (90±14 to 79±11mmHg, p<0.001),
and also in 24h ABPM SBP (150±20 to 132±14mmhg, p<0.001) and DBP (83±10 to 74
±9mmHg, p<0.001). There was also a significant decrease in LV mass from 152±32 to 136
±34g/m2 (p<0.001), an increase in LV end diastolic volume (93±18 to 111±27 mL, p =
0.004), an increase in LV ejection fraction (65±9 to 68±9%, p = 0.001) and mitral valve E
deceleration time (225±49 to 247±51ms, p = 0.015) at 1-year follow up. There were no sig-
nificant changes in left atrium volume index or in the distribution of patients among the differ-
ent left ventricle geometric patterns and diastolic function subgroups.
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Conclusions
In this single centre registry of patients with resistant hypertension, renal denervation was
associated with significant reduction in both office and ABPM blood pressure and a significant
decrease in left ventricle mass evaluated by transthoracic echocardiogram at 1 year follow-up.
Introduction
Long-standing hypertension (HTN) results in cardiac remodelling including myocardial
hypertrophy, diastolic dysfunction and left atrial (LA) enlargement leading to atrial and ven-
tricular arrhythmias, heart failure and ultimately to myocardial infarction and stroke, which
are the leading causes of death and morbidity in developed countries [1].
The link between chronic sympathetic hyperactivity and drug-resistant HTN is well known
for several years, and is the rationale behind the development of catheter-based sympathetic
renal denervation (RDN). This treatment approach for drug resistant HTN had very promising
results in early non-blinded studies [2,3]. Recently, the lack of positive results on a randomized
sham-controlled trial raised doubts on the efficacy and patient selection for this procedure, rein-
forcing the need for further research in this field [4]. Sympathetic drive is also implicated in the
development of left ventricular hypertrophy (LVH) [5,6], but little is known about the impact of
RDN in left ventricular performance. The aim of the present study was to evaluate the effects of
RDN on LV structure and function (systolic and diastolic) in patients with resistant HTN.
Methods
Study design and population
From a single centre prospective registry including 65 consecutive patients with resistant HTN
submitted to RDN between July-2011 and April-2015, 31 patients with baseline and 1-year fol-
low-up 24h ABPM and transthoracic echocardiogram were included in this analysis. As per
protocol, all patients underwent a comprehensive transthoracic echocardiogram (TTE) at base-
line and at 1-year after RDN. The inclusion, exclusion criteria and clinical feature regarding
this registry were previously reported [7]. The research was approved by the Ethics committee
of Hospital de Santa Cruz and Nova Medical School, Lisbon, Portugal. Written informed con-
sent was collected for all the patients. Study design is summarized in Fig 1.
In summary, the patients selected had to be older than 18 years, with an office systolic blood
pressure (SBP) above 160mHg while receiving a stable antihypertensive regimen involving at
least three drugs (including a diuretic). Before RDN, during pre-scheduled visits at the outpa-
tient clinic for a period not less than 6 weeks, secondary causes for HTN were excluded, com-
pliance to medical treatment was assured and drug therapy was adjusted until maximal
tolerated regimens. Only then, if target BP values were not obtained, patients were considered
for RDN. Anatomical criteria were adopted from Symplicity trials.[2,8] Demographic variables,
clinical characteristics, anthropometric data, laboratory values, drug treatment and procedure
details were recorded and stored in a dedicated database. Creatinine clearance was calculated
using MDRD formula.[9]
Blood pressure measurement and definition of responders
Office BP readings were taken in a seated position with an oscillometric semiautomatic sphyg-
momanometer Omron HEM-907 monitor (Omron Healthcare, USA) after 5 min of rest
Impact of Renal Denervation on Left Ventricle Structure and Function
PLOS ONE | DOI:10.1371/journal.pone.0149855 March 2, 2016 2 / 13
146
SYMPATHETIC RENAL DENERVATION FOR RESISTANT HYPERTENSION
according to the European Guidelines for the management of arterial hypertension [10] At
baseline, BP was measured in both arms and the arm with the higher BP was used for all subse-
quent readings. Averages of the triplicate measures were calculated and used for analysis.
Twenty-four hours ambulatory blood pressure measurements (ABPM) were taken with an
ABMmonitor (Spacelabs Healthcare, USA), according to the current European Society of
Hypertension guidelines[10].
Blood pressure responders to RDN treatment were defined as those who had a reduction in
office SBP of10 mmHg at one year follow-up or a reduction of 2mmHg in ABPM 24 hours
SBP according to Symplicity HTN3 trial design[11].
Renal denervation procedure
We have previously reported the details of the RDN procedure in our center [12]. Briefly, all
procedures were performed under mild anaesthesia for sedation and pain control (propofol
and remifentanil in weight-adjusted doses). Anticoagulation with unfractionated heparin was
used in order to obtain an activated clotting time between 250–300 seconds. After gaining fem-
oral artery access in all cases except one (where the radial artery was used), abdominal aortog-
raphy and selective renal artery angiograms were performed to confirm anatomic eligibility. At
the end, in cases with femoral access, the site was closed using a sealing device (Angio-Seal1
-St. Jude Medical, USA).
RDN was performed using the Symplicity1 (n = 25), the EnligHTN1 (n = 4), OneShot1
(n = 2) catheter using the standard technique, as previously reported [7,12,13].
Transthoracic echocardiography
Comprehensive two-dimensional and Doppler transthoracic echocardiographic studies were
performed at baseline and at 1-year follow-up in all patients, using VIVID 7 ultrasound system
(General Electric Heathcare). All echocardiographic recordings were stored in digital format
Fig 1. Flowchart with patient selection. From the total number of patients evaluated in a dedicated
outpatient hypertension clinic (n = 318), 65 patients were submitted to renal denervation, after the exclusion
of 253 due to several reasons listed. From these 65 patients, it was possible to obtain complete 1 year follow
up with ambulatory blood pressure measurement and transthoracic echocardiogram. RDN—renal
denervation; HTN—hypertension; eGFR—estimated glomerular filtration rate; ABPM –24 hours ambulatory
blood pressure measurement; TTE-transthoracic echocardiogram.
doi:10.1371/journal.pone.0149855.g001
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on a dedicated workstation for off-line subsequent analysis. The exams were performed by one
of two experienced operators (EH and MJA), while analysed and interpreted by the non-per-
former operator, both blinded to patients’ clinical, BP status and sequence of images.
Left ventricular size was evaluated by both linear (using M-mode 2D guided diameters
obtained perpendicular to the LV long axis) and volumetric (using the biplane method of disks
summation from tracings of the blood-tissue interface in the apical four- and two-chamber
views), according to accepted recommendations from the American Society of Echocardiogra-
phy and the European Association of Cardiovascular Imaging [14]. LV ejection fraction was
calculated using the following formula: EF = (EDV − ESV)/EDV, with LV volume estimates
obtained by the biplane method of disks.
Assessment of LV mass (LVM) was performed by the linear method using the cube formula
(LV mass = 0.8 � 1.04 � [(IVS + LVID + PWT)3 −LVID3]+0.6g), with 2D guided M-mode mea-
surements obtained at end-diastole from the parasternal approach perpendicular to the LV
long axis measured at the level of the mitral valve leaflet tips. LV hypertrophy was considered
present when LV mass exceeded 115 g/m2 for men and 95 g/m2 for women.
We also calculated the relative wall thickness (RWT) measured as twice the posterior wall
thickness divided by left ventricular end-diastolic diameter, and determined the LV anatomical
pattern in each participant. Normal LVM and RWT were defined as normal LV anatomy, nor-
mal LVM and RWT>0.42 as concentric LV remodeling, increased LVM and RWT>0.42 as
concentric LVH and increased LVM in the presence of RWT<0.42 as eccentric LVH [15]. Left
atrial (LA) volume measurement was done using the disk summation algorithm similar to that
used to measure LV volume, when the LA chamber was at its greatest dimension (end of LV
systole).
LV diastolic function was assessed by pulsed-wave Doppler examination of mitral inflow
and Doppler tissue imaging of the mitral annulus. Peak velocities of early (E) and late (A)
trans-mitral flow and deceleration time (DT) were determined, and the ratio E/A was calcu-
lated. Doppler tissue imaging with pulsed-wave Doppler at the level of septal and lateral mitral
annulus was used to measure e’ velocities. The average of septal and lateral mitral annulus e’
peak velocities, were used to calculate the E/e’ ratio. The Valsalva maneuver was performed to
distinguish normal from pseudo-normal patterns. Spectral recordings were obtained at a sweep
speed of 100 mm/s at end-expiration, and each measurement was averaged over multiple car-
diac cycles to account for inter-beat variability.
Grade 1 diastolic dysfunction (impaired relaxation) was defined by the presence of an E/A
ratio<0.8, a deceleration time>200 ms and E/e0 ratio<8 in the presence of an enlarged left
atrium. Moderate (pseudo-normal, grade 2) diastolic dysfunction was defined as a mitral E/A
ratio>0.8 and<1.5 that decreases by 50% during the Valsalva maneuver, E/e’ ratio 9 to 12 and
e’<8 cm/s. Finally, severe (grade 3) diastolic dysfunction corresponds to restrictive LV filling
defined by E/A ratio>2, DT<160 ms, and average E/e’>13. All subjects with impaired LV
relaxation, pseudo-normal or restrictive filling patterns were defined as having LVDD [16].
Statistical analyses
Continuous variables are reported as mean ± standard deviation. Normality was tested with
the Kolmogorov-Smirnov test and/or Q-Q Plot visual assessment. Normally distributed vari-
ables were compared between baseline and one year follow-up using a paired Student t test or a
Wilcoxon matched-pairs test if not normally distributed. Discrete variables are expressed as
frequencies and percentages (in brackets). Statistical comparisons of baseline characteristics
and at follow-up were performed using the chi-square test or Fisher’s exact test, when appro-
priate, for categorical variables and the paired t-Student’s test or the Saterwate test for
Impact of Renal Denervation on Left Ventricle Structure and Function
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continuous variables. A two-tailed p value<0.05 is considered as statistically significant. Linear
regression analyses were used to calculate the correlation between the change in blood pressure
and the change in echocardiographic parameters. SPSS, Statistical Package for the Social Sci-
ences1, V.21.0 (IBM SPSS Inc, Chicago, IL) software was used for data processing and statisti-
cal analysis.
Results
Patient characteristics
From the total number of patients evaluated in a dedicated outpatient hypertension clinic
(n = 318), 65 patients were submitted to renal denervation, after the exclusion of 253 due to
several reasons (listed in Fig 1). From these 65, it was possible to obtain complete 1 year follow
up with ambulatory blood pressure measurement and transthoracic echocardiogram in 31
patients that were the final population included in this analysis. Mean age was 65±7 years, 48%
were males (n = 15), and all were caucasians. Concerning traditional cardiovascular risk fac-
tors, obesity was present in 68% of the patients (mean body mass index 32±6 Kg/m2), type 2
diabetes in 71%, dyslipidaemia in 68% and active smoking in one patient (3.2%). Coronary
artery disease was present in 10 patients (32%) and any vascular disease in 11 (36%). Estimated
mean glomerular filtration rate was 76±25mL/min/1.73m2, with five patients having chronic
kidney disease, defined as eGFR<60 ml/min/1.73 m2. Baseline characteristics are shown in
Table 1.
Table 1. Patient’s baseline and RDN procedure characteristics.
Demographic and clinical variables
Age (years) 65±7
Male (%) 15 (48.4)
Caucasians (%) 31 (100)
Weight (kg) 86±16
Height (m) 1.65±0.1
BMI (kg/m2) 31.8±5.5
Obesity (%) 21 (67.7)
Atrial ﬁbrillation (%) 1 (3.2)
Previous stroke (%) 2 (6.5)
Type 2 Diabetes (%) 22 (71)
Dyslipidaemia (%) 21 (67.7)
Smoking (%) 1 (3.2)
Sleep apnea (%) 5 (19.1)
eGFR (ml/min/1,73m2) 76.4±24.7
CKD* (%) 5 (16.1)
Hypertension > 10 years (%) 28 (90.3)
Coronary artery disease (%) 10 (32.3)
Any vascular disease (%) 11 (35.5)
RDN Procedure
Mean number of applications right renal artery 5.1±1.3
Mean number of applications left renal artery 5.7±1.1
Mean number of applications per patient 10.8±2.3
eGFR, estimated glomerular ﬁltration rate;
CKD, *Chronic kidney disease(eGFR <60 ml/min/1,73m2)
doi:10.1371/journal.pone.0149855.t001
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The majority of patients (90%) had hypertension lasting for more than 10 years, treated
with a median of 5.8 anti-hypertensive agents from a median of 5.5 different pharmacological
classes. Almost all patients were treated with calcium antagonists, 96.8% (n = 30), 87% with
diuretics, 74% with spironolactone, 61% with ACE inhibitors, 61% with ARB inhibitors, 84%
with beta-blockers and 71% with a sympatholytic drug. (Table 2)
Blood pressure control by RDN
At baseline, mean office SBP and diastolic blood pressure (DBP) were 176±24 mmHg and 90
±14 mmHg, respectively, and mean heart rate was 73±11 bpm. The 24-hour ABPM showed
the following average values: SBP 150±20 mmHg, DBP 83±10 mmHg, pulse pressure 67
±18mmHg (Table 3).
Overall, at one-year follow-up, there was a significant reduction in both office SBP (176±24
to 149±13mmHg, p<0.001) and DBP (90±14 to 79±11mmHg, p<0.001). On 24-hour ABPM,
there was a significant drop on: SBP (150±20 to 132±14 mmHg, p<0.001, mean decrease of 18
mmHg), on DBP (83±10 to 74±9 mmHg, average decrease of 9 mmHg, p<0.01) and on pulse
pressure from 67±18 to 58±13 mmHg, p = 0.001, a mean decrease of 5 mmHg (Fig 2).
This was found in spite of the significant reduction in the number of both antihypertensive
drugs and classes in use at 1-year: 5.8±1.1 to 5.0±1.2 (p = 0.002) and 5.5±0.9 to 4.9±1.1
(p = 0.015) respectively.
At 1-year follow-up, 22 of patients (71%) were considered office SBP responders and 26
(84%) ABPM SBP responders based on a drop of more than 10mmHg on office SBP and
2mmHg on 24 hours ABPM SBP.
Echocardiographic parameters
Transthoracic echocardiography at baseline revealed LV hypertrophy in 27 patients (87%),
with a mean LV mass of 152±32 g/m2. Distribution among different geometric patterns is
shown in Fig 3. The large majority had concentric hypertrophy (74%), with only 3% presenting
a normal pattern. All patients had a preserved EF (>55% by Simpson’s biplane method), with a
mean LVEF of 65±9%. Mean LA volume was 33±8mL/m2, and 48.4% had 34ml/ m2.
LVDD was diagnosed in 29 (93.5%) patients, 11 (37.9%) of them had grade 1 diastolic dys-
function, 18 patients a pseudo-normal pattern (62.1%); 2 patients were in atrial fibrillation and
Table 2. Antihypertensive medication.
Baseline One year p
Mean number of antihypertensive drugs 5.8±1.1 5.0±1.2 0.002
Mean number of classes 5.5±0.9 4.9±1.1 0.015
ACE inhibitors 19 (61.3) 17(54.8) 0.688
ARBs (%) 19 (61.3) 18 (58.1) 1.0
Beta-blockers (%) 26 (83.9) 27 (87.1) 1.0
Calcium channel blockers (%) 30 (96.8) 21 (67.7) 0.012
Diuretics (%) 27 (87.1) 24 (77.4) 0.727
Spironolactone (%) 23 (74.2) 26 (83.9) 0.453
Sympatholytic (%) 22 (71) 19 (61.3) 0.508
Aliskirene 4 (12.9) 0 0.046
ACE, Angiotensin converting enzyme; ARB, Angiotensin receptor blockers
doi:10.1371/journal.pone.0149855.t002
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there were no patients with a restrictive filling pattern (Fig 4). For the entire population, E/A
ratio was 0.8±0.2, E-wave deceleration time 225±49ms and E/e’ ratio 11±3.
After one-year, there was an overall significant reduction in LVmass (152±32 to 136±34g/m2,
p<0.001—Fig 2), an increase in mitral valve deceleration time (from 225±49ms to 247±51ms,
p = 0.015—Table 4). There were no significant changes in the distribution of patients among the
different LV geometric patterns (Fig 3) or in the percentage of patients in each diastolic function
group (Fig 4) from baseline to 1 year after renal denervation.
Relation between blood pressure reduction and echocardiographic
findings
Reduction in LV mass reached statistical significance in ABPM SBP responders (n = 26): 148
±32 to 133±29g/m2, p<0.001. In non-responders (n = 5), LV mass also decreased: 166±23 to
129±15g/m2, p = 0.05, although not reaching statistical significance certainly due to sample
Table 3. RDN results on blood pressure and heart rate.
Baseline One-year P
Ofﬁce systolic BP (mmHg) 176±24 149±13 < .001
Ofﬁce diastolic BP (mmHg) 90±14 79±11 < .001
Heart rate (bpm) 73±11 70±11 .261
ABPM systolic BP (mmHg) 150±20 132±14 < .001
ABPM diastolic BP (mmHg) 83±10 74±9 < .001
ABPM pulse pressure (mmHg) 67±18 58±13 .001
ABPM mean pressure (mmHg) 105±9 95,3±8,4 < .001
ABPM heart rate (bpm) 67.6±9.1 65.5±9.5 .090
ABPM SBP responders* (%) - 26 (83.9) -
Ofﬁce SBP responders** (%) - 22 (71) -
BP, blood pressure; bpm, beats per minute; ABPM, 24 hours ambulatory blood pressure measurement;
* ABPM SBP responders: a decrease of 2mmHg between baseline ABPM SBP and at one year;
**Ofﬁce SBP responders: a decrease of 10mmHg between baseline ofﬁce SBP and at one year.
doi:10.1371/journal.pone.0149855.t003
Fig 2. Results at 1 year after renal denervation (blood pressure and left ventricle mass index). Results
in systolic blood pressure (both office and ABPM) and LVMI in TTE at 1-year follow-up are shown, with
significant reductions in both parameters. BP- blood pressure; ABPM –24 hours ambulatory blood pressure
measurement; LVMI—left ventricle mass index; TTE-transthoracic echocardiogram.
doi:10.1371/journal.pone.0149855.g002
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size. From the scatter-plot graphic (Fig 5) where the relationship between LV mass and ABPM
SBP changes at one year for the entire population is shown, we observe that changes in SBP
and LV mass are not correlated, as depicted by the very low r2 values obtained.
Safety
There were 3 mild hematomas and 1 femoral pseudoaneurysm, treated with surgery without
any permanent sequelae. There were no complications related to the renal arteries, namely dis-
section or perforation.
Discussion
The main findings of our study were: 1) Renal denervation in patients with resistant HTN was
associated with significant reduction in both office and ABPM blood pressure at 1 year follow-
Fig 3. Comparison of different LV geometric patterns at baseline and 1 year after renal denervation.
The percentage of patients in each LV geometric pattern class is depicted. Concentric remodelling was
defined as relative wall thickness (RWT) of >0.42 with normal LV mass and normal geometry was defined as
a RWT of0.42 with normal LV mass.
doi:10.1371/journal.pone.0149855.g003
Fig 4. Comparison of LV diastolic function at baseline and 1 year after renal denervation. The
percentage of patients in each diastolic function group (Normal, Impaired relaxation, pseudonormal and
restrictive) is depicted.
doi:10.1371/journal.pone.0149855.g004
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Table 4. Echocardiographic parameters at baseline and at one-year follow-up in patients submitted to
RDN.
Baseline One-year p
Anatomy
LVEDV (mL) 93.3±18,2 110.9±27.4 .004
LVESV (mL) 35.8±12.6 38.2±3.1 .121
IVSTd (mm) 13.4±1.9 13.1±2.4 .616
PWTd (mm) 11.7±1.6 11.8±1.7 .620
LVEDD (mm) 48.7±5.8 47.8±5.4 .230
LVESD (mm) 28.9±5.7 27.9±6.5 .296
LV mass/BSC (g/m2) 152.3±32.4 135.7±33.9 < .001
LA volume index (ml/m2) 32.8±8.3 34.1±6.2 .227
Function
LVEF Simpson (%) 64.5±9.2 67.7±9.1 .001
Stroke volume (ml) 81.7±14.9 102.7±16.7 .075
Mitral valve E Vmax (cm/s) 73.6±15.2 73.2±16.4 .881
Mitral valve A Vmax (cm/s) 88.3±16.5 86.0±21 .469
Mitral valve E/A ratio 0.84±0.21 0.86±0.20 .574
Mitral valve E deceleration time (ms) 224.9±49.4 247.3±50.5 .015
Mitral valve lateral E’ (cm/s) 7.2±1.8 7.3±2.1 .417
Mitral valve lateral E/E’ 11.0±3.3 10.5±3.5 .228
LVEDVI, left ventricle end-diastolic volume; LVESVI, left ventricle end-systolic volume; IVSTd,
interventricular septum thickness on diastole; PWTd, posterior wall thickness on diastole; LVEDD, left
ventricle end-diastolic diameter, LVESD, left ventricle end-systolic diameter; LV, left ventricle; BSC, body
surface area; LA, left atrium; LVEF, left ventricle ejection fraction.
doi:10.1371/journal.pone.0149855.t004
Fig 5. Relation between LVmass index and ABPM systolic BP changes at 1 year follow-up. Horizontal
line set at 2mmHg for responder in ABPM systolic BP reduction. Five patients had regression in LVMI without
significant (>2mmHg) reduction in ABPM systolic BP and 5 additional patients were ABPM systolic BP
responders but without reduction in LVMI. BP- blood pressure; ABPM –24 hours ambulatory blood pressure
measurement; LV—left ventricle.
doi:10.1371/journal.pone.0149855.g005
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up; 2) There was a significant reduction in left ventricle mass index, a recognized marker of
HTN target organ damage.
Renal denervation has been associated with significant reductions in both office and ABPM
blood pressure in many trials[2,3,17] and registries[18]. In a recent large randomized trial the
reductions in systolic blood pressure, the primary endpoint of the trial, was not significant as
compared to a sham control arm, in striking contrast with previous trial.[4] Many possible
confounding factors were pointed out that could explain these apparent contradictory findings,
[19] but most importantly these inconsistent results of renal denervation makes a strong case
for additional studies looking beyond blood pressure measurements. With this rational we
sought to evaluate the impact of renal denervation in left ventricle hypertrophy, which is one of
the most important markers of target organ damage of HTN and has been associated with an
increased rate of cardiovascular events and death independent of BP values[20–22]. At 1 year
after renal denervation, there was a significant reduction in left ventricle mass and our results
are in line with previous studies using both transthoracic echocardiogram [23,24] and cardiac
magnetic resonance [25].
Brandt MC et al[24] in a study including 46 patients, found that renal denervation was asso-
ciated with a significant reduction in LV mass index and filling and improvements in mitral
valve lateral E/E´, indicator of LV filling pressure in transthoracic echocardiogram. In another
small study using similar methodology, Schirmer SH et al [23] evaluated the impact of renal
denervation in left ventricle hypertrophy by echocardiogram and were able to document that
in patients with resistant HTN, the observed reductions in LV mass were similar across tertiles
of systolic blood pressure, suggesting that the pathophysiology could be related also to a direct
effect of sympathetic hyperactivity, not dependent on blood pressure or heart rate. In our regis-
try we didn´t found a correlation between LV mass and ABPM SBP changes at one year (Fig
5), which suggests that LV hypertrophy reduction, after RDN, might be affected by other
mechanisms beyond BP reduction. This is not new in the field of HTN and it has been previ-
ously described that for similar BP reduction, different pharmacological agents could lead to
different impact on LV hypertrophy [26]. In one interesting study, a greater regression in LV
hypertrophy was documented for a drug combination that targeted neuroendocrine activity
(both renin-angiotensine-aldosterone system and sympathetic nervous system), for the same
magnitude of BP reduction [27]. Regarding the pathophysiological mechanism of the observed
reduction of LV mass, it could be the result not only of a reduction in myocyte hypertrophy
but also of absolute collagen content and diffuse interstitial myocardial fibrosis, as was sug-
gested in a recent cardiac MRI study [28].
In a multicenter study including 72 patients and using cardiac magnetic resonance imaging,
Mahfoud F et al [25] also demonstrated that at 6 months follow-up renal denervation was asso-
ciated with a significant reduction in left ventricle mass index, an improvement in ejection frac-
tion and a reduction in left ventricle circumferential strain, a surrogate of diastolic function.
Taken together these studies are consistent in regression of LV mass and improvement in sev-
eral markers of diastolic function. In our study, we also found a significant reduction in LV
mass but there were no significant changes in transthoracic echocardiogram parameters of dia-
stolic function. In addition, we didn’t found any reduction in left atrial volume index. There
was a small but significant increase in LV ejection fraction and LV end-diastolic volume, which
could be explained at least partially by the numerically lower heart rate at 1 year follow-up doc-
umented both on office and on the average 24-hour heart rate from the ABPM recording. This
small increase in EF is in line with some [24,25] but not all of the previous studies [23].
Some additional particular features of the present study should also be taken in consider-
ation. First, our results come from a registry with a very rigorous selection process of patients
for renal denervation, perceived from the high mean number (5.8) of antihypertensive drugs,
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the baseline office and ABPM blood values and the patient selection flowchart presented in Fig
1, with an almost 5:1 proportion of patients evaluated/treated (only 65 patients submitted to
RDN out of the 318 with resistant HTN evaluated in our outpatient clinic). It is also worth
mentioning that an average of 5.8 drugs is higher than that reported by other similar studies
evaluating the impact of RDN on LV mass (ranging from 4.3 in the study of Schirmer SH et al
[23] to 4.7 in the study of Brandt MC et al [24]. Secondly, in our study we have a very high per-
centage of patients taking spironolactone on baseline (74%). This high aldosterone antagonist
use is in line with the described strict selection process, and in addition it might have also con-
tributed to explain the positive results after renal denervation, since it has been demonstrated
that patients previously treated with spironolactone where better responders to this procedure.
[4,19] Thirdly, we used 24-hour ABPM in all patients and this is considered to be a more accu-
rate evaluation of the impact of treatment on blood pressure.[10] Lastly, our results both in
blood pressure and LV mass were evaluated at 1 year, a significantly longer follow up than that
reported by the previous studies that evaluated patients at 6 months follow up.[23–25]
Limitations
The present study has several limitations that should be acknowledged: 1) It is a single centre
prospective registry with a small sample size. 2) The lack of a control group and the fact that
there was no blinding either for RDN (sham not performed) or for the physicians performing
the follow-up echocardiograms; 3) There were changes on antihypertensive drug therapy dur-
ing the clinical follow-up which can influence the reductions in blood pressure and LV mass,
although in our study the mean number of drugs was reduced. This way, the reduction
obtained with renal denervation could have been underestimated in this real world setting; 4)
No specific techniques were used to control for patient adherence to medication; 5) Echocar-
diograms were not reviewed in a core lab, which could potentially be associated with less repro-
ducible measurements; 6) Cardiac MRI was not used and could have provided a more accurate
evaluation of LV mass changes.
Conclusions
In this single centre registry of patients with resistant hypertension, renal denervation was
associated with significant reduction in both office and 24h-ABPM blood pressure, and a sig-
nificant decrease in left ventricle mass evaluated by transthoracic echocardiogram at 1 year fol-
low-up. There were no significant changes in left atrium volume index or in the distribution of
patients among the different left ventricle geometric patterns and diastolic function subgroups.
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Abstract
Introduction: Sympathetic renal denervation (RDN) was developed as a treatment for the man-
agement of patients with resistant hypertension. This procedure may have a positive impact on
hypertension-related target organ damage, particularly renal disease, but the evidence is still
limited.
Objective: To assess the impact of RDN on the albumin-to-creatinine ratio (ACR) at 12-month
follow-up.
Methods and Results: From a single-center prospective registry including 65 patients with
resistant hypertension undergoing renal denervation, 31 patients with complete baseline and
12-month follow-up blood pressure (BP) measurements (both ofﬁce and 24-h ambulatory blood
pressure monitoring [ABPM]) and ACR were included in the present study. Mean age was 65±
7 years, 52% were female, most (90%) had been diagnosed with hypertension for more than
10 years, 71% had type 2 diabetes and 33% had vascular disease in at least one territory. Mean
estimated glomerular ﬁltration rate was 73.6±25.1 ml/min/1.73 m2 and 15 patients (48%) had
an ACR >30 mg/g. After 12 months, 22 patients were considered BP responders (73%). ACR
decreased signiﬁcantly from a median of 25.8 mg/g (interquartile range [IQR] 9.0-574.0 mg/g)
to 14.8 mg/g (IQR 4.5-61.0 mg/g, p=0.007). When the results were split according to systolic
BP responder status on ABPM, we found a signiﬁcant reduction in responders (from 25.6 mg/g
[IQR 8.7-382.8 mg/g] to 15.9 mg/g [IQR 4.4-55.0 mg/g], p=0.009), and a numerical decrease in
the non-responder subgroup (from 165.0 mg/g [IQR 8.8-1423.5 mg/g] to 13.6 mg/dl [IQR 5.7-
1417.0 mg/g], p=0.345).
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Conclusions: Besides signiﬁcant reductions in blood pressure (both ofﬁce and 24-h ABPM), renal
denervation was associated with a signiﬁcant reduction in ACR, a recognized marker of target
organ damage.
© 2017 Sociedade Portuguesa de Cardiologia. Published by Elsevier Espan˜a, S.L.U. All rights
reserved.
PALAVRAS-CHAVE
Hipertensão arterial
resistente;
Desnervac¸ão renal;
Albuminúria;
Pressão arterial
Rácio albumina-creatinina aos 12 meses de seguimento após desnervac¸ão renal
Resumo
Introduc¸ão: A desnervac¸ão simpática renal (RDN) foi desenvolvida como uma forma de trata-
mento para os doentes com hipertensão arterial resistente (R-HTN). Este procedimento poderá
ter um impacto favorável nas lesões de órgão alvo relacionadas com a hipertensão, nomeada-
mente a doenc¸a renal, no entanto, a evidência disponível ainda é escassa.
Objetivo: Avaliar o impacto da RDN no rácio albumina-creatinina (ACR) aos 12 meses de segui-
mento após RDN.
Métodos e resultados: Registo prospetivo de centro único incluindo 65 doentes com R-HTN sub-
metidos a RDN, dos quais 31 doentes com avaliac¸ão basal e a um ano completa da pressão
arterial (na consulta e na monitorizac¸ão ambulatória [ABPM]) e da ACR foram incluídos no pre-
sente estudo. A idade média foi de 65±7 anos, 52% do sexo feminino. A maioria da populac¸ão
tinha diagnóstico de HTN há >10 anos, 71% tinha diabetes tipo 2 e 33% tinham doenc¸a vas-
cular em pelo menos um território. A taxa de ﬁltrac¸ão glomerular estimada foi de 73,6±
25,1 ml/min/1,73 m2 e 48% (15 doentes) tinham uma ACR>30 mg/g. Aos 12 meses de segui-
mento, 22 doentes foram considerados respondedores na pressão arterial (73%). A ACR teve
uma descida signiﬁcativa de uma mediana de 25,8 mg/g (IQR 9,0-574,0 mg/g) para 14,8 mg/g
(IQR 4,5-61,0 mg/g, p=0,007). Quando os resultados foram divididos em subgrupos, de acordo
com o estado de respondedor à pressão arterial na ABPM, veriﬁcou-se uma reduc¸ão signiﬁcativa
nos respondedores (de 25,6 mg/g [IQR 8,7-382,8 mg/g] para 15,9 mg/g [IQR 4,4-55,0 mg/g],
p=0,009), e uma tendência no subgrupo de não respondedores (de 165,0 mg/g [IQR 8,8-1423,5
mg/g] para 13,6 mg/dl [IQR 5,7-1417,0 mg/g], p=0,345).
Conclusão: Para além da descida signiﬁcativa da pressão arterial (quer na consulta quer na
monitorizac¸ão ambulatória de 24 h), a desnervac¸ão renal associou-se a uma reduc¸ão signiﬁcativa
da ACR, um reconhecido marcador de lesão de órgão alvo na hipertensão arterial.
© 2017 Sociedade Portuguesa de Cardiologia. Publicado por Elsevier Espan˜a, S.L.U. Todos os
direitos reservados.
Introduction
Cardiovascular disease is the leading cause of morbidity and
mortality in developed countries and hypertension is one of
its most important risk factors.1 Some hypertensive patients
have drug-resistant hypertension and are at a higher risk
of events.2,3 Besides clinical events, assessment of target
organ damage can provide earlier insights into the biologi-
cal impact of hypertension. For several years, albuminuria
has been recognized as an indicator of cardiovascular risk,
although the pathophysiology behind this association is still
not fully understood.4--6
In recent years sympathetic renal denervation (RDN) has
been developed as a treatment for the management of
patients with resistant hypertension7,8 and it may have a
positive impact on hypertension-related target organ dam-
age. An example is recently published reports of reductions
in left ventricular hypertrophy after RDN.9--11 The kidney is
also an important organ in this context, but evidence on the
effect of RDN on proteinuria is still limited and results are
conﬂicting.12,13 The aim of the present study was to assess
the impact of RDN on the albumin-to-creatinine ratio (ACR)
at 12-month follow-up.
Methods
Study design and patient population
From a single-center prospective registry including
318 patients with resistant hypertension referred for RDN
between July 2011 and April 2015, we included for the
purpose of the present study 31 patients with complete
information on blood pressure (BP) measurements (both
ofﬁce and 24-h ambulatory blood pressure monitoring
[ABPM]) at baseline and 12 months, transthoracic echocar-
diogram and renal function (creatinine clearance and ACR),
out of 65 patients who were considered good candidates
and underwent RDN (Figure 1).
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Patients referred for RDN between 2011 and 2015 (n=318)
Observed in an outpatient hypertension clinic
Excluded from RDN (n=253):
-BP controlled after dose/drug changes (n=139)
-Secondary cause of hypertension (n=31)
-Unsuitable renal anatomy
 
(n=22)
-eGFR <30 ml/min/1.73 m2 (n=85)
-Patient refusal/other (n=41)
Underwent RDN
(n=65)
Complete one-year follow-up available
(n=31)
(with ABPM and ACR)
Figure 1 Flowchart of patient selection. Of the total num-
ber of patients observed in an outpatient hypertension clinic
(n=318), 253 were excluded for various reasons (see main text)
and 65 underwent renal denervation. Of these 65, complete
12-month follow-up with ambulatory blood pressure monitor-
ing and transthoracic echocardiographic data were available in
31 patients. ABPM: 24-h ambulatory blood pressure monitoring;
ACR: albumin-to-creatinine ratio; BP: blood pressure; eGFR:
estimated glomerular ﬁltration rate; RDN: renal denervation.
The details of this patient population have been pre-
viously described.11,14 Brieﬂy, all patients who underwent
RDN were aged over 18 years, with persistent ofﬁce systolic
blood pressure (SBP) above 160 mmHg even after optimal
antihypertensive therapy (at least three drugs, including a
diuretic). Before RDN all patients were studied for secondary
causes of hypertension and visited regularly (for at least six
weeks) in order to ensure drug regime optimization and full
compliance with medical treatment.
Demographic, clinical, anthropometric, laboratory and
procedural data were recorded and stored in a dedicated
database and written informed consent was obtained from
all patients. The study was approved by the ethics com-
mittee of Hospital de Santa Cruz and Nova Medical School,
Lisbon, Portugal.
Blood pressure measurement and deﬁnition
of responders
Ofﬁce BP readings were measured in a seated position, after
a 5 min rest (in accordance with the European guidelines for
the management of arterial hypertension), using an Omron
HEM-907 semiautomatic oscillometric sphygmomanometer
(Omron Healthcare, USA).
At baseline, before RDN, BP measurements were taken in
both arms and the armwith the higher BP was selected for all
subsequent readings. The mean of three measurements was
used for analysis. An ABM monitor (Spacelabs Healthcare,
USA) was used for 24-h ABPM assessment.
Patients with a decrease of 10 mmHg or more in ofﬁce
SBP or of 2 mmHg or more in 24-h ABPM SBP at 12-month
follow-up were considered to be BP responders to RDN.11,15
Renal function and albuminuria measurement
Creatinine clearance was estimated using the Chronic Kid-
ney Disease Epidemiology Collaboration (CKD-EPI) formula.
Albuminuria was obtained in spot urine and measured
using the ACR, expressed in mg/g, which is equivalent to
24-h albumin excretion in mg/day. ACR values were acquired
before RDN (at baseline) and at 12-month follow-up.
Renal denervation procedure
RDN procedures were performed using mild anesthesia
(propofol and remifentanil) for sedation and pain con-
trol. An activated clotting time of 250-300 s was obtained
with unfractionated heparin. After femoral artery access,
abdominal aortography and selective renal artery angiogra-
phy were performed to conﬁrm anatomic eligibility. In all
cases, the femoral access site was closed using a sealing
device (Angio-Seal
®
, St. Jude Medical, USA).
Denervation was performed using the following radiofre-
quency systems: Symplicity
®
(n=25), EnligHTN
®
(n=4) and
OneShot
®
(n=2), in accordance with standard techniques.
Statistical analysis
Continuous variables are reported as mean ± standard devi-
ation. Normality was tested with the Kolmogorov-Smirnov
test and/or visual assessment of a Q-Q plot. Normally dis-
tributed variables were compared between baseline and
12-month follow-up using a paired Student’s t test, or a
Wilcoxon matched-pairs test if not normally distributed.
Discrete variables are expressed as frequencies and percent-
ages. Statistical comparisons of characteristics at baseline
and at follow-up were performed using the chi-square test
or Fisher’s exact test, as appropriate, for categorical varia-
bles and the paired Student’s t test for continuous variables.
A two-tailed p value <0.05 was considered as statistically
signiﬁcant.
SPSS
®
version 21.0 (IBM SPSS Inc, Chicago, IL) was used
for data processing and statistical analysis.
Results
Patient characteristics
A total of 318 patients were observed in an outpa-
tient hypertension clinic between 2011 and 2015. Of
these, 253 were excluded due to: (a) BP control being
achieved after dose and/or drug changes (n=139); (b) a
secondary cause of hypertension (n=31); (c) renal anatomy
considered unsuitable for RDN on computed tomography
angiography; (d) estimated glomerular ﬁltration rate (eGFR)
<30 ml/min/1.73 m2; (e) patient refusal after discussion of
the expected beneﬁts and risks. A total of 65 patients were
considered good candidates and underwent RDN. Of these,
the ﬁrst 31 with complete data on blood and urine samples,
ofﬁce BP and 24-h ABPM, and transthoracic echocardiogram
at both baseline and 12-month follow-up were included in
the present analysis (Figure 1). Data on left ventricular mass
and function have been reported elsewhere.11
Document downloaded from http://www.elsevier.es, day 22/10/2017. This copy is for personal use. Any transmission of this document by any media or format is strictly prohibited.
161
 ATTACHMENTS
346 H. Sousa et al.
Table 1 Baseline characteristics and renal denervation
procedures.
Demographic and clinical variables
Age (years) 65±7
Male (%) 15 (48.4)
Caucasian (%) 31 (100)
Weight (kg) 86±16
Height (m) 1.65±0.1
BMI (kg/m2) 31.8±5.5
Obesity (%) 21 (67.7)
Atrial ﬁbrillation (%) 1 (3.2)
Previous stroke (%) 2 (6.5)
Type 2 diabetes (%) 22 (71)
Dyslipidemia (%) 21 (67.7)
Smoking (%) 1 (3.2)
Sleep apnea (%) 5 (19.1)
eGFR (ml/min/1.73 m2) 76.4±24.7
CKD (%) 5 (16.1)
Hypertension >10 years (%) 28 (90.3)
Coronary artery disease (%) 10 (32.3)
Any vascular disease (%) 11 (35.5)
RDN procedure
Mean no. of RF applications, right renal
artery
5.1±1.3
Mean no. of RF applications, left renal
artery
5.7±1.1
Mean no. of RF applications per patient 10.8±2.3
BMI: body mass index; CKD: chronic kidney disease (eGFR
<60 ml/min/1.73 m2); eGFR: estimated glomerular ﬁltration
rate; RDN: renal denervation; RF: radiofrequency.
Mean age was 65±7 years, all patients were Caucasian
and 48% (n=14) weremale. Regarding cardiovascular risk fac-
tors, 71% had type 2 diabetes, 68% were obese (mean body
mass index 32±6 kg/m2), 68% had dyslipidemia and only
one patient was an active smoker. Ten patients (33%) had
manifestations of vascular disease (mainly coronary artery
disease). Mean eGFR was 76.4±24.7 ml/min/1.73 m2 and
ﬁve patients had chronic kidney disease (eGFR <60 ml/min/
1.73 m2) (Table 1). At baseline, median ACR was 25.8
(interquartile range [IQR] 9.0-574.0) and 15 (48%) patients
had ACR >30 mg/g.
Most patients (90%) had known hypertension for at
least 10 years and were treated at baseline with a mean
of 5.8 anti-hypertensive drugs, corresponding to a mean of
5.5 different drug classes. Of note, 74% were treated with
spironolactone. Details on antihypertensive medication at
baseline and follow-up are presented in Table 2.
Blood pressure control
Mean ofﬁce SBP and diastolic BP (DBP) at baseline were
176±24 mmHg and 90±14 mmHg, respectively, and mean
heart rate was 73±11 bpm. On 24-h ABPM, mean SBP and
DBP were 150±20 mmHg and 83±10 mmHg, respectively
(Table 3).
At 12-month follow-up mean SBP had decreased from
176±24 to 149±13 mmHg (p<0.001) and DBP from 90±14
to 79±11 mmHg (p<0.001). These changes were consistent
with the results of 24-h ABPM, in which mean SBP decreased
from 150±20 to 132±14 mmHg (p<0.001) and mean
DBP from 83±10 to 74±9 mmHg (p=0.001). At 12-month
follow-up, 71% of patients were considered ofﬁce SBP
responders and 84% were considered ABPM SBP responders
(Table 3). During this period there was also a reduction in
the number of antihypertensive drugs and classes taken;
the number of drugs decreased from 5.8±1.1 to 5.0±1.2
(p=0.002) and drug classes from 5.5±0.9 to 4.9±1.1
(p=0.02) (Table 2).
Changes in albumin-to-creatinine ratio after renal
denervation and relation with blood pressure
control
At baseline, median ACR was 25.8 mg/g (IQR 9.0-574.0
mg/g) and 48.4% of patients (n=15) had an ACR >30 mg/g.
We found a signiﬁcant reduction at 12-month follow-up to a
median of 14.8 mg/g (IQR 4.5-61.0 mg/g, p=0.007) (Table 3).
Interestingly, we also found a signiﬁcant reduction in the
percentage of patients with ACR >30 mg/g between base-
line and 12-month follow-up (Figure 2). Considering patients
with any ACR reduction as ACR responders, 77.4% (n=24) of
patients were ACR responders. The distribution of patients
across the different classes of urinary albumin excretion also
demonstrated a favorable effect (Figure 3).
Table 2 Antihypertensive medication.
Baseline 12 months p
Mean no. of antihypertensive drugs 5.8±1.1 5.0±1.2 0.002
Mean no. of drug classes 5.5±0.9 4.9±1.1 0.015
ACE inhibitors 19 (61.3) 17 (54.8) 0.688
ARBs (%) 19 (61.3) 18 (58.1) 1.0
Beta-blockers (%) 26 (83.9) 27 (87.1) 1.0
Calcium channel blockers (%) 30 (96.8) 21 (67.7) 0.012
Diuretics (%) 27 (87.1) 24 (77.4) 0.727
Spironolactone (%) 23 (74.2) 26 (83.9) 0.453
Sympatholytics (%) 22 (71) 19 (61.3) 0.508
Aliskiren 4 (12.9) 0 0.046
ACE: angiotensin-converting enzyme; ARB: angiotensin receptor blockers.
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Table 3 Blood pressure, heart rate and albumin-to-creatinine ratio before and 12 months after renal denervation.
Baseline 12 months p
Ofﬁce SBP (mmHg) 176±24 149±13 <0.001
Ofﬁce DBP (mmHg) 90±14 79±11 <0.001
Heart rate (bpm) 73±11 70±11 0.261
ABPM SBP (mmHg) 150±20 132±14 <0.001
ABPM DBP (mmHg) 83±10 74±9 <0.001
ABPM pulse pressure (mmHg) 67±18 58±13 0.001
ABPM mean BP (mmHg) 105±9 95.3±8.4 <0.001
ABPM heart rate (bpm) 67.6±9.1 65.5±9.5 0.090
ABPM SBP respondersa (%) - 26 (83.9) -
Ofﬁce SBP respondersb (%) - 22 (71) -
eGFR (ml/min/1.73 m2) 73.6±25.1 72.5±25.1 0.711
ACR (mg/g) 25.8 (9.0-574.0) 14.8 (4.5-61.0) 0.007
ACR in ABPM BP responders (mg/g) 25.6 (8.7-382.8) 15.9 (4.4-55.0) 0.009
ACR in ABPM BP non-responders (mg/g) 165.0 (8.8-1423.5) 13.6 (5.7-1417.0) 0.345
ACR in ABPM dippers (mg/g) 20.8 (6.8-290.0) 9.4 (3.7-41.1) 0.028
ACR in ABPM non-dippers (mg/g) 62.3 (9.1-852.3) 20.8 (9.3-197.1) 0.096
ACR in diabetic patients (mg/g) 48.9 (9.1-1116.3) 23.1 (4.3-123.8) 0.028
ACR in non-diabetic patients (mg/g) 25.4 (5.2-68.6) 10.9 (3.4-20.8) 0.066
ABPM: 24-h ambulatory blood pressure; ACR: albumin to creatinine ratio; BP: blood pressure; bpm: beats per minute; DBP: diastolic
blood pressure; eGFR: estimated glomerular ﬁltration rate; SBP: systolic blood pressure.
a Decrease of 2 mmHg between baseline ABPM SBP and at 12 months.
b Decrease of 10 mmHg between baseline ofﬁce SBP and at 12 months.
When the results were split according to ABPM SBP
responder status, we found a signiﬁcant reduction in
responders (from 25.6 mg/g [IQR 8.7-382.8 mg/g] to
15.9 mg/g [IQR 4.4-55.0 mg/g], p=0.009), and a numer-
ical decrease in non-responders (from 165.0 mg/g [IQR
8.8-1423.5 mg/g] to 13.6 mg/dl [IQR 5.7-1417.0 mg/g],
p=0.345), probably due to the small number of patients in
this subgroup (Table 3 and Figure 4). The same analysis was
performed according to dipper status and the results were
similar, with a signiﬁcant reduction in patients with dipper
status on baseline ABPM (Table 3 and Figure 5).
With regard to diabetic status, patients with diabetes had
a higher median baseline ACR and showed a statistically sig-
niﬁcant decrease (from 48.9 mg/g [IQR 9.1-1116.3 mg/g]
to 23.1 mg/g [IQR 4.3-123.8 mg/g], p=0.028); there was
also a numerical decrease in ACR in non-diabetic patients
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32.3
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ACR (mg/g) % patients with ACR >30 mg/g eGFR (ml/min/1.73 m2)
Baseline 12-month follow-up
p=0.007
p=0.711
p=0.023
Figure 2 Values of albumin-to-creatinine ratio and estimated glomerular ﬁltration rate at 12 months after renal denervation.
There was a signiﬁcant reduction in the median values of ACR and the percentage of patients with ACR >30 mg/g, without signiﬁcant
changes in eGFR. ACR: albumin-to-creatinine ratio; eGFR: estimated glomerular ﬁltration rate.
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Figure 3 Percentages of patients in the different albumin-
to-creatinine ratio subgroups. There was a numerical decrease
in the percentage of patients with an ACR >300 mg/g and
an increase in patients with normal urinary albumin excretion
between baseline and 12-month follow-up. ACR: albumin-to-
creatinine ratio.
(from 25.4 mg/g (IQR 5.3-68.6 mg/g) to 10.9 mg/dl (IQR
3.4-20.8 mg/g), p=0.066), probably also due to the small
patient sample in this subgroup (n=9) (Table 3 and Figure 6).
Safety
There were four vascular access complications: three
hematomas and one femoral pseudoaneurysm. No signiﬁcant
changes in eGFR were seen (Table 3 and Figure 2).
Discussion
The main ﬁndings of our study are: (1) RDN was associ-
ated with a signiﬁcant BP reduction at 12-month follow-up;
(2) there was a signiﬁcant decrease in median ACR, with-
out signiﬁcant changes in eGFR, and a signiﬁcant reduction
in the percentage of patients with ACR >30 mg/g between
baseline and 12-month follow-up; (3) the reduction in ACR
was observed in both BP responders and non-responders.
Although the initial results with catheter-based RDN
were very promising,7,8,16 the most recent and largest
randomized trial, SYMPLICITY HTN-3,15 failed to meet its
primary efﬁcacy endpoint, raising doubts about the real
biological effect of this treatment. The unexpected nega-
tive results of HTN-3 have been extensively discussed and
many possible reasons have been put forward, both clin-
ical (mainly related to patient selection) and technical
(procedure-related, particularly the number and pattern of
radiofrequency applications).17 Another possible factor is
how the efﬁcacy of RDN is currently measured, and exam-
ining target organ damage may provide a better assessment
than BP values. In line with this are the recent results in
LV mass and function after RDN, for which several groups
have published positive results at six-month follow-up based
on both transthoracic echocardiography11,18 and cardiac
magnetic resonance imaging (MRI).10 Our group recently
reported a signiﬁcant reduction in left ventricular mass at
12-month follow-up, without correlation with changes in sys-
tolic ABPM.11
Another approach to monitoring hypertension-related
target organ damage is to calculate ACR, a recognized
marker which has been linked to cardiovascular outcomes
in several studies on hypertension.4--6 Ott et al.19 found
a signiﬁcant reduction in ACR at six-month follow-up in
59 patients with resistant hypertension (mean 24-h ABPM
SBP 156 mmHg, treated with a mean of 5.5 antihypertensive
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Figure 4 Values of albumin-to-creatinine ratio at 12 months after renal denervation in 24-h ambulatory blood pressure monitoring
responder subgroups. There was a signiﬁcant reduction in median ACR in the BP responder subgroup, and a numerical decrease in
non-responders. ACR: albumin-to-creatinine ratio; BP: blood pressure.
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Figure 5 Values of albumin-to-creatinine ratio at 12 months after renal denervation according to dipper status on 24-h ambulatory
blood pressure monitoring. There was a signiﬁcant reduction in median ACR in the dipper subgroup, and a numerical decrease in
non-dippers. ACR: albumin-to-creatinine ratio.
drugs). In contrast with the latter study, we also included
patients with normal (<30 mg/g) baseline ACR and therefore
our median values are lower that those reported by Ott et al.
Of note, even among this mixed population of different ACR
baseline proﬁles, half of whom had normal urinary albumin
excretion (51.6% with ACR <30 mg/dl), the mean age
(65 years), baseline ABPM SBP (150 mmHg) and mean num-
ber of drugs (5.8) were very similar to the study by Ott et al.
Our study also included a higher percentage of patients with
type 2 diabetes (71%, compared to 51% in Ott et al.’s study).
In another recently published single-center study, Verloop
et al.13 failed to demonstrate any signiﬁcant decrease in
either LV mass (by cardiac MRI) or urinary albumin excre-
tion, and found only a modest impact on blood pressure.
These results are in contrast with previous studies and our
results, and may have been due to differences in patient
populations. In the study by Verloop et al.,13 the mean age
was lower (58 years) and so was the mean number of drugs
(4, as opposed to 5.5 in Ott et al. and 5.8 in our study).
Other important differences are the much lower prevalence
of diabetes (only 15%) and the fact that the authors did not
exclude patients with eGFR <45 ml/min/1.73 m2.
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Figure 6 Values of albumin-to-creatinine ratio at 12 months after renal denervation according to diabetic status. There was a
signiﬁcant reduction in median ACR in patients with diabetes, and a numerical decrease in the smaller subgroup of patients without
diabetes. ACR: albumin-to-creatinine ratio.
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One interesting observation in our study is the fact that
the reduction in ACR was also found in BP non-responders,
although this did not reach statistical signiﬁcance, prob-
ably due to the small size of this patient subgroup. This
raises the question of whether RDN, by reducing sympa-
thetic hyperactivity, might have a positive direct effect on
glomerular endothelial function independent of the hemo-
dynamic effect derived from blood pressure reduction, since
there is a close association between urinary albumin excre-
tion and glomerular endothelium dysfunction and glycocalyx
loss.5,20 These two factors may be modulated by autonomic
nervous system tone and, in theory, this positive impact
on endothelial physiology could be linked to the expected
decrease in overall cardiovascular risk that is the ultimate
goal of RDN. On the other hand, endothelial dysfunction is
only one of several effects of increased sympathetic activ-
ity, a common denominator in cardiovascular and renal
pathophysiology.21 Finally, the ACR reduction seen in our
study should be interpreted in the context of the high car-
diovascular risk of patients with resistant hypertension,2,3
and this reduction is expected to help to lower this risk,
although no prospective studies have been published on the
prognostic impact of RDN on clinical outcomes.
Limitations
The present study has some limitations that should be men-
tioned: (1) it is a single-center prospective registry with a
small sample size; (2) the physicians following patients after
RDN were not blinded, although the most important out-
come measurements (24-h ABPM and ACR) were performed
by cardiac and laboratory technicians unaware of treatment
status; (3) there was no control group or sham procedure;
(4) changes were made in antihypertensive therapy during
follow-up, which could have inﬂuenced reductions in blood
pressure and ACR (but the mean number of drugs actually
decreased during follow-up, which could lead to underesti-
mation of the beneﬁt of RDN in this daily practice setting).
Conclusions
In this single-center unblinded study of patients with resis-
tant hypertension undergoing RDN, we found a signiﬁcant
reduction in both ofﬁce BP and 24-h ABPM which was asso-
ciated with a signiﬁcant decrease in median ACR, without
signiﬁcant changes in eGFR. At 12-month follow-up, there
was a reduction in the percentage of patients with patho-
logical urinary albumin excretion, and this reduction was
independent of BP responder status.
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